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  iv│Abstract  
ABSTRACT 
Left ventricular hypertrophy (LVH) is an independent predictor of cardiovascular morbidity and all-
cause mortality. Significantly, it is considered a modifiable cardiovascular risk factor as its 
regression increases overall survival and reduces the frequency of adverse cardiac events. A clear 
understanding of LVH pathogenesis is thus imperative to facilitate improved risk stratification and 
therapeutic intervention.  
Hypertrophic cardiomyopathy (HCM), an inherited cardiac disorder, is a model disease for 
elucidating the molecular mechanisms underlying LVH development. LVH, in the absence of 
increased external loading conditions, is its quintessential clinical feature, resulting from mutations 
in genes encoding sarcomeric proteins. The LVH phenotype in HCM exhibits marked variability 
even amongst family members who carry the same disease-causing mutation. Phenotypic 
expression is thus determined by the causal mutation and additional determinants including the 
environment, epigenetics and modifier genes.   
Thus far, factors investigated as potential hypertrophy modifiers in HCM have been relatively 
removed from the primary stimulus for LVH; and the few studies that have been replicated yielded 
inconsistent results. We hypothesized that the factors that closely interact with the primary stimulus 
of faulty sarcomeric functioning, have a greater capacity to modulate it, and ultimately the LVH 
phenotype in HCM. Plausible candidate modifiers would include factors relating to the structure or 
function of the sarcomere, including known HCM-causal genes; and the enzymes that function in 
sarcomere-based energetics. Indeed, the literature highlights the relevance of sarcomeric proteins, 
Ca2+-handling and myocardial energetics in the development of LVH in HCM.  
This study, therefore, set out to evaluate the hypertrophy-modifying capacity of such factors by 
means of family-based genetic association testing in 27 South African HCM families in which one 
of three unique HCM-causing founder mutations segregates. Moreover, the single and combined 
effects of 76 variants within 26 candidate genes encoding sarcomeric or sarcomere-associated 
proteins were investigated.  
The study identified a modifying role in the development of hypertrophy in HCM for each of the 
candidate genes investigated with the exception of the metabolic protein-encoding gene, PRKAG1. 
More specifically, single variant association analyses identified a modifying role for variants within 
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the genes MYH7, TPM1 and MYL2, which encode proteins of the sarcomere, as well as the genes 
CPT1B, CKM, ALDOA and PRKAB2, which encode metabolic proteins. Haplotype-based 
association analyses identified combined modifying effects for variants within the genes ACTC, 
TPM1, MYL2, MYL3 and MYBPC3, which encode proteins of the sarcomere, as well as the genes 
CD36, PDK4, CKM, PFKM, PPARA, PPARG, PGC1A, PRKAA2, PRKAG2 and PRKAG3, which 
encode metabolic proteins. Moreover, a number of variants and haplotypes showed statistically 
significant differences in effect amongst the three HCM founder mutation groups.  
The HCM-modifier genes identified were prioritised for future studies according to the number of 
significant results obtained for the four tests of association performed. The genes TPM1 and 
MYBPC3, which encode sarcomeric proteins, as well as the genes PFKM and PRKAG2, which 
encode metabolic proteins, were identified as stronger candidates for future studies as they 
delivered multiple significant results for various statistical tests. 
 This study makes a novel contribution to the field of hypertrophy research as it tested the 
hypothesis that structural or energy-related factors located within the sarcomere may act as 
modifiers of cardiac hypertrophy in HCM, and succeeded in identifying a modifying role for many 
of the candidate genes selected. The significant results include substantial single and within-gene-
context variant effects; and identified sizeable variation in the risk of developing LVH owing to the 
compound effect of the modifier and the individual founder mutations. Collectively, these findings 
enhance the current understanding of genotype/phenotype correlations and may, as consequence, 
improve patient risk stratification and choice of treatment. Moreover, these findings emphasize the 
potential for modulation of disease by further elucidation of some of the avenues identified.  
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OPSOMMING 
Linker ventrikulêre hipertrofie (LVH) is ‘n onafhanklike voorspeller van kardiovaskulêre 
morbiditeit en van mortaliteit weens alle oorsake. Van belang is dat dit ‘n wysigbare 
kardiovaskulêre risiko faktor is, aangesien die afname daarvan algehele oorlewing verhoog en die 
frekwensie van nadelige kardiale voorvalle verlaag. ‘n Duidelike begrip van LVH patogenese is dus 
noodsaaklik om verbeterde risiko stratifikasie en terapeutiese intervensie te fasiliteer.  
Hipertrofiese kardiomiopatie (HKM), ‘n oorerflike hart-siekte, is ‘n model-siekte vir die uitpluis 
van die molekulêre meganismes onderliggend aan die ontwikkeling van LVH. LVH, in die 
afwesigheid van verhoogde eksterne lading, is die kern kliniese simptoom van HKM en die gevolg 
van mutasies in die gene wat kodeer vir sarkomeriese proteïene. Die LVH fenotiepe in HKM toon 
merkbare veranderlikheid selfs in familie-lede wat dieselfde siekte-veroorsakende mutasie dra. Die 
fenotiepe word dus bepaal deur die siekte-veroorsakende mutasie asook addisionele determinante 
insluitend die omgewing, epigenetika en modifiserende gene.    
Potensiële hipertrofie-modifiseerders wat tot dusver bestudeer is, is betreklik verwyder van die 
primêre stimulus vir LVH en die paar studies wat gerepliseer is, het teenstrydige resultate gelewer. 
Ons hipoteseer dat die faktore wat in noue interaksie met die primêre stimulus van foutiewe 
sarkomeriese funksionering is, ‘n groter kapasitieit het om dit en uiteindelik die LVH fenotiepe in 
HKM, te moduleer. Aanneemlike kandidaat-modifiseerders sou insluit faktore wat betrekking het 
tot die struktuur en funksie van die sarkomeer insluitend HKM-oorsaaklike gene en die ensieme wat 
funksioneer in sarkomeer-gebaseerde energetika. Die literatuur beklemtoon inderdaad die relevansie 
van sarkomeriese proteïene, Ca2+-hantering en miokardiese energetika in die ontwikkeling van 
LVM in HKM. 
Hierdie studie het beoog om die hipertrofie-modifiserende kapasiteit van sulke faktore te evalueer 
deur middel van familie-gebaseerde genetiese assosiasie toetse in 27 Suid-Afrikaanse HKM 
families waarin een van drie unieke HKM-stigter mutasies segregeer. Verder was die enkel en 
gekombineerde effekte van 76 variante binne 26 kandidaat gene wat kodeer vir sarkomeer en 
sarkomeer-geassosieerde proteïene, ondersoek.  
Hierdie studie het ‘n modifiserende rol in die ontwikkeling van hipertrofie in HKM geïdentifiseer 
vir elk van die kandidaat gene wat ondersoek is, met uitsluiting van die PRKAG1, wat kodeer vir ‘n 
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metaboliese proteïen. Meer spesifiek, enkel variant assosiasie analises het ‘n modifiserende rol 
geïdentifiseer vir variante in die gene MYH7, TPM1 en MYL2, wat kodeer vir sarkomeriese 
proteïene, asook die gene CPT1B, CKM, ALDOA en PRKAB2, wat kodeer vir metabolise proteïene. 
Haplotipe-gebaseerde assosiasie-analises het gekombineerde modifiserende effekte geïdentifiseer 
vir variante in die gene ACTC, TPM1, MYL2, MYL3 en MYBPC3, wat kodeer vir strukturele 
proteïene van die sarkomeer asook die gene CD36, PDK4, CKM, PFKM, PPARA, PPARG, PGC1A, 
PRKAA2, PRKAG2 en PRKAG3, wat kodeer vir metabolise proteïene. Verder het ‘n aantal variante 
en haplotipes statisties betekenisvolle verskille in effek tussen die drie HKM-stigter mutasie groepe 
getoon. 
Die HKM-modifiserende gene wat geïdentifiseer is, is verder geprioritiseer vir toekomstige studies 
volgens die aantal beduidende resultate wat vir die vier assosiasie toetse verkry is. Die gene TPM1 
and MYBPC3, wat kodeer vir sarkomeriese proteïene, asook die gene PFKM and PRKAG2, wat 
kodeer vir  metaboliese proteïene, is geïdentifiseer as sterker kandidate vir verdere studies omdat 
veelvuldige beduidende resultate vir die verskeie statistiese toetse deur hulle gelewer is.  
Hierdie studie maak ‘n nuwe bydrae tot die veld van hipertrofie navorsing omdat dit die hipotese 
dat strukturele en energie-verwante faktore, wat binne die sarkomeer geposisioneer is, potensieel as 
modifiseerders van kardiale hipertropfie in HKM kan optree, ondersoek het. Dit slaag ook daarin 
om ‘n modifiserende rol vir baie van die geselekteerde kandidaatgene te identifiseer. Die 
beduidende resultate sluit in aansienlike enkel en binne-geen-konteks variant-effekte en aansienlike 
variasie in die risiko vir LVH ontwikkeling verskuldig aan die gekombineerde effek van 
modifiseerder en individuele stigter mutasies. Gesamentlik verbeter hierdie bevindinge die huidige 
begrip van genotipe/fenotipe korrelasies en dit mag tot gevolg hê verbeterde pasiënt risiko 
stratifikasie en keuse van behandeling. Verder beklemtoon hierdie bevindinge die potensiaal vir 
siekte modulering deur verdere uitpluis van sekere van hierdie geïdentifiseerde navorsingsrigtings.  
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CHAPTER ONE 
INTRODUCTION 
1.1 Left ventricular hypertrophy 
Left ventricular hypertrophy (LVH) is predictive of cardiovascular morbidity and all-cause 
mortality, independent of other disease risk factors, e.g. age and gender, and its progression is 
associated with an increased risk of heart failure (HF), stroke, myocardial infarction (MI), coronary 
heart disease (CHD), arrhythmias and sudden cardiac death (SCD) (Koren et al., 1991;Levy et al., 
1990a;Mathew et al., 2001;Schillaci et al., 2000;Messerli et al., 1984;Wolf et al., 1991;Kannel et 
al., 1970;Kannel & Schatzkin, 1985;Levy et al., 1987;Dahlof et al., 2002).  
The value of LVH as a modifiable cardiovascular risk factor is apparent from studies linking its 
regression, achieved via antihypertensive therapy, to increased overall survival and a reduced 
frequency of adverse cardiac events; these beneficial effects were independent of blood pressure 
(BP) and drug choice (Devereux et al., 2004;Okin et al., 2004). The Heart Outcomes Prevention 
Evaluation (HOPE) trial is one such study where electrocardiographic LVH regression was 
associated with reduced risk of death, MI, stroke and HF (Mathew et al., 2001).  
However, there are limitations to the antihypertensive treatment of LVH, as is evident from the lack 
of correlation between the level of BP reduction and LVH regression, as well as from instances 
where LVH is seen even in normotensive individuals (Koren et al., 1991). This highlights the 
involvement of other non-hemodynamic factors in the development of LVH (Schunkert et al., 
1994;Levy et al., 1988).  
To eventually facilitate improved therapeutic intervention and risk stratification, an increased 
understanding of LVH pathogenesis is thus imperative. That genetic factors can modify LVH risk is 
evident from the literature. Research motivating such genetic contributions include twin studies 
highlighting the influence of heritable factors on left ventricular mass (LVM), which is an indicator 
of LVH (Adams et al., 1985;Verhaaren et al., 1991), and association of the angiotensin-converting 
enzyme (ACE) gene, seemingly independent of BP-control, with increased risk of LVH (Schunkert 
et al., 1994). However, identification of genetic markers of LVH against the backdrop of complex 
disorders, in which LVH is just one of many features, is challenging. Hypertrophic cardiomyopathy 
(HCM), an inherited cardiac disorder, with LVH as its primary clinical feature, is considered a 
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model disease for elucidating the molecular mechanisms underlying cardiac hypertrophy 
development and progression (Watkins et al., 1995c).  
1.2 Hypertrophic cardiomyopathy 
HCM is a heritable myocardial disorder estimated to occur in 1 of 500 young adults (Maron et al., 
1995;Willard & Ginsburg, 2009). It is clinically defined by unexplained LVH, i.e. LVH occurring 
in the absence of other hypertrophy triggers, such as hypertension, whilst the histopathological 
features include myocyte hypertrophy and extensive myocytic and myofibrillar disarray, as well as 
interstitial fibrosis (Refer to Figure 1.1). In addition, HCM patients are at risk of SCD, whether or 
not they manifest any of the other clinical symptoms, including arrhythmias, dyspnea, palpitations 
and syncope (Seidman & Seidman, 2001;Chung et al., 2003;Marian, 2002;Reviewed by Marian, 
2010). 
The hypertrophic phenotype in HCM is most frequently asymmetric, typically including the 
interventricular septum (IVS), and ultimately resulting in a decreased left ventricular cavity size 
(Chung et al., 2003;Seidman & Seidman, 2001;Willard & Ginsburg, 2009). Nonetheless, the 
disease exhibits extreme variability, including that of the age of onset, disease progression, 
occurrence of SCD and spectrum and extent of symptoms, and most noticeably, also the degree and 
location of hypertrophy (Seidman & Seidman, 2001;Wigle et al., 1995;Maron, 2002;Spirito & 
Maron, 1989). Moreover, the disease heterogeneity can range from clinically and morphologically 
unaffected with an asymptomatic course and normal longevity, to severe dysfunction, including HF 
or SCD, with the latter often being the first manifestation of disease (Lawson, 1987;Reviewed by 
Marian, 2010;Spirito et al., 1997). 
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Figure 1.1 Gross and microscopic findings of hypertrophic cardiomyopathy. Severe concentric 
hypertrophy is apparent from this pathologic specimen from a patient with HCM (a), compared to a normal 
heart (b). With HCM, there is markedly increased wall thickness throughout the left ventricle, most 
prominent in the interventricular septum (IVS), but also present in the free lateral wall (LW). Histological 
sections, stained with hematoxylin and eosin, demonstrate the pathognomonic features of HCM, i.e. myocyte 
disarray and fibrosis (a). In contrast, normal myocardium demonstrates a very orderly arrangement of 
myocytes (b). Images are at ×100 magnification. Images courtesy of Dr. Robert Padera, Department of 
Pathology, Brigham and Women’s Hospital, Boston, MA (Taken from Ho, 2009) 
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1.2.1 Molecular genetics of HCM 
HCM is inherited in an autosomal dominant fashion, although both genetic and intragenic 
heterogeneity is present (Soor et al., 2009;Reviewed by Bonne et al., 1998). Classically described 
as a ‘disease of the sarcomere’ (Thierfelder et al., 1994), with more than 1000 causative mutations 
(Seidman & Seidman, 2011) identified primarily in genes encoding myofilament proteins 
(myofilament HCM), the genetic spectrum currently extends to mutations in genes encoding 
sarcomeric Z-disc (Z-disc HCM) and calcium-handling (calcium-handling HCM) proteins (Willard 
& Ginsburg, 2009;Konno et al., 2010). These HCM susceptibility genes, their relevant protein 
products, loci and HCM-causing mutation totals are listed in Table 1.1, according to HCM subtype. 
Table 1.1 Summary of HCM susceptibility genes grouped according to HCM subtype 
HCM subtype Gene Protein Locus 
HCM 
mutations 
described 
Myofilament HCM     
Giant filament TTN Titin 2q24.3 2 
Thick filament MYH7 β-Myosin heavy chain 14q11.2–q12 233 
 MYH6 α-Myosin heavy chain 14q11.2–q12 2 
 MYL2 Ventricular regulatory myosin light 
chain 
12q23–q24.3 15 
 MYL3 Ventricular essential myosin light 
chain 
3p21.2–p21.3 7 
Intermediate filament MYBPC3 Cardiac myosin-binding protein C 11p11.2 187 
Thin filament TNNT2 Cardiac troponin T 1q32 39 
 
TNNI3 Cardiac troponin I 19p13.4 37 
 
TPM1 α-Tropomyosin 15q22.1 15 
 
ACTC1 α-Cardiac actin 15q14 7 
 
TNNC1 Cardiac troponin C 3p21.3–p14.3 7 
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HCM subtype Gene Protein Locus 
HCM 
mutations 
described 
Z-disc HCM     
 
ANKRD1 Cardiac ankyrin repeat protein 10q23.33 3 
 
LBD3 LIM binding domain 3 10q22.2–q23.3 6 
 
CSRP3 Muscle LIM protein 11p15.1 7 
 
TCAP Telethonin 17q12–q21.1 2 
 
VCL Vinculin/metavinculin 10q22.1–q23 2 
 
ACTN2 α-actinin 2 1q42–q43 6 
 
MYOZ2 Myozenin 2 4q26–q27 2 
Calcium-handling HCM     
 
JPH2 Junctophilin-2 20q12 3 
 
PLN Phospholamban 6q22.1 4 
Abbreviations: α-alpha; β-beta; p-short arm of chromosome; q-long arm of chromosome; HCM-Hypertrophic 
cardiomyopathy (Xu et al., 2010;Adapted from Bos et al., 2009;Alves et al., 2010;Theis et al., 2006;Medin et al., 2007)  
Myofilament HCM is the most prevalent subtype, due mainly to mutations in eight genes that 
encode sarcomere contractile proteins, and affects the integrity of the thin, intermediate and thick 
myofilaments (Willard & Ginsburg, 2009). These eight genes include the β-myosin heavy chain 
gene (MYH7) (Geisterfer-Lowrance et al., 1990); ventricular regulatory myosin light chain (MYL2); 
ventricular essential myosin light chain (MYL3) (Poetter et al., 1996); cardiac myosin-binding 
protein C (MYBPC3) (Watkins et al., 1995a); cardiac troponin T (TNNT2) (Thierfelder et al., 1994); 
cardiac troponin I (TNNI3) (Kimura et al., 1997); α-Tropomyosin (TPM1) (Thierfelder et al., 1994); 
α-Cardiac actin (ACTC) (Mogensen et al., 1999) (Refer to Figure 1.2 and to Table 1.1).  
Overall, the leading HCM-causing genes are MYH7 and MYBPC3, collectively accounting for an 
estimated 50–60% of cases. Combined, the remainder of the aforementioned sarcomeric genes 
explain less than 20%, with the largest contributors being TNNT2 and TNNI3 mutations at 
individual gene frequencies of 3–5%. Other myofilament protein encoding genes are only rare 
causes of the condition (individual frequencies <1%); they include titin (TTN), whose contribution 
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to HCM is well established, and cardiac troponin C (TNNC1) and α-Myosin heavy chain (MYH6), 
whose contributions are less concrete (Baars et al., 2010;Reviewed by Marian, 2010). 
 
Figure 1.2 Diagrammatic representation of the myocardial-contractile apparatus i.e. the sarcomere, 
indicating the components of the thick, intermediate and thin myofilaments (Adapted from 
http://www.genedx.com/site/hypertrophic_cardiomyopathy_and_its_genetics). 
Similarly, Z-disc and calcium-handling HCM occurs infrequently, with implicated genes (Refer to 
Table 1.1), viz. those encoding the Z-disc proteins responsible for anchoring myofibrils to the 
cytoskeleton and signal transduction, and calcium-handling proteins essential for excitation-
contraction coupling of the cardiomyocyte, each accounting for <1% of cases. The exception to this 
rule is the LIM domain binding 3 (LBD3) gene, which accounts for 1–5% of HCM cases (Pyle & 
Solaro, 2004;Willard & Ginsburg, 2009). 
Finally, mutations in non-myofilament genes have been implicated in HCM-mimicking disorders, 
so-called HCM phenocopies. These include metabolic cardiomyopathies, previously considered as 
metabolic-HCM, caused by mutations in AMP-activated protein kinase gamma 2 (PRKAG2), 
lysosome-associated membrane protein 2 (LAMP2)  and α-galactosidase A (GLA) (Nakao et al., 
1995;Arad et al., 2005;Blair et al., 2001b). Although recently revised as distinct from HCM, due to 
differing histopathologies, these cardiomyopathies all show LVH, thereby highlighting the 
contribution of metabolic genes to the development of hypertrophy that can be measured on a gross 
morphological scale (Bos et al., 2007;Willard & Ginsburg, 2009;Konno et al., 2010). The 
Thick 
myofilament 
Thin 
myofilament 
Intermediate 
myofilament 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
7│Chapter 1 
aforementioned as well as other HCM phenocopies, including triplet repeat syndromes and 
mitochondrial cytopathies, are listed in Table 1.2 along with the relevant gene, locus, protein 
product and syndrome.  
Table 1.2 Summary of HCM Phenocopies listed according to chromosome locus 
Gene Locus Protein Syndrome 
AGL 1p21 Amylo-1,6-glucosidase Forbes disease 
SOS1 2p22–p21 Son of sevenless homolog 1 Noonan syndrome 
BRAF1 3p25 V-RAF murine sarcoma viral oncogen homolog B1 CFC syndrome 
PRKAG2 7q35–q36.36 AMP-activated protein kinase gamma 2 WPW syndrome (pre-
excitation); conduction 
disturbances 
FXN 9q13 Frataxin Friedreich ataxia 
KRAS2 12p12.1 Kirsten rat sarcoma viral oncogen homolog Noonan syndrome, 
Leopard, CFC syndrome  
PTPN11 12q24.1 Protein-tyrosine phosphatise non-receptor-type 11 Noonan syndrome, 
Leopard syndrome, CFC 
syndrome 
MAP2K1 15q22.1–q22.33 Mitogen-activated protein kinase kinase 1 CFC syndrome 
GAA 17q25.2–q25.3 Glucosidase alpha acid Pompe disease 
DTNA 18q12 α-dystrobrevin Barth syndrome/LVNC 
MAP2K2 19p13.3 Mitogen-activated protein kinase kinase 2 CFC syndrome 
GLA Xq22 α-galactosidase  Fabry disease 
LAMP2 Xq24 Lysosome-associated membrane protein 2 Danon  disease/WPW 
TAZ Xq28 Tarfazzin  Barth syndrome/LVNC 
Abbreviations: α-alpha; β-beta; p-short arm of chromosome; q-long arm of chromosome; X-chromosome X; AMP-
adenosine monophosphate; CFC-cardiofaciocutaneous; HCM-Hypertrophic cardiomyopathy; Leopard-mnemonic for 
syndrome with clinical characteristics of lentigines, electrocardiographic conduction abnormalities, ocular 
hypertelorism, pulmonary hypertension, abnormal genitalia, retarded growth, deafness; LVNC-left ventricular 
noncompaction; WPW-Wolff-Parkinson-White syndrome (Adapted from Bos et al., 2009;Baars et al., 2010) 
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1.2.2 Clinical variability in HCM 
HCM shows marked phenotypic heterogeneity even within families, i.e. amongst individuals who 
carry the same causal mutation; this intrafamilial variation is comparable to the variability observed 
between different families, involving different mutations (Epstein et al., 1992;Fananapazir & 
Epstein, 1994;Posen et al., 1995). As previously discussed, this heterogeneity is evident in the age 
of onset, disease progression, risk of SCD and the severity of hypertrophy (Refer to Section 1.2).  
Although the hypertrophy is most frequently asymmetric, involving the IVS, in rare instances it 
may present as concentric (symmetric). Further variability exists in the pattern or distribution of 
hypertrophy, as well as the extent of hypertrophy. Thus, hypertrophy distribution may range from 
diffusely distributed hypertrophy to hypertrophy localised to a single segment (e.g. apical). The 
extent of hypertrophy may include LV wall thicknesses (LVWT) in HCM-mutation carriers ranging 
from complete absence of hypertrophy, or minimal hypertrophy (with LVWT less than 13 
millimetres (mm) in adults regarded as normal), to massive hypertrophy (defined as maximum 
LVWT of 35 mm or more in adults, and its age-adjusted value in children). For this reason, the 
diagnostic cut-off LVWT value used in HCM pedigrees (the extended family of HCM probands) is 
more stringent (11 mm), as even marginal hypertrophy may prove significant within a familial 
context (Reviewed by Maron, 2002;Spirito et al., 1997).  
This clinical heterogeneity can in part be explained by genotype/phenotype correlations pertaining 
to the relevant causal gene, the specific mutation therein and gene dosage, i.e. the presence of 
multiple sarcomeric mutations (Ho, 2010a;Reviewed by Marian, 2010). Recognised causal gene 
relationships include the frequent association of MYH7 mutations with early disease onset, high 
disease penetrance, and severe disease, e.g. severe hypertrophy, heart failure and increased risk of 
SCD (Fowler et al., 2009;Watkins et al., 1992). In contrast, MYBPC3 mutations have typically been 
characterised by a relatively late onset and a less severe clinical phenotype, as well as incomplete 
penetrance (Fowler et al., 2009;Van Driest et al., 2004). TNNT2 mutations, on the other hand, 
typically present with less severe hypertrophy, but with an increased occurrence of SCD (Fowler et 
al., 2009;Moolman et al., 1997;Watkins et al., 1995b).  
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Specific mutations within a given gene have also been thought to provide prognostic insights, with, 
for example, different MYH7 mutations giving rise to varying clinical manifestations: The R403Q 
and R453C mutations were thought to result in the aforementioned, severe MYH7 phenotype, whilst 
mutations N232S, G256E, V606M and V403Q have been associated with a more favourable 
outcome (Fowler et al., 2009;Anan et al., 1994;Marian & Roberts, 1998). Further reports include 
the increased risk of heart failure associated with the R719WMYH7, K183delTNNI3 and 
IVS32del25ntMYBPC3 mutations (Konno et al., 2010).  
However, genotype/phenotype correlations are clearly imperfect, with many contradictory reports 
of such correlations, as well as the occurrence of clinically unaffected mutation carriers (Dausse et 
al., 1993;Carrier et al., 1997). More recent description of phenotypic similarities between MYH7-
HCM and MYBPC3-HCM (Van Driest et al., 2004), as well as the marked clinical variability 
amongst homogenous carriers of the same disease-causing mutation indicate that the phenotype is 
not determined solely by the causal mutation. This implies the existence of additional determinants 
of disease expression, such as the environment, epigenetics and modifier genes.   
1.2.3 Genetic modifiers of the hypertrophic phenotype in HCM 
Modifier genes can further contribute to the genotype/phenotype disparity. These genes form part of 
the genetic background of a person, and are neither necessary nor sufficient to cause disease, but 
influence the clinical phenotype when present in addition to a disease-causing mutation (Alcalai et 
al., 2008). The contribution of genetic background to disease expression is demonstrated in the 
diverse phenotypic expression of disease in families of different ethnic origin who carry the same 
causal mutation, as well as in monozygotic and dizygotic twin studies and transgenic animal models 
using different strains of animals, as described below:  
Fananapazir and Epstein (1994) compared disease expression in unrelated Caucasian and Korean 
kindreds who carry an identical HCM-causing mutation in MYH7, R403Q. The phenotypic 
presentation varied significantly amongst the two different ethnic groups with reports of SCD and 
syncope or pre-syncope in the Caucasian kindred, but the complete absence thereof in the Korean 
family. Furthermore the majority of the Korean kindred showed LV outflow obstruction that was 
not observed in the Caucasian group. One possible explanation for the varying outcome is the 
differences in genetic make-up of the two ethnic groups.  
Stellenbosch University  http://scholar.sun.ac.za
  
10│Chapter 1 
Twin studies have shown greater intra-pair variance of LVM in dizygotic twins than in 
monozygotic twins, and higher concordance for cardiac size in monozygotic twins, dizygotic twins, 
and sibling pairs relative to non-related subjects, thereby highlighting the role of familial 
components, i.e. shared environment as well as shared genetic factors, in LVM (Adams et al., 
1985;Verhaaren et al., 1991).  
Numerous studies using transgenic animal models have identified genetic loci that affect LVM, 
independent of BP. Examples include a quantitative trait locus (QTL) on chromosome 2 and 
another on chromosome 3, identified via genome-wide searches, in spontaneously hypertensive rats 
(Innes et al., 1998) and two inbred normotensive rat strains (Sebkhi et al., 1999), respectively. 
Moreover a murine model of HCM, designated α-MHC403/+ as it represents the human MYH7 
R403Q causal mutation, allowed for breeding of the mutation into different mice strains, that is its 
introduction into different genetic backgrounds. Strain-dependent hypertrophic responses were 
observed in mice kept under the same conditions, thereby indicating a role for genetic modifiers that 
differed with the genetic background. Similar genetic loci, equivalent to the aforementioned QTLs 
identified in animal studies, may influence cardiac hypertrophy in humans (Semsarian et al., 2001). 
1.2.4 Candidate genetic modifiers  
Efforts aimed at identifying candidate modifier genes need to consider what is currently known 
regarding the pathogenesis of the cardiac phenotype in HCM. Although only partially elucidated, 
the latter is suggested to be multifaceted, including the primary disease-causing stimulus stemming 
from the diverse causal mutations and the resulting activation of signalling cascades that mediate 
the hypertrophic response (Kaludercic et al., 2009;Alcalai et al., 2008;Reviewed by Marian, 2010).  
This is evident from a switch on-switch off bigenic mouse model that demonstrated induction and 
subsequent reversal of cardiac phenotypes of HCM as consequence of switching on and off, 
respectively, expression of a mutant transgene, Troponin T (TnT)-Q92, known to cause human 
HCM (Lutucuta et al., 2004;Marian, 2009). The relevant cardiac phenotypes included interstitial 
fibrosis, enhanced cardiac systolic function, as well as increased expression of signalling kinases 
and pro-collagen genes. The same group further targeted various signalling pathways related to the 
cardiac hypertrophic response in animal models (Lombardi et al., 2009;Marian et al., 2006;Patel et 
al., 2001;Senthil et al., 2005;Tsybouleva et al., 2004;Marian, 2009). These included efforts directed 
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at oxidative stress known to contribute to cardiac hypertrophy and fibrosis (Takimoto & Kass, 
2007) and the development of HCM (Lombardi et al., 2009;Marian et al., 2006) via the 
administration of the antioxidant N-acetylcysteine (NAC) in two transgenic animal models of 
human HCM, namely β-MyHC-Q403 rabbits and cardiac troponin T (cTNT)-Q92 mice. The NAC 
treatment, which increases glutathione, an endogenous thiol that acts as intracellular defence against 
oxidative stress, reversed cardiac hypertrophy and fibrosis, whilst preventing left ventricular 
systolic dysfunction in these animal models.  
Indeed, current opinion regarding the pathogenesis and treatment of cardiac hypertrophy in HCM 
suggests that the underlying molecular mechanisms are partially distinct, as the varying functional 
effects of the causal mutations (Refer to Section 1.2.1) give rise to diverse primary disease-causing 
stimuli that are suggested to be altered contractility, structure, myocardial energetics, and/or 
calcium (Ca2+) homeostasis. However, the eventual HCM phenotype is similar, comprising cardiac 
hypertrophy, thereby indicating that these different stimuli eventually activate common mechanisms 
pertaining to the cardiac hypertrophic response. Accordingly, the proposed targets for treatment of 
cardiac hypertrophy in HCM include the molecular mechanisms relevant to the initial stimulus or 
cardiac hypertrophic growth (Alcalai et al., 2008;Ashrafian et al., 2011;Reviewed by Marian, 
2010). It stands to reason that as the aforementioned factors contribute to the development of 
cardiac hypertrophy in HCM, they can likewise be considered as candidate modifier genes, 
influencing the severity of the cardiac hypertrophy phenotype.  
To date, it has mainly been components of pathways involved in the control of blood pressure 
(peptide hormones), for example, the components of the renin-angiotensin aldosterone system 
(RAAS), and other trophic factors such as endothelin-1 and tumor necrosis factor-α (TNF-α) that 
have been investigated as hypertrophy modifiers in HCM based on their functions relating to 
cardiac growth and remodelling (Marian, 2002;Patel et al., 2000;Alcalai et al., 2008;Friedrich et al., 
2009;Marian, 2002;Nabel, 2003). However, replication studies in this field are few, and the few that 
have been reported have yielded inconsistent results (Marian, 2002;Nabel, 2003). Furthermore, it is 
important to note that these factors are relatively separated from the primary stimulus for cardiac 
hypertrophy. Arguably, the factors that closely interact with the primary stimulus have a greater 
capacity to modulate this stimulus, and ultimately the cardiac hypertrophic phenotype in HCM. 
That is to say, as the primary stimulus for hypertrophy arises from faulty sarcomeric functioning, 
factors that either improve or further weaken the structure or function of the sarcomere, including 
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sarcomere and sarcomere-associated proteins, and the enzymes that supply the sarcomere with the 
fuel it requires, should thus be considered as plausible candidate modifiers.  
The aforementioned is supported by findings that gene dosage or the presence of multiple functional 
sarcomeric variants (compound and double heterozygotes), estimated to occur in 3–6% (Girolami et 
al., 2010) of mutation positive individuals, are associated with a more severe disease expression and 
increased incidence of SCD (Reviewed by Keren et al., 2008;Ingles et al., 2005;Mohiddin et al., 
2003;Lekanne Deprez et al., 2006;Richard et al., 1999;Ho et al., 2000). Similarly, more severe 
clinical phenotypes have been described in rare reports of triple mutations and homozygosity of 
causal mutations (Ho et al., 2000;Girolami et al., 2010;Scheffold et al., 2011). The impact of 
additional sarcomeric variants on the hypertrophic phenotype will be discussed further in Section 
1.2.4.1. 
It is, therefore, important to consider the key factors that influence sarcomeric functioning together 
with the consequences of sarcomere gene mutations. An overview of these factors is given in the 
following section. 
The sarcomere is the fundamental contractile unit in cardiac muscle (Refer to Figure 1.2). It is 
comprised of actin and myosin, the major constituents of the thin and thick filaments, respectively. 
They interact to produce contractile force; as a result of this, they slide over each other and 
ultimately give rise to muscle contraction (Reviewed by Harvey & Leinwand, 2011). This 
interaction, and thus contraction, is influenced by numerous factors, including adenosine-5'-
triphosphate (ATP)-mediated conformational changes in myosin, Ca2+-dependent changes in the 
spatial configuration of the trimeric troponin (Tn) complex, which indirectly determines the 
availability of the myosin binding site on actin, as well as additional sarcomeric proteins, which 
function in the assembly and integrity of the sarcomere as well as regulation of contraction 
(Seidman & Seidman, 2001;Flashman et al., 2004;Reviewed by Chapelle, 1999).  
HCM-causing mutations are mainly dominant-negative, in effect giving rise to ‘poison peptides’, 
i.e. incorporation of proteins with aberrant function into the sarcomere, affecting the function of the 
contractile unit. A further proposed consequence of at least some causal mutations is 
haploinsufficiency, which entails the reduced integration of functional protein into the sarcomere. 
More importantly, the causal mutations alter key biophysical properties of the contractile proteins, 
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including their Ca2+-sensitivity, ATPase activity and maximal force production. For example, the 
R403Q mutant myosin isolated from HCM model mice exhibited increased actin-activated ATPase 
activity, actin filament sliding velocity and force production (Ho, 2010b;Palmiter et al., 2000;Tyska 
et al., 2000). Conversely, functional studies of mutant TnT indicated reduced actin-activated 
ATPase activity and force production (Mukherjea et al., 1999). It has been suggested that these 
diverse defects give rise to energy deficiency and altered Ca2+-handling as the primary stimulus for 
the development of the cardiac hypertrophy phenotype in HCM (Konno et al., 2010;Ashrafian et 
al., 2011). Collectively, the aforementioned highlight the importance of the structural integrity of 
the proteins of the sarcomere, Ca2+-handling and myocardial energetics in normal sarcomeric 
functioning as well as in the development of the cardiac hypertrophy phenotype in HCM.  
Thus, it can be hypothesised that amongst other possible candidate LVH-modifying genes, genes 
involved in sarcomere integrity and contractility or its regulation, or myocardial energetics at the 
sarcomere, are certainly plausible as modifiers of cardiac hypertrophy in HCM. The following 
sections will investigate the proof of principle for this hypothesis.  
1.2.4.1 Sarcomeric modifiers  
To recap, HCM-causing mutations mainly compromise the integrity of sarcomeric proteins and 
factors in proximity, both physical and functional, to this primary defect, i.e. additional sarcomeric 
variants, have a greater potential to modify the outcome of the primary functional defect, owing to 
the complex interrelations of the sarcomeric protein components. This notion is supported by 
studies detailing the phenotypic consequence of multiple functional sarcomeric gene variants.  
As previously mentioned, individuals homozygous, double heterozygous or compound 
heterozygous for sarcomeric gene variants are often more severely affected in terms of hypertrophy, 
and at greater risk of death, than individuals who are heterozygous for single causal mutations 
(Richard et al., 1999;Ingles et al., 2005;Keren et al., 2008;Lekanne Deprez et al., 2006;Mohiddin et 
al., 2003;Tsoutsman et al., 2008a;Ho et al., 2000). Ho et al. (2000) reported on the S179FTNNT2 
mutation, which, when present in the heterozygous state, is associated with a benign HCM 
phenotype. In contrast, homozygosity for the mutation was associated with striking biventricular 
hypertrophy and juvenile lethality. Individuals double heterozygous for HCM-causing mutations 
(E483KMYH7/E1096*MYBPC3) were first described by Richard et al. (1999). These authors noted 
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marked left ventricular hypertrophy in these patients relative to single heterozygous mutation 
carriers (mIVST of 30.5 ± 3.5 mm vs. 19.5 ± 2.1 mm; p < 0.05). Similarly, Ingles et al. (2005) 
found that individuals compound heterozygous for causal mutations (D745GMYBPC3/P873HMYBPC3, 
E542QMYBPC3/A851VMYBPC3, or R326QMYBPC3/Q1233*MYBPC3) showed significantly larger LVWT 
compared to patients heterozygous for a single mutation (LVWT of 30.7 ± 3.1 mm vs. 24.4 ± 7.4; p 
< 0.05). Moreover, SCD events occurred more frequently in patients from multiple-mutation 
families than in affected members from single-mutation families (6/14 (43%) vs. 10/55 (18%); p = 
0.05).  
Studies of transgenic animal models mirror these effects, as homozygotes and double heterozygotes 
proved less viable or more severely affected than heterozygotes (Fatkin et al., 1999;Berul et al., 
2001;Tsoutsman et al., 2008a). The α-MHC403/403 mouse model, representing homozygosity for the 
HCM-causing R403WMYH7 mutation identified in humans, showed neonatal onset of the phenotype, 
characterised by decreased LVWT, reduced systolic contraction, progression to dilated 
cardiomyopathy (DCM), and ultimately 100% mortality by postnatal day eight (Fatkin et al., 
1999;Debold et al., 2007). Similarly, double-mutant mice heterozygous for both the aforementioned 
mutation and the G203STNNI3 mutation exhibited neonatal onset of phenotype, eventual DCM, and 
100% mortality albeit by age 21 days (Tsoutsman et al., 2008b). However, a less severe phenotype 
is seen in mice heterozygous for the mutation (α-MHC403/+), with a relatively later onset at 30 
weeks, a normal life span and typical HCM characteristics, including left ventricular hypertrophy, 
myocyte disarray and fibrosis (Tsoutsman et al., 2008a;Berul et al., 2001).   
Specific attention should be given to additional variants present in the same gene as the primary 
sarcomeric HCM-causing mutation (Hershberger, 2010). A cis-acting variant tightly linked to the 
latter (within the same gene) is more likely to cosegregate with the disease-allele and consistently 
impact on the HCM phenotype (Blair et al., 2001a). As previously hypothesised, factors that closely 
interact with the primary stimulus have a greater capacity to influence it (Refer to Section 1.2.4). 
Variants in cis with the primary mutation are deemed closest; a striking example of their capacity to 
influence the primary trigger is the development of one of two distinct diseases caused by the same 
primary mutation (D179N) in the prion protein gene (PRNP). The eventual phenotype is dictated by 
a common polymorphism on the same allele (codon 129), with the presence of Met or Val resulting 
in the development of fatal familial insomnia (FFI) or Creutzfeldt-Jakob disease (CJD), respectively 
(Genin et al., 2008;Goldfarb et al., 1992). Furthermore, this study emphasizes the importance of 
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investigating variants present on the non-mutated allele, i.e. variants in trans relative to the primary 
mutation. The FFI disease severity varies according to the state of the codon 129 polymorphism. 
The homozygous Met/Met129 genotype is associated with a shorter disease course and thalamic 
hypometabolism, whereas the heterozygous Met/Val129 state is met with increased disease duration 
and more widespread brain hypometabolism (Tabernero et al., 2000;Montagna et al., 2003).  
Finally, trans-acting variants may give rise to more severe phenotypes, as these can completely 
abolish the normal functioning of the relevant protein (Demo et al., 2009). An example is the 
association of a high-risk HCM phenotype with the compound genotype of R719WMYH7 and 
M349TMYH7. Where these mutations were present in trans, the patient had no normal myosin, 
resulting in a severe phenotype characterised by cardiac arrest at age 6 and a half years. 
Interestingly, M349TMYH7, characterised as a recessive mutation due to its absence from 130 control 
individuals, was not sufficient to cause disease on its own, but exacerbated the phenotype normally 
associated with the R719WMYH7 mutation. The latter is typically associated with a severe 
hypertrophy phenotype and a high incidence of SCD in young adults. These findings thus suggest 
that the disease phenotype may reflect effects of a trans allele, which would otherwise be tolerated 
in the presence of normal protein, but of which the effect is amplified in the absence of normal 
protein (Jeschke et al., 1998).  
A further aspect to consider is that cis-acting variants are believed to regulate mRNA expression, 
thereby contributing to inter-individual phenotypic variability, including risk of developing disease. 
Similarly, these cis-variants and the resulting variation in allelic expression may modify disease 
severity particularly in combination with a causal mutation (Jentarra et al., 2011;Southam et al., 
2007;Bray et al., 2003). Tuberous sclerosis complex (TSC) disorder is characterised by phenotypic 
heterogeneity, even amongst individuals from the same pedigree who carry an identical causal 
mutation (Lyczkowski et al., 2007;Jentarra et al., 2011), which is reminiscent of the situation in 
HCM. It is an autosomal dominant disease; affected individuals are therefore heterozygous 
mutation carriers with one mutated and one non-mutated allele (van Slegtenhorst et al., 1997). 
Jentarra et al. (2011) aimed to elucidate the factors underlying the phenotypic variability and 
hypothesised that the expression of the two alleles relative to each other may modify the disease 
phenotype. For example, high expression of the mutant protein perhaps due to a cis-acting variant 
may exacerbate the severity of the disease phenotype. Conversely, high levels of expression of the 
non-mutated allele as a result of a variant in trans relative to the causal mutation, that is a variant on 
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the normal allele, may ameliorate the effects of the mutant protein. Considering that HCM shares 
many of these aspects, it could similarly be hypothesised that cis- or trans-acting variants that 
influence mRNA expression may modulate the HCM hypertrophy phenotype.  
Moreover, the premise that a second variant may ameliorate the effects of the causal mutation is 
supported by investigations in Drosophila (Kronert et al., 1999;Prado et al., 1995;Naimi et al., 
2001). Flies exhibiting a raised wing phenotype as a consequence of the held-up2 (hdp2) missense 
mutation in the Troponin I (wupA) gene were mutagenized to induce suppressor mutants. A second 
mutation in the Troponin I (TnI) gene rescued the structural and functional defects linked to the 
hdp2 phenotype, as muscle carrying both mutations showed near normal myofibrillar structure, as 
compared to the hdp2-only muscle, which is characterised by shortened and supercontracted 
sarcomere and the absence of a defined M-band (Prado et al., 1995). Similarly, Naimi et al. (2001) 
characterised a mutation in the Tropomyosin-2 (Tm2) gene that completely suppresses the hdp2 
phenotype. These findings evidenced a functional link between distinct sarcomeric gene mutations, 
where an alteration in one sarcomeric protein could suppress the effect of a mutation in another or 
the same sarcomeric gene, thus acting as a modifier of sarcomeric function. Intriguingly, Wei et al. 
(2010) reported that two dominant-negative mutations in the TnI and TnT genes (R111C and an 
abnormal splicing variant, respectively), individually implicated in the development of DCM in 
wild turkeys, could rescue cardiac function when present in combination in a transgenic mouse 
model (Biesiadecki et al., 2004;Wei et al., 2010;Biesiadecki & Jin, 2002).  
Most importantly, the literature includes reports of sarcomeric variants that by themselves do not 
cause disease, but, when present in combination with an HCM-causing mutation, influence disease 
severity. The first example of this is the afore-described M349TMYH7 mutation not found to be 
associated with HCM when present alone. However, compound heterozygosity of M349TMYH7 and 
R719WMYH7 is characterised by a more severe HCM phenotype than that typically associated with 
the R719WMYH7 mutation (Jeschke et al., 1998;Wang et al., 2005). A further study identified the 
A/G18443 polymorphism in the MYBPC3 gene, and consequently revealed an association between 
the GG-genotype and increased LVWT (25.2 ± 5.9 mm) in HCM patients. The genotype 
frequencies were similar in the patient and control groups, thereby suggesting that the 
polymorphism is a modifier variant rather than a causal mutation (Wang et al., 2005). Therefore, it 
seems plausible that variations in sarcomeric genes, and possibly even those that appear to be non-
pathogenic in themselves, can contribute to the phenotypic expression of the causal mutation, not 
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only causing exacerbation of the phenotype, but, in some cases, also completely or partially 
suppressing the phenotype. 
However, not only factors that are physically “close”, but also those that are functionally “close” to 
the causal mutation may plausibly be more likely to affect the phenotype. This implies that factors 
that relate to the pathoetiological mechanism, viz., the effect of the causal mutation, may be 
plausible modifiers. In HCM, this includes factors involved in sarcomeric and myocytic energetics. 
1.2.4.2 Energy modifiers 
Cardiac function demands a high and continuous supply of energy (Lopaschuk et al., 2010). Altered 
cardiac energy metabolism has been linked to numerous disease states, including cardiac 
hypertrophy. Whether compensatory or maladaptive, it is clear that such alterations play a role in 
modulating disease development (Huss & Kelly, 2005;Ussher & Lopaschuk, 2006). As previously 
postulated, this study aimed to evaluate the contribution of sarcomere and sarcomere-associated 
genes as disease modifiers, as these arguably have a greater potential to influence the primary 
stimulus, which is disrupted sarcomere integrity (Refer to Section 1.2.4). Genes related to 
myocardial energetics form part of this category of candidates, as there is evidence for the binding 
of, for example, glycolytic enzymes to numerous regions of the sarcomere (Kraft et al., 2000;Offer 
et al., 1988;Ashby et al., 1979;Freydina et al., 1986). Furthermore, myosin ATPase is the main 
consumer of ATP in the cardiac myocyte and the disruption thereof, in keeping with the central 
hypothesis, would directly compromise the activity of key sarcomeric proteins and hence 
sarcomeric integrity (Cambronero et al., 2009). It is therefore necessary to consider the relevant 
energy metabolic pathways; a brief description of myocardial energetics and accompanying figures 
are provided in the following section: 
1.2.4.2.1 Overview of myocardial energetics 
In the adult heart, β-oxidation of fatty acids is the predominant source of fuel responsible for up to 
95% of ATP-production, whereas carbohydrate substrate utilisation, comprising mainly glucose 
breakdown via glycolysis, accounts for an estimated 5% thereof (Scolletta & Biagioli, 
2010;McDonagh et al., 2011) (Refer to Figure 1.3). Other substrates, including lactate, amino acids 
and ketone bodies, can be oxidised under specialised conditions (McDonagh et al., 2011;Kodde et 
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al., 2007). The initial step of lipid metabolism is the facilitated transport of long chain fatty acids 
(LCFAs) across the plasma membrane (PM) by means of the fatty acid translocase transmembrane 
protein (FAT/CD36), in combination with the plasma membrane LCFA-binding protein. Once in 
the cytoplasm, LCFAs are converted to their active form, LCFA-coenzyme A (LCFA-CoA), and 
transported across the outer and inner mitochondrial membranes (OMM and IMM) by carnitine 
palmitoyl transferase I and II (CPT1 and CPT2), respectively. Thereafter, LCFA-CoA undergoes 
stepwise degradation by the β-oxidation pathway to form acetyl-CoA (Luiken et al., 
2009;McDonagh et al., 2011).  
However, glucose can also be used as an energy source in heart muscle. Glucose metabolism entails 
firstly the transport of glucose across the plasma membrane via glucose transporter family members 
1 and 4 (GLUT1 and GLUT4) (Scolletta & Biagioli, 2010;Schwenk et al., 2008). Next, glucose 
enters the glycolytic pathway, where it is oxidized to pyruvate. The latter is transported into the 
mitochondria, where it undergoes further oxidation by the pyruvate dehydrogenase (PDH) complex 
to form acetyl-CoA (Patel & Roche, 1990;Schwenk et al., 2008). 
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Figure 1.3 Pathways involved in myocardial energetics. Fatty acid and glucose oxidation are the principal 
ATP-generating pathways (Adapted from McDonagh et al., 2011). 
Both fatty acid- and glucose-derived acetyl-CoA condenses with oxaloacetate to form citrate, 
thereby entering the tricarboxylic acid (TCA) cycle (Refer to Figure 1.4). The cycle is characterised 
by a series of biochemical reactions that degrade the acetyl-CoA entering the cycle into its carbon, 
hydrogen and electron components. The first is released as carbon dioxide (CO2), whilst the 
remainder reduce the hydrogen-carrier molecules nicotinamide adenine dinucleotide (NAD+) and 
flavin adenine dinucleotide (FAD),
 
generating NADH and FADH2, respectively. 
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Figure 1.4 Reactions of the tricarboxylic acid cycle. The pathway oxidises the acetyl group of acetyl-CoA, 
resulting in formation of CO2 and reduction of the electron transporting coenzymes NAD+ and FAD (Taken 
from Da Poian et al., 2010). 
The reduced molecules subsequently enter the electron transport chain that is characterised as the 
primary site of ATP synthesis. More specifically, the high-energy electrons are extracted from 
NADH and FADH and passed down a series of electron-carrier molecules, with the energy released 
used to transport hydrogen ions from the mitochondrial matrix to the intermembrane space. This 
gives rise to both a pH gradient and a potential difference across the IMM that encourages the flow 
of hydrogen ions (H+) back into the matrix. The resulting movement activates the ATP synthase 
enzyme responsible for the formation of ATP from adenosine diphosphate (ADP) + Pi. The 
progressive transfer of electrons concludes with oxygen (O2) as the ultimate acceptor; the process 
is, therefore, known as oxidative phosphorylation (Refer to Figure 1.5) (McDonagh et al., 
2011;Huss & Kelly, 2005;Sherwood, 2004). 
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Figure 1.5 The electron transport chain and oxidative phosphorylation. The transfer of high-energy 
electrons via the electron transport chain releases energy that drives ATP synthesis (Taken from 
http://www.biologycorner.com/APbiology/cellular/notes_cellular_respiration.html). 
ATP transfer to the site of energy consumption at the myofibrils is achieved by means of either 
direct channelling or via the creatine kinase (CK) energy shuttle (Refer to Figure 1.6). Firstly, the 
high-energy phosphate of mitochondrial ATP is transferred to creatine (Cr) to form phosphocreatine 
(PCr) and ADP, in a reaction catalysed by mitochondrial creatine kinase (MtCK). Next, PCr 
diffuses to the myofibrils, where myofibrillar/muscle-type creatine kinase (MM-CK) catalyses the 
reverse reaction, thereby regenerating ATP for muscle contraction. Moreover, the creatine kinase 
system is an essential energy buffer that maintains normal ATP levels under various conditions, 
including during times of rapid ATP utilisation (stressed conditions) (Scolletta & Biagioli, 
2010;Bessman & Geiger, 1981;Gabr et al., 2011;McDonagh et al., 2011;Wilding et al., 2006).  
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PCr + ADP + H+ ↔ Cr + ATP 
 
Figure 1.6 The creatine kinase (CK) shuttle. Creatine kinase contributes to myocardial energy homeostasis 
by acting as an intracellular energy shuttle that transfers high-energy phosphates from the mitochondria to 
the myofibrils, thereby coupling cellular sites of ATP production and those of ATP utilisation (Adapted from 
Gabr et al., 2011). 
1.2.4.2.2 Energy genes as candidate modifiers 
Support for the hypothesised role of energy compromise in the development of hypertrophy 
includes the disrupted myocardial energetics observed in diseases phenotypically similar to HCM, 
inefficient ATP usage as consequence of sarcomeric mutations, and the decreased PCr/ATP ratio 
and metabolic remodelling observed in HCM patients (Ashrafian et al., 2011;Jung et al., 1998;Ho, 
2010b;Blair et al., 2001b).  
For example, Friedreich ataxia is characterised by an HCM-like phenotype and is caused by the 
reduced expression of the mitochondrial protein frataxin due to a GAA repeat expansion in the 
FRDA gene. Results from an in vivo study indicated not only a consequential decrease in skeletal 
muscle mitochondrial ATP production but an inverse correlation thereof with the number of GAA 
repeats. Collectively these findings suggest that such metabolic defects may contribute to HCM 
development (Puccio & Koenig, 2000;Lodi et al., 1999). Similarly, mutations in mitochondrial 
transfer RNA (tRNA) genes have shown association with syndromes phenotypically 
indistinguishable from HCM. Reports include a point mutation in the mitochondrial tRNAglycine 
gene (T-to-C transition at nucleotide 9997), where the authors noted a resulting decrease in ATP 
synthesis and a relationship between the degree of mutant mitochondrial DNA (mtDNA) and the 
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severity of symptoms. These findings propose that mitochondrial defects, and consequential 
disrupted energy homeostasis, could contribute to HCM, and, given the phenomenon of 
heteroplasmy, account for the phenotypic variability observed even amongst family members 
(Merante et al., 1994).  
The notion is supported by findings of impaired mitochondrial function and organization in HCM 
studies of both patients and mouse models. Observations included, amongst others, relatively fewer 
mitochondria in direct contact with myofibrils, as well as larger mitochondria with disorganised 
cristae, noted upon electron microscopic analysis of ventricular specimens taken from HCM 
patients. The authors speculated that the altered localisation may decrease the efficiency with which 
ATP produced in the mitochondria reaches the myofibrillar sites of energy consumption (Unno et 
al., 2009;Lucas et al., 2003). The equivalent was observed in an HCM animal model, as 
ultrastructural characterisation of TnI-203/MHC-403 mice hearts revealed altered distribution of 
mitochondria between myofibrils (Tsoutsman et al., 2008b).  
Likewise, defects in genes encoding proteins key to myocardial energetics give rise to an HCM-like 
phenotype (Cambronero et al., 2009). For instance, these include impaired myocardial LCFA fatty 
acid uptake, due to CD36-deficiency, and glycogen accumulation, due to mutations in PRKAG2, 
which encodes the gamma 2 regulatory subunit of AMP-activated protein kinase (AMPK), a sensor 
and regulator of energy homeostasis (Refer to section 1.2.1) (Scheffold et al., 2011;Okamoto et al., 
1998;Hardie & Carling, 1997).  
Further motivation for the proposed role of energy genes as candidate modifiers is that the 
numerous HCM-causing sarcomeric mutations do not exhibit unified effects on the force-generating 
capabilities and/or the calcium-sensitivity of the sarcomere, as they seemingly give rise to either 
hyper- or hypocontractility (Refer to section 1.2.4) (Luedde et al., 2009;Redwood et al., 
1999;Reviewed by Bonne et al., 1998;Blair et al., 2001b). Rather, myocardial energy deficiency, 
resulting from inefficient or excessive ATP utilisation, has been proposed as the abnormality 
common to the diverse HCM-causing mutations (Ashrafian et al., 2003;Ashrafian et al., 
2003;Crilley et al., 2003;Ferrantini et al., 2009;Blair et al., 2001b). The contractile reserve and 
energy required for homeostatic function, such as Ca2+ re-uptake, is consequently compromised, 
resulting in hypertrophy (Ashrafian et al., 2003;Javadpour et al., 2003).  
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Studies of HCM mouse models bearing either the R92Q mutation in the cTnT gene or the R403Q 
mutation in the murine α-myosin heavy chain (αMyHC) gene, serve as key examples as they are 
believed to give rise to hypercontractility and hypocontractility, respectively, but ultimately show 
myocardial energy deficiency. Investigations of the first model yielded findings indicating reduced 
free energy of ATP hydrolysis (∆G
~ATP), resulting from decreased [PCr], increased inorganic 
phosphate [Pi] and [ADP], as well as normal total creatine, and an inability to support increased 
contractile performance upon inotropic challenge. The authors speculated that these observations 
could be attributed to increased ATP consumption, either by the myofibrillar ATPase or by the 
sarcoplasmic reticulum Ca2+-ATPase (SERCA), or to decreased ATP synthesis. Having considered 
additional findings from the literature, as well as their own experimental data, Javadpour et al. 
(2003) concluded that the mutation alters the TM-actin interaction, and thereby crossbridge cycling, 
which ultimately increases myofibrillar ATP consumption. For example, the authors noted that 
R92Q and non-transgenic (NTG) hearts did not differ significantly upon comparison of their 
SERCA mRNA levels or their ATP-generating capacity (Javadpour et al., 2003;Tardiff et al., 
1999).  
Similarly, the R403Q mouse model showed decreased [PCr] and increased [Pi], with a resulting 
decrease in ∆G
~ATP (Javadpour et al., 2003;Spindler et al., 1998). Ferrantini et al. (2009) proposed 
that the decrease in the latter may prove sufficient to compromise SERCA function and Ca2+ 
reuptake into the sarcoplasmic reticulum (SR) and that, as consequence, increased Ca2+ 
concentrations within select microdomains would activate signalling pathways that mediate 
hypertrophy. The R403Q mutation is proposed to increase the cost of contraction, as mutant myosin 
heads create a drag on wild-type crossbridges, which may precipitate the aforementioned alterations 
in cardiac energetics (Spindler et al., 1998;He et al., 2007;Crilley et al., 2003).  
Most noteworthy is that neither of the two aforementioned mutations is located close to the myosin 
ATP-hydrolysis region, yet they give rise to increased ATP utilisation, which highlights the 
contribution of structural alterations to disrupted myocardial energetics (Javadpour et al., 2003).  
In addition, a muscle LIM protein (MLP)-null mouse model of HCM exhibited cytoarchitectural 
perturbation, which included disorganized myofibrils and looser integration of mitochondria 
relative to the SR and myofibrils (Wilding et al., 2006). The study compared SR calcium uptake in 
myofibres from MLP-null mice and controls, whilst varying the method whereby ATP required for 
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the process was transferred from the mitochondria to the SR calcium pump, i.e. via CK-mediated 
transport or via mitochondrial direct ATP channelling. Calcium uptake was similar amongst mutant 
and wild type fibres when the energy was delivered by means of CK transport and 36% lower when 
provided by the mitochondria directly, despite normal mitochondrial content and oxidative capacity. 
Congruent with the foregoing, these findings link structural defects to altered energy transfer and 
compromised myocardial energetics.  
Furthermore, numerous HCM-causing mutations that augment Ca2+-sensitivity, also exhibit a 
resulting increase in energy consumption (Wu et al., 2012;Ho, 2010b). More specifically, Wu et al. 
(2012) simulated the ATP consumption rates of such cardiac troponin I (cTnI) mutants (G203S, 
K206Q, R162W, ∆K183, R145Q and R145G) and wild type fibres at the level of contraction, 
SERCA and the Na+, K+-ATPase, and concluded that the higher energy consumption is specifically 
due to the increased demands of contraction.  
The contribution of compromised myocardial energetics is further evident from 31P magnetic 
resonance spectroscopy (MRS) studies of HCM patients, as reflected by their significantly 
decreased PCr/ATP ratios. More importantly, clinically unaffected mutation carriers similarly 
exhibit decreased PCr/ATP ratios, suggesting that disrupted myocardial energetics is primary to 
hypertrophic growth (Luedde et al., 2009;Ho, 2010b;Jung et al., 1998). Parallel to these findings, 
Jung et al. (1998) observed a shift in energy substrate utilisation from fatty acid to glucose 
metabolism in asymptomatic HCM patients. The altered myocardial metabolism is proposed to be 
beneficial, as glucose metabolism produces more ATP at a lower oxygen cost relative to fatty acid 
utilisation (Horowitz et al., 2010;Tuunanen et al., 2006). In keeping with these observations, 
treatment of HCM patients with perhexiline, an inhibitor of the LCFA transporters CPT-1/2, 
corrected energy deficiency and improved exercise capacity (Ashrafian et al., 2011;Abozguia et al., 
2010). Similarly, results from the previously mentioned Wu et al. (2012) simulations indicated 
~40% lower fatty acid oxidation (FAO) in cTnI-mutant groups compared to wild type during high-
energy-requirement conditions.  
In contrast, the upregulation of metabolic genes linked to fatty acid metabolism was observed in a 
transgenic rat model of HCM characterised by the overexpression of a truncated cTnT (Luedde et 
al., 2009). Upregulation was proposed to be compensatory and was identified in the absence of 
altered left ventricular function and morphology, again suggesting that changes in myocardial 
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energetics is primary in HCM development, rather than being the result of hypertrophy. The 
metabolic measurements of HCM patients who harbour the D175TPM1 mutation showed increased 
myocardial FFA and oxidative metabolism (Tuunanen et al., 2007). Moreover, a spontaneously 
hypertensive rat (SHR) model, characterised by CD36-deficiency, indicated that diet 
supplementation with short-chain fatty acids (SCFA), the uptake of which is CD36-independent, 
eliminated cardiac hypertrophy. The results linked defective fatty acid uptake, and by implication 
CD36, to cardiac hypertrophy, leading the authors to suggest a role for SCFA supplementation in 
human hypertrophic cardiomyopathy (Hajri et al., 2001). Finally, acute FFA withdrawal in 
cardiomyopathic HF patients depressed cardiac work and efficiency. The failing heart seemingly 
requires both glucose and fatty acid oxidation for optimal function (Tuunanen et al., 2006).  
Although contradictory, these findings irrefutably implicate altered myocardial energetics in the 
pathogenesis of HCM and suggest that modulation of cardiac energetics should not aim to shift 
metabolism towards either glucose or fatty acid utilisation, but should rather focus on improving the 
metabolic adaptability of the heart (Kolwicz, Jr. & Tian, 2009).  
In summary, the energy compromise hypothesis suggests that the HCM phenotype arises from 
decreased ATP synthesis (e.g. mitochondrial mutations), inefficient ATP utilisation (e.g. increased 
myofibrillar demand) or altered energy sensing (AMPK mutations) (Watkins et al., 2011). It is 
probable that such energy-related factors may also act to modify the HCM phenotype, as motivated 
by the recent screening of a 2-year-old-boy who presented with severe HCM. Genetic analysis 
revealed two HCM-causing mutations in the MYBPC3 gene (R326Q and Q1233X), and a third in 
the PRKAG2 gene (P83S). The triple mutation status was further detected in his symptomatic 
mother, whilst only the two MYBPC3 mutations and the PRKAG2 mutation alone was identified in 
his 10-year-old unaffected brother and his 13-year-old-brother exhibiting left ventricular 
hypertrophy in the absence of clinical symptoms, respectively. The PRKAG2 mutation, although not 
a modifier per se, as it is suspected to cause glycogen storage disease (GSD), augmented the 
severity of the HCM phenotype, whilst showing variable expression in the 2-year-old-boy and his 
mother (Scheffold et al., 2011). 
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1.3 The present study 
The present study forms part of a larger investigation aimed at identifying genetic factors that 
modulate the development of hypertrophy in 27 South African HCM families of either Caucasian or 
Mixed Ancestry descent in which one of three unique HCM-causing founder mutations, namely 
R92WTNNT2, R403WMYH7 and A797TMYH7, segregates. Based on the preceding literature review, it is 
evident that factors pertaining to sarcomere integrity and contractility, as well as factors pertaining 
to myocardial energetics are plausible modifiers of cardiac hypertrophy in HCM. The current study 
thus aimed to evaluate the contributions of sarcomeric genes, encoding proteins involved most 
directly in the control of the crossbridge cycling, of which many have themselves been implicated 
as primary HCM-causing genes, as well as genes encoding enzymes and proteins involved in 
energy metabolism, in the modulation of LVH in this South African HCM cohort. A total of 26 
candidate genes (Refer to sections 2.3.1 and 2.3.3) were selected from the literature based on their 
functions either as structural proteins constituting the functional part of the sarcomere, or as 
metabolic proteins relating to myocardial energetics. Medium-high-throughput genotyping was 
achieved using ABI TaqMan® SNP Validated genotyping assays. Quantitative indices of 
hypertrophy, including various wall thickness measurements and LVM, were then tested for 
association with multiple single polymorphisms within any given candidate gene, as well as genetic 
haplotypes, by means of family-based statistical analysis, independent of HCM-causing founder 
mutation and known covariates of hypertrophy. 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
28│Chapter 2 
CHAPTER TWO 
MATERIALS AND METHODS 
2.1 Study participants 
The current research project (N04/03/062) received ethical clearance by the University of 
Stellenbosch Health Sciences Faculty’s Institutional Review Committee that adheres to the 
principles of the Declaration of Helsinki. All study participants gave written informed consent 
permitting blood sample collection, DNA extraction and molecular genetic testing. 
A panel of South African HCM probands, from either Caucasian or Mixed Ancestry descent, was 
previously screened for HCM-causing mutations in 11 sarcomeric genes. This lead to the 
identification of 27 probands bearing one of three mutations previously characterised by Moolman-
Smook et al. (1999) as South African HCM-founder mutations, namely R403W in MYH7 
(MYH7R403W), A797T in MYH7 (MYH7A797T) and R92W in TNNT2 (TNNT2R92W). Pedigree tracing 
was performed, consenting relatives older than 18 years were entered into the modifier gene study 
and their carrier-status determined for each of the founder mutations. 
At the time of this modifier gene study the founder-mutation familial cohort thus consisted of 388 
genetically and clinically affected and unaffected individuals from 27 South African HCM families 
(Refer to Table 2.1) of self-reported Caucasian or Mixed Ancestry descent.  
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Table 2.1 Composition of the study population of the South African HCM-families  
Pedigree 
number Ethnic group Gene Mutation 
N 
Mutation carriers Non-carriers 
100 Mixed Ancestry TNNT2 R92W 16 30 
103 Mixed Ancestry TNNT2 R92W 2 3 
109 Mixed Ancestry TNNT2 R92W 6 4 
139 Mixed Ancestry TNNT2 R92W 15 22 
137 Mixed Ancestry TNNT2 R92W 2 5 
149 Mixed Ancestry TNNT2 R92W 4 6 
173 Mixed Ancestry TNNT2 R92W 2 1 
179 Mixed Ancestry TNNT2 R92W 5 4 
188 Mixed Ancestry TNNT2 R92W 3 1 
106 Mixed Ancestry MYH7 R403W 29 35 
134 Mixed Ancestry MYH7 R403W 4 7 
157 Mixed Ancestry MYH7 R403W 1 3 
101 Caucasian MYH7 A797T 12 9 
104 Mixed Ancestry MYH7 A797T 7 7 
123 Mixed Ancestry MYH7 A797T 6 10 
124 Caucasian MYH7 A797T 1 4 
131 Caucasian MYH7 A797T 12 11 
138 Caucasian MYH7 A797T 13 17 
145 Mixed Ancestry MYH7 A797T 3 2 
147 Mixed Ancestry MYH7 A797T 4 5 
158 Caucasian MYH7 A797T 2 3 
159 Mixed Ancestry MYH7 A797T 5 7 
163 Caucasian MYH7 A797T 6 3 
172 Caucasian MYH7 A797T 7 10 
177 Caucasian MYH7 A797T 3 1 
180 Caucasian MYH7 A797T 4 1 
190 Caucasian MYH7 A797T 2 1 
Abbreviations: A-Alanine; MYH7-myosin heavy chain gene 7; N-per-family number of individuals screened for 
variants in the present study, including mutation-carriers and non-carriers; R-Arginine; T-Threonine; TNNT2-troponin 
T gene 2, cardiac; W-Tryptophan 
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2.1.2 Clinical evaluation  
Study individuals 18 years and older were clinically characterised by a single experienced 
cardiologist, Dr Miriam Revera (Pavia University, Italy), who performed the echocardiographic 
evaluations whilst being blinded to participant mutation status. The echocardiographic data included 
recordings in M-mode, two dimensional (2D) and Doppler blood-flow imaging acquired by a 2.5 
Hertz (Hz) transducer in standard parasternal long- and short-axis orientation and apical four-
chamber and two-chamber views; these were visualised with a GE Healthcare Vivid7 
cardiovascular ultrasound system.   
The segmental analysis of the left ventricle (LV) wall entailed acquisition of 2D-echocardiographic 
measurements at three levels of the heart muscle, namely, mitral valve-, papillary muscle- and 
supra-apex levels (see Figure 2.1). A total of 16 segments were assessed, of which six, the anterior 
interventricular septum (aIVS), posterior interventricular septum (pIVS), anterior wall (AW), lateral 
wall (LW), inferior wall (IW) and posterior wall (PW), were captured at both the mitral valve and 
papillary muscle levels. The remaining four measurements, viz., the IVS, AW, LW and PW 
segments, were acquired at supra-apex level as derived from four-chamber view (see Figure 2.2). 
This analysis allowed for calculation of maximal left ventricular wall thickness (mLVWT), 
maximal interventricular septum thickness (mIVST) and maximal posterior wall thickness 
(mPWT), simply defined as the largest of the relevant quantifications. All measurements were taken 
as per the recommendations of the American Society of Echocardiography 
(http://www.asecho.org/quidelines.php). In addition, atrium volumes were measured using the 
biplane area-length method (Schiller et al., 1989). Table 2.2 lists the echocardiography-derived 
indices of the extent and distribution of the cardiac hypertrophy phenotype. 
Subject demographics, including medical history and covariates of cardiac structure namely age, 
sex, body surface area (BSA), heart rate (HR), systolic BP (SBP), diastolic BP (DBP), were 
documented. Sitting blood pressure was measured twice following 5 min of rest, and the second 
measurement recorded. Participants were considered to be hypertensive if using anti-hypertensive 
medication or by documented measurement of systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm 
Hg. Resting heart rate was evaluated from standard electrocardiography performed with a 
MAC1200ST, recorded in the supine position, and following 5 min of rest.  
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Figure 2.1 Graphic representation of the left ventricle indicating the three levels of the heart muscle at 
which the wall thickness measurements were taken. (A) Long-axis view of the left ventricle, with the 
three blue dotted lines indicating the three levels of the heart at which the echocardiographic parameters 
were measured i.e. the mitral valve-, papillary muscle- and apex level. (B) A 2D echocardiogram of the left 
ventricle. Abbreviations: AV- aortic valve, LA-left atrium, LV-left ventricle, LVOT-left ventricular outflow 
tract, MV- mitral valve, RVOT-right ventricular outflow tract. (Taken from 
http://www.med.yale.edu/.../aortic_regurgitation.html with minor modifications by JC Moolman-Smook) 
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Figure 2.2 Diagrammatic representation of the left ventricle segments assessed by echocardiography 
Short-axis view of the six segments measured at the papillary and mitral valve levels, whilst the apex level is 
characterised by division into only four segments with the exclusion of the anterior- and posterior 
interventricular septum (Brink P, personal communication). 
In addition, other hypertrophy indices were derived from the abovementioned measures, namely 
LVM, the cumulative wall thickness (CWT) score and the first principal component score (PC1). 
Calculation of LVM was done according to the American Society of Echocardiography’s 
recommended formula for estimation of LVM from 2D-LV linear dimensions: 
LVM (g) = 0.8 x (1.04 x [(LVIDd + PWTd + SWTd)3 − (LVIDd)3]) + 0.6 g 
g, gram; LVIDd, left ventricular internal dimension at end-diastole; PWTd, posterior wall thickness 
at end-diastole; SWTd, intraventricular septum thickness at end-diastole 
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LVM index (either to height or to BSA) was not calculated as adjustments were made for BSA by 
incorporating it into the statistical model. The CWT score was obtained by summing the thicknesses 
of the 16 quantified LV wall segments. Principal component analysis (PCA) (Refer to Section 
2.6.3) was used to derive PC1, a composite score or weighted sum of the 16 wall thickness 
measurements that best reflected the ventricle-wide hypertrophy and so the variability in LVH in 
the present HCM cohort as it explained 75% of the variation in the 16 wall thickness measurements. 
Table 2.2 Echocardiographically derived hypertrophy traits used to characterise the extent 
and distribution of the cardiac hypertrophy 
Level Hypertrophy trait Description 
Mitral valve level mLVWTmit maximal left ventricular wall thickness at the mitral valve 
 
mIVSTmit maximal interventricular septum thickness at the mitral valve 
 
pIVSmit posterior interventricular septum  thickness at the mitral valve 
 
aIVSmit anterior interventricular septum  thickness at the mitral valve 
 
AWmit anterior wall thickness at the mitral valve 
 
LWmit lateral wall thickness at the mitral valve 
 
IWmit inferior wall thickness at the mitral valve 
 
PWmit posterior wall thickness at the mitral valve 
Papillary level mLVWTpap maximal left ventricular wall thickness at the papillary level 
 
mIVSTpap maximal interventricular septum thickness at the papillary level 
 
pIVSpap posterior interventricular septum  thickness at the papillary level 
 
aIVSpap anterior interventricular septum  thickness at the papillary level 
 
AWpap anterior wall thickness at the papillary level 
 
LWpap lateral wall thickness at the papillary level 
 
IWpap inferior wall thickness at the papillary level 
 
PWpap posterior wall thickness at the papillary level 
Apex level mLVWTapx maximal left ventricular wall thickness at the supra-apex level 
 
IVSapx interventricular septum thickness at the supra-apex level 
 
AWapx anterior wall thickness at the supra-apex level 
 
LWapx lateral wall thickness at the supra-apex level 
 
PWapx posterior wall thickness at the supra-apex level 
Overall LVM left ventricular mass 
 
mIVST maximal interventricular septum thickness 
 
mLVWT maximal left ventricular wall thickness 
 
mPWT maximal posterior wall thickness 
Composite scores CWTscore cumulative wall thickness score 
 
PC1 principal component score 1 
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2.2 Blood sample collection and DNA extraction 
A total of three blood samples were obtained from each participant, which included collection in         
2× 5 ml ethylene-diamine-tetra-acetic acid (EDTA) tubes (Vacutainer, RSA) to allow for DNA 
extraction and a single 10 ml heparin tube (Vacutainer, RSA) for establishment of permanent 
lymphoblastoid cell lines. Blood samples obtained from patients at other centres in South Africa 
were couriered to the research laboratory within 24 hours post collection.  
DNA extraction from nucleated cells was achieved by applying minor modifications to the method 
previously described by Corfield et al. (1993) whilst immortalised cell line establishment relied on 
the method detailed by Neitzel (1986) (Corfield et al., 1993;Neitzel, 1986). The aforementioned 
techniques and the subsequent cell maintenance was performed by Mrs I le Roux (Refer to 
Appendix I for DNA extraction solutions). 
2.3 Bioinformatics 
2.3.1 Candidate gene selection 
The role of genes linked to sarcomere integrity and contractility as well as myocardial energetics as 
plausible modifiers of hypertrophy in HCM has been hypothesised in Chapter 1. A comprehensive 
literature search utilising the Pubmed database (http://www.pubmed.gov) thus focused on genes 
encoding cardiac proteins relating to sarcomere structure and function as well as energy 
metabolism. The search terms utilised included ‘hypertrophic cardiomyopathy’, ‘sarcomere’, 
‘energy’, ‘metabolism’, ‘structure’ and ‘genes’. Table 2.3 lists the 26 candidate modifier genes 
selected from the literature and their relevant details (Refer to Section 2.3.3 for detailed 
gene/protein descriptions).  
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Table 2.3 Candidate modifier genes selected for investigation  
Gene 
symbol Gene 
Exon 
total 
Size 
(kb) Protein function 
Sarcomeric candidate modifier genes 
Thin filament components 
ACTC1 Actin, alpha, cardiac muscle 1 7 7.63 Essential constituent of the cytoskeleton thin 
filament; Crossbridge formation with myosin to 
generate force 
TNNT2 Troponin T type 2, cardiac 16 18.66 Structural constituent of the cytoskeleton thin 
filament; Tropomyosin-binding subunit of the Tn 
complex thereby contributing to Ca2+-sensitive 
regulation of contraction 
TNNI3 Troponin I type 3, cardiac 8 5.91 Structural constituent of the cytoskeleton thin 
filament; inhibits actomyosin ATPase via the 
binding of actin; component of the Tn complex 
thereby contributing to Ca2+-sensitive regulation 
of contraction 
TPM1 Tropomyosin 1, alpha 10 23.45 Structural constituent of cytoskeleton thin 
filament; 
Actin-binding subunit of the Tn complex thereby 
contributing to Ca2+-sensitive regulation of 
contraction and both stabilisation and stiffening 
of thin filament 
ACTN3 Actinin, alpha 3 21 16.40 Structural constituent of the cytoskeleton thin 
filament; Anchors myofibrillar actin filaments; 
linking of sarcomere to muscle fibre membrane; 
binding of metabolic enzymes 
Thick filament components 
MYL3 Myosin light chain 3, alkali, 
ventricular, skeletal, slow 
7 5.62 Structural constituent of cytoskeleton thin 
filament; Stabilises α-helical myosin neck region; 
regulation of contraction 
MYH7 Myosin heavy chain 7, cardiac 
muscle, beta 
40 22.92 Principal component of the cytoskeleton thick 
filament; Essential for muscle contraction via its 
roles in actin and ATP binding and ATP 
hydrolysis  
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Gene 
symbol Gene 
Exon 
total 
Size 
(kb) Protein function 
MYL2 Myosin light chain 2, regulatory 
cardiac, slow 
7 9.73 Structural constituent of the cytoskeleton thick 
filament; 
Stabilises α-helical myosin neck region; 
Modulatory role in tuning the kinetics of the 
actin-myosin interaction 
Intermediate filament component 
MYBPC3 Myosin binding protein C, 
cardiac 
33 21.27 Structural constituent of the cytoskeleton 
intermediate filament that functions in sarcomere 
stability and phosphorylation-dependent 
modulation of contractility 
Energy metabolism candidate modifier genes 
Fatty acid metabolism components 
CD36 
 
CD36 antigen (FAT) 15 38.40 Membrane responsible for uptake of LCFAs 
across sarcolemma membrane 
CPT1B Carnitine palmitoyltransferase 
1B, muscle 
19 9.60 Essential for the transport of LCFA across the 
outer membrane of mitochondria for β-oxidation 
of FAs 
PPARA Peroxisome proliferator-
activated receptor alpha 
10 72.42 Receptor that regulates genes involved in lipid 
metabolism 
PPARG Peroxisome proliferator-
activated receptor gamma 
7 82.85 Receptor that regulates genes involved in lipid 
metabolism 
PGC1A Peroxisome proliferator-
activated receptor gamma, 
coactivator 1 alpha 
13 98.10 A transcriptional coactivator for PPARs involved 
in fatty acid metabolism; central in mitochondrial 
biogenesis  
Glucose metabolism components 
ALDOA Aldolase A, fructose-
bisphosphate 
14 17.24 Functions as enzyme in the glycolytic pathway 
PFKM Phosphofructokinase, muscle 22 23.34 Enzyme that catalysing the rate-limiting step in 
glycolysis 
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Gene 
symbol Gene 
Exon 
total 
Size 
(kb) Protein function 
PDK4 
 
Pyruvate dehydrogenase kinase, 
isozyme 4 
11 13.11  The PDH complex links glycolysis and FA 
metabolism by converting pyruvate to acetyl-
CoA. The enzyme encoded by PDK4 regulates 
the PDH complex thereby influencing choice of 
substrate used under various physiological 
conditions 
Creatine kinase energy shuttle components 
CKM Creatine kinase, muscle 8 16.46 Structural constituent of the cytoskeleton (m-
bridges); Contributes to myocardial energetics by 
catalysing the reversible transfer of high-energy 
phosphates between creatine and ATP, ultimately 
coupling sites of ATP production and utilisation 
CKB Creatine kinase, brain 8 3.17 Contributes to myocardial energetics by 
catalysing the reversible transfer of high-energy 
phosphates between creatine and ATP, ultimately 
coupling sites of ATP production and utilisation  
Cellular energy homeostasis 
PRKAA1 Protein kinase, AMP-activated, 
alpha 1 catalytic subunit 
10 38.82 Catalytic subunit of the AMPK energy-sensing 
enzyme that monitors cellular energy status 
PRKAA2 
 
Protein kinase, AMP-activated, 
alpha 2 catalytic subunit 
9 63.10 Catalytic subunit of the AMPK energy-sensing 
enzyme that monitors cellular energy status 
PRKAB1 Protein kinase, AMP-activated, 
beta 1 non-catalytic subunit 
7 13.67 Regulatory subunit of the AMPK energy-sensing 
enzyme that monitors cellular energy status 
PRKAB2 Protein kinase, AMP-activated, 
beta 2 non-catalytic subunit 
8 17.44 Regulatory subunit of the AMPK energy-sensing 
enzyme that monitors cellular energy status 
PRKAG1 Protein kinase, AMP-activated, 
gamma 1 non-catalytic subunit 
12 16.54 Regulatory subunit of the AMPK energy-sensing 
enzyme that monitors cellular energy status 
PRKAG2 Protein kinase, AMP-activated 
gamma 2 non-catalytic subunit 
16 321.1
1 
Regulatory subunit of the AMPK energy-sensing 
enzyme that monitors cellular energy status 
PRKAG3 Protein kinase, AMP-activated, 
gamma 3 non-catalytic subunit 
14 9.41 Regulatory subunit of the AMPK energy-sensing 
enzyme that monitors cellular energy status 
Abbreviations: α-alpha; β-beta; AMP-Adenosine monophosphate; AMPK-AMP-activated protein kinase; ATP-
Adenosine-5'-triphosphate; Ca2+-calcium; FA-fatty acid; kb-kilobases; LCFAs-long chain fatty acids; PPARs-
peroxisome proliferator-activated receptors; Tn-troponin complex 
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2.3.2 SNP Selection 
SNPs spanning each of the identified candidate genes were selected by means of the SNPbrowserTM 
Software v 4.0.1 (De La Vega et al., 2006) to allow for association testing. The software visually 
depicts SNP location and density throughout the relevant genes by utilising the embedded database 
containing genotype data from four Haplotype Map (HapMap) project populations to construct 
physical or linkage disequilibrium (LD) maps based on kb or LD Unit (LDU) distances, 
respectively. The HapMap populations consist of 30 trios of YRI (Yoruba in Ibadan, Nigeria), 45 
unrelated samples of JPT (Japanese in Tokyo, Japan), 45 unrelated samples of CHB (Han Chinese 
in Beijing, China) and 30 CEPH (Centre d’Etude du Polymorphisme Humain) collected CEU trios 
(Utah residents with ancestry from northern and western Europe). 
An LDU is an additive metric measurement representative of the genetic map distance between 
SNPs based on the extent of allelic association between them (Maniatis et al., 2002), e.g., SNPs in 
complete LD have zero map distance between them, compared to SNPs with no significant 
correlation that are separated by over three map LDUs (De La Vega et al., 2006). SNPbrowser™ 
employs the LDMAP program to construct metric LD (LDU) maps (Kuo et al., 2007), analogous to 
the genetic map expressed in centi-Morgans (cM), which positions SNPs on a coordinate system as 
resource for population-based association study design (Collins et al., 2004). 
The criteria for SNP selection in the present study were 0.5 LDU even spacing in the HapMap CEU 
and YRI populations and ABI TaqMan® SNP Validated genotyping assay availability; SNPs 
meeting these criteria were identified using the default parameters of the software (De La Vega, 
2007). Previous association studies from our own laboratory show that the LD structure of the CEU 
and YRI populations best represent the, as yet undefined, LD structure of the South African 
population and thereby the current study cohort (Swanepoel, 2010, PhD;Uys, 2010, PhD;Carstens, 
2009, MSc). Genome-wide genotyping data has indicated that South African individuals with 
mixed ancestry also contain admixture from Asian populations (including CHB and JPT), although 
to a minor extent (de Wit et al., 2010). Table 2.4 details the SNPs selected for this study whilst 
Figures 2.3 through 2.29 (except Figure 2.12) graphically depict their physical locations within the 
candidate genes. 
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Table 2.4 Details of the SNPs selected for genotyping 
Candidate 
gene Chromosome locus SNP ID 
Chromosome 
position (bp) 
Nucleotide 
change 
ABI Taqman 
assay ID 
Sarcomeric candidate modifier genes 
Thin filament components 
ACTC1 15q11–q14 rs1370154 35082225 C/T C___2088343_10 
 
 rs2070664 35085201 C/T C__15867651_10 
TNNT2 1q32 rs2365652 201331664 A/C C____473120_10 
 
 rs1892028 201336641 A/G C____469074_10 
 
 rs947485 201345352 A/G C__11621865_10 
TNNI3 19q13.4 rs3729841 55665410 C/T C__27509020_10 
 
 rs3729838 55668310 C/G C__27472594_10 
 
 rs11667847 55668819 A/G C___2829707_10 
TPM1 15q22 rs11071720 63341996 C/T C____493909_10 
 
 rs4238370 63347363 G/T C____102224_10 
 
 rs1071646 63351840 A/C C___9644173_10 
 
 rs707602 63363737 C/T C___1455653_10 
ACTN3 11q13–q14 rs1791690 66317823 G/A C__3109120_10 
 
 rs2275998 66326581 C/T C__15880288_10 
 
 rs1815739 66328095 T/C C___590093_1_ 
Thick filament components 
MYL3 3p21.3–p21.2 rs1531136 46901654 C/T C___9698374_10 
 
 rs3792558 46903094 C/T C__27517244_10 
MYH7 14q12 rs765019 23883848 C/T C___3083715_10 
 
 rs2277475 23888665 A/T C___1843584_1_ 
 
 rs1951154 23897466 A/G C__11436423_10 
 
 rs2754163 23897507 C/T C___1839847_10 
 
 rs2239578 23903380 A/G C___1839842_1_ 
MYL2 12q23–q24.3 rs933296 111352848 A/C C__11489722_10 
 
 rs4766517 111359712 C/G C__27944102_10 
Intermediate filament component 
MYBPC3 11p11.2 rs4752825 47352409 A/G C___1301098_10 
 
 rs1052373 47354787 C/T C___8890616_10 
 
 rs10838696 47363285 A/G C___1301015_10 
 
 rs11570058 47369443 A/G C__25654298_10 
Energy metabolism candidate modifier genes 
Fatty acid metabolism components 
CD36 7q11.2 rs10268417 80239837 A/C C__29938396_10 
 
 rs3211892 80290369 A/G C__25644352_10 
 
 rs3173804 80299850 A/T C___1803772_10 
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Candidate 
gene Chromosome locus SNP ID 
Chromosome 
position (bp) 
Nucleotide 
change 
ABI Taqman 
assay ID 
CPT1B 22q13.33 rs470117 51009953 T/C C___2531739_1_ 
 
 rs1557502 51013998 T/C C___2531734_1_ 
PPARA 22q13.31 rs881740 46567388 A/G C__26334975_20 
 
 rs4823613 46598307 A/G C___2985275_10 
 
 rs4253776 46629479 A/G C___2985253_1_ 
PPARG 3p25 rs12631028 12341406 C/T C___9384466_10 
 
 rs12490265 12384542 A/G C___1129874_10 
 
 rs2938392 12434608 A/G C__11908952_10 
 
 rs1175540 12465243 A/C C___8756549_10 
PGC1A 4p15.1 rs768695 23798818 A/G C___1643185_10 
 
 rs4619879 23834876 A/C C___1643198_10 
 
 rs11724368 23862933 A/T C___1643210_10 
 
 rs13131226 23874981 C/T C___1643226_20 
Glucose metabolism components 
ALDOA 16q22–q24 rs9928448 30072530 T/C C__26725629_10 
 
 rs11860935 30080780 T/C C__3234225_10 
PFKM 12q13.3 rs1859445 48518591 A/C C__11477997_10 
 
 rs10875749 48531917 A/T C___2626552_10 
PDK4 7q21.3 rs2073978 95215272 C/T C___2535297_1_ 
 
 rs2301630 95221269 C/T C__15756512_10 
Creatine kinase energy shuttle components 
CKM 19q13.2q13.3 rs8111989 45809208 C/T C___3145002_10 
 
 rs7260463 45814860 G/T C___3145006_10 
 
 rs1133190 45818835 A/G C__15757328_10 
 
 rs344816 45825626 A/T C____958453_10 
CKB 14q32 rs1803283 103986255 C/T C___1292617_20 
 
 rs2071407 103987140 C/T C__15868868_10 
 
 rs1136165 103988180 G/T C___8901441_10 
Cellular energy homeostasis 
PRKAA1 5p12 rs12517210 40764440 C/T C__30750962_10 
 
 rs11747210 40774673 G/T C__26082115_10 
 
 rs466108 40796746 A/C C___3280925_10 
PRKAA2 1p31 rs1124900 57112222 G/T C__26467839_10 
 
 rs2796495 57142979 C/T C__16120204_10 
 
 rs932447 57170229 C/T C___9583690_1_ 
PRKAB1 12q24.1 rs6490267 120106376 G/T C____348015_10 
 
 rs278143 120109014 A/G C____339921_10 
 
 rs10849690 120114205 C/G C__11751875_10 
 
 rs278149 120114507 G/T C___2258897_10 
 
 rs4213 120119183 G/T C___3259867_10 
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Candidate 
gene Chromosome locus SNP ID 
Chromosome 
position (bp) 
Nucleotide 
change 
ABI Taqman 
assay ID 
PRKAB2 1q21.1 rs6937 146626922 T/C C___1745071_20 
 
 rs1348316 146643555 G/A C___8719009_30 
PRKAG1 12q12–q14 rs10875910 49402393 C/G C___9260196_10 
 
 rs2117029 49408440 A/T C___2023779_10 
PRKAG2 7q36.1 rs8961 151254175 C/T C___2667965_1_ 
 
 rs2727537 151373046 A/G C__16284061_10 
 
 rs6464170 151476860 C/G C__29193665_10 
 
 rs13240743 151566914 C/G C__31459975_10 
PRKAG3 2q35 rs1000935 219691495 G/T C___8841107_10 
 
 rs16859382 219693856 C/T C__32733031_10 
Abbreviations: A-adenine; ABI-Applied Biosystems Incorporated; ACTC1-Actin, alpha, cardiac muscle 1; ACTN3-
Actinin, alpha 3; ALDOA-Aldolase A, fructose-bisphosphate; bp-base pairs; C-cytosine; CD36-CD36 antigen, 
thrombospondin receptor; CKB-Creatine kinase, brain; CKM-Creatine kinase, muscle; CTP1B- Carnitine 
palmitoyltransferase 1B, muscle; G-guanine; MYBPC3-Myosin binding protein C, cardiac; MYH7-Mysoin heavy chain 
7, cardiac muscle, beta; MYL2-Myosin light chain 2, regulatory cardiac, slow; MYL3-Myosin light chain 3, alkali, 
ventricular, skeletal slow; p-short arm of chromosome; PDK4-Pyruvate dehydrogenase kinase, isozyme 4; PFKM-
Phosphofructokinase, muscle; SNP-single nucleotide polymorphism; T-thymine; TNNI3-Troponin I type 3, cardiac; 
TNNT2-Troponin T type 2, cardiac; TPM1-Tropomyosin 1; PPARA-Peroxisome proliferator-activated receptor alpha; 
PPARG-Peroxisome proliferator-activated receptor gamma; PGC1A-Peroxisome proliferator-activated receptor 
gamma, coactivator 1 alpha; PRKAA1-Protein kinase, AMP-activated, alpha 1 catalytic subunit; PRKAA2-Protein 
kinase, AMP-activated, alpha 2 catalytic subunit; PRKAB1-Protein kinase, AMP-activated, beta 1 non-catalytic 
subunit; PRKAB2-Protein kinase, AMP-activated, beta 2 non-catalytic subunit; PRKAG1-Protein kinase, AMP-
activated, gamma 1 non-catalytic subunit; PRKAG2-Protein kinase, AMP-activated gamma 2 non-catalytic subunit; 
PRKAG3-Protein kinase, AMP-activated, gamma 3 non-catalytic subunit; q-long arm of chromosome 
 
2.3.3 Detailed candidate gene descriptions and graphic SNP positioning  
2.3.3.1 Sarcomeric candidate modifier genes  
i) α-Actin 
Cardiac α-actin, encoded by ACTC1, is the predominant actin isoform in the adult heart where it 
functions in cytoskeletal integrity and muscle contraction. Through polymerisation, the monomeric 
protein (globular actin or G-actin) gives rise to fibres with a double-helical structure, F-actin, which 
is the principal component of the thin filament. The monomer is further divided into subdomains, of 
which the first allows for the binding and subsequent activation of the myosin head and motor 
function. This myosin-actin interaction is a key step in the crossbridge cycle that allows for the 
sliding of thin filaments past the thick filaments, and thus, ultimately, for muscle contraction 
(Bertola et al., 2008;dos Remedios et al., 2003;Laing & Nowak, 2005). 
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Figure 2.3 The genomic structure of ACTC1 and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. The upstream and 
downstream regions of the gene are indicated in red. 
ii) Myosin 
Myosin is the principal component of the thick filament and its functions, viz., actin-binding and 
ATP-binding and -hydrolysis, are essential for muscle contraction. The known cardiac isoforms, α-
MHC and β-MHC, encoded by MYH6 and MYH7 respectively, show tissue-specific expression, i.e. 
α-MHC is expressed predominantly in the human atrium and β-MHC in the human ventricle 
(Dalloz et al., 2001). 
 
Figure 2.4 The genomic structure of MYH7 and the physical locations of SNPs selected throughout this 
gene. Exons and introns are denoted by green and blue boxes, respectively. The two HCM-causing MYH7 
mutations which segregate in the current cohort as founder mutations are indicated in red.  
iii) The Troponin (Tn) complex 
The Troponin complex, consisting of three protein subunits, namely TnT, Troponin C (TnC) and 
TnI, is responsible for the Ca2+-dependent regulation of contraction (force and velocity), which is 
achieved by modulating the functional interaction between actin and myosin. The complex 
undergoes a spatial change in configuration in response to Ca2+-binding, pulling the tropomyosin 
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away from the myosin binding site on the actin filament. This allows the myosin heads to interact 
with actin for crossbridge formation and subsequent muscle contraction (Reviewed by Chapelle, 
1999). 
a) Troponin T 
Troponin T is the tropomyosin-binding subunit of the Tn complex; however its functions extend to 
actin-binding and regulation of actomyosin ATPase activity (Reviewed by Filatov et al., 1999). A 
total of 4 cardiac isoforms, created via alternative splicing of the TNNT2 gene, have been reported 
in the mammalian heart, designated cTNT1-cTNT4 (Dalloz et al., 2001;Anderson et al., 1995;Zot 
& Potter, 1987). 
 
Figure 2.5 The genomic structure of TNNT2 and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. The HCM-causing TNNT2 
mutation which segregates in the current cohort as a founder mutation is indicated in red. The physical 
location of the insertion/deletion polymorphism for which the cohort was previously screened is shown in 
purple.  
b) Troponin I 
The chief function of Troponin I is the inhibition of actomyosin ATPase activity via the binding of 
actin. It also interacts with the other Tn complex components; the location of their binding sites 
allows for the transfer of a conformational signal, induced by Ca2+-binding to TNC, through TNI, to 
TNT and tropomyosin. In addition, these various interactions are modulated by phosphorylation of 
TNI by protein kinases, i.e. protein kinase A (PKA), protein kinase G (PKG) and protein kinase C 
(PKC). The cardiac TNI isoform is encoded by the TNNI3 gene (Dalloz et al., 2001;Reviewed by 
Filatov et al., 1999). 
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Figure 2.6 The genomic structure of TNNI3 and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively.  
iv) α-Tropomyosin 
Striated muscle α-TM, generated from the alternative splicing of TPM1, is the main isoform in 
cardiac muscle. It is an actin-binding protein of dual function, as it stabilises and stiffens the thin 
filament, in addition to regulating muscle contraction via its association with the Tn complex 
(Weigt et al., 1990;Dalloz et al., 2001). Moreover, Ca2+-binding to the Tn complex results in the 
repositioning of TM on actin, thereby exposing the myosin crossbridge-binding sites on actin and 
allowing for muscle contraction (Jagatheesan et al., 2009;Gunning et al., 2008). 
 
Figure 2.7 The genomic structure of TPM1 and the physical locations of SNPs selected throughout this 
gene. Exons and introns are denoted by green and blue boxes, respectively.  
v) The myosin light chains 
The essential (ELC) and regulatory (RLC) myosin light chains bind to the regulatory region of the 
myosin head where they stabilise and affect the rigidity of the long alpha-helical neck of the 
myosin. The RLC also undergoes phosphorylation, thought to regulate contractility (Dalloz et al., 
2001;Poetter et al., 1996). Moreover, the RLC modulates the position of crossbridges relative to the 
actin filament, in a myosin light chain kinase (MLCK) phosphorylation-mediated manner, affecting 
the likelihood of crossbridge-binding and thus contraction. ELC interactions with the thin filament 
Stellenbosch University  http://scholar.sun.ac.za
  
45│Chapter 2 
have been reported, which may limit crossbridge cycling and shortening velocity, adding another 
layer of regulation of contractility. Cardiac ELC and RLC are encoded by MYL3 and MYL2, 
respectively (Colson et al., 2010;Harris et al., 2011;Taylor et al., 2004;Schaub et al., 1998).  
 
Figure 2.8 The genomic structure of MYL2 and the physical locations of SNPs selected throughout this 
gene. Exons and introns are denoted by green and blue boxes, respectively. The upstream and downstream 
regions of the gene are indicated in red. 
 
Figure 2.9 The genomic structure of MYL3 and the physical locations of SNPs selected throughout this 
gene. Exons and introns are denoted by green and blue boxes, respectively. 
vi) Myosin binding protein C 
MYBPC3 encodes cardiac myosin-binding protein-C (c-MyBP-C), which functions in sarcomere 
stability and modulation of contraction (Carrier et al., 1997). The protein has been suggested to 
stabilise the thick filament structure via its interactions with the thick filament backbone and/or 
titin. In addition, c-MyBP-C phosphorylation via PKA increases the proximity of crossbridges to 
actin, thereby influencing both the speed and strength of contraction. In addition, it can reversibly 
bind to actin, suggesting a further means of modulating contraction (Colson et al., 2010;Furst et al., 
1992;Labeit et al., 1992;Moss et al., 1983;Zoghbi et al., 2008;Harris et al., 2011). 
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Figure 2.10 The genomic structure of MYBPC3 and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. The upstream and 
downstream regions of the gene are indicated in red. The physical location of the 25 bp deletion for which 
the cohort was screened is shown in purple.  
vii) α-Actinin-3 
The ACTN3 gene encodes α-actinin-3, the expression of which, according to the bulk of the 
literature, is limited to skeletal muscle (North & Beggs, 1996). This is however contradicted by the 
presence of validated ACTN3 transcripts in heart muscle (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=ACTN3&search=actn3). The functions of α-actinins in skeletal muscle, as 
main components of the Z-line, relate to structure, metabolism and signalling, and may provide 
insight into the relevance of α-actinin-3 in cardiac muscle. The α-actinins interact with numerous 
structural proteins to ensure cytoskeletal integrity, e.g., anchoring and stabilising actin filaments 
from adjacent sarcomeres, as well as linking of sarcomeres to the muscle fibre membrane via 
dystrophin (Squire, 1997;Hance et al., 1999). They also bind metabolic enzymes, including aldolase 
and fructose-1,6-biphosphatase, at the Z-line, possibly ensuring local energy availability (Macarthur 
& North, 2004;Rakus et al., 2003).  
 
Figure 2.11 The genomic structure of ACTN3 and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
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2.3.3.2 Energy metabolism candidate modifier genes 
 
Figure 2.12 Diagram of the candidate genes relating to myocardial energetics. The illustration has been 
compiled from and summarises the succeeding overview of those candidate genes that function in 
myocardial energetics. 
i) Fatty acid translocase 
The FAT/CD36 gene encodes an ubiquitously expressed, ditopic glycosylated membrane protein 
responsible for the uptake of LCFAs across the sarcolemmal membrane (Aras & Dilsizian, 
2007;Harmon & Abumrad, 1993;Luiken et al., 2003). Research has established a link between the 
reduced expression of CD36 and the development of an HCM-like phenotype (Cambronero et al., 
2009;Luedde et al., 2009;Okamoto et al., 1998;Soor et al., 2009).  
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Figure 2.13 The genomic structure of CD36 and the physical locations of SNPs selected throughout this 
gene. Exons and introns are denoted by green and blue boxes, respectively. 
ii) Carnitine palmitoyltransferase I 
Carnitine palmitoyltransferase is essential for the transport of LCFAs across the outer membrane of 
mitochondria for β-oxidation; this translocation is the rate-limiting step in this energy-generating 
process. The muscle isoform, CPT-1b, encoded by CPT1B, is predominantly expressed in the heart 
(Yamazaki et al., 1996;Yamazaki et al., 1996;McGarry & Brown, 1997).  
 
Figure 2.14 The genomic structure of CPT1B and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
iii) Pyruvate dehydrogenase kinase 
The PDH complex converts pyruvate to acetyl-CoA for subsequent ATP generation via the 
mitochondrial Krebs cycle, linking glycolysis and fatty acid metabolism, and thus influencing the 
choice of substrate used under various physiological conditions (Houten et al., 2009;Randle, 
1986;Patel & Roche, 1990;Patel & Roche, 1990). Its activity is regulated by pyruvate 
dehydrogenase kinase (PDK) enzymes, of which isoenzyme 4, encoded by PDK4, is predominantly 
expressed in skeletal and cardiac muscle (Roche et al., 2001;Bowker-Kinley et al., 1998).  
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Figure 2.15 The genomic structure of PDK4 and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
iv) Creatine kinase 
Creatine kinase contributes to myocardial energy homeostasis by catalysing the reversible transfer 
of high-energy phosphates between creatine and ATP, ultimately coupling cellular sites of ATP 
production and ATP utilisation. The CKM and CKB genes encode the M-CK and B-CK subunits, 
respectively, which in turn combine to form the three cytosolic isoforms: brain-type (BB-CK), 
sarcomeric muscle type (MM-CK) and the combined isoform  (MB-CK); all of these are expressed 
in the heart, although MB-CK is the predominant cardiac isoform (Au, 2004;Nahrendorf et al., 
2005;Hornemann et al., 2000). A small fraction (~5–10%) of the muscle-specific isoform is known 
to bind to the sarcomeric M-line, suggesting not only an extension from its cytosolic enzyme 
function to that of an intramyofibrillar ATP regenerator at the site of high-energy demand, but also 
that it plays a structural role within the sarcomere, at the M-line (m-bridges) (Clark et al., 
2002;Hornemann et al., 2000).  
 
Figure 2.16 The genomic structure of CKM and the physical locations of SNPs selected throughout this 
gene. Exons and introns are denoted by green and blue boxes, respectively. The upstream and downstream 
regions of the gene are indicated in red. 
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Figure 2.17 The genomic structure of CKB and the physical locations of SNPs selected throughout this 
gene. Exons and introns are denoted by green and blue boxes, respectively. 
v) Aldolase A 
Aldolases function in the glycolytic pathway by catalysing the reversible cleavage of fructose 1,6-
bisphosphate to dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate (G3P). 
Aldolase A, encoded by the ALDOA gene, is the predominant isoform in the heart, colocalising with 
fructose 1,6-bisphosphatase (FBPase) in the cytoplasm, including in the Z-line and the intercalated 
discs, and in the nucleus of cardiomyocytes (Mamczur et al., 2007;Asaka et al., 1983;Koeck et al., 
2004;Medin et al., 2007;Rutter, 1964). 
 
Figure 2.18 The genomic structure of ALDOA and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
vi) Phosphofructo-1-kinase 
Phosphofructo-1-kinase catalyses the rate-limiting step in glycolysis, converting fructose-6-
phosphate to fructose-1,6-bisphosphate (Swoboda et al., 1997). The muscle type is the predominant 
isoenzyme in the heart, and mutations in its encoding gene, PFKM, have been associated with type 
VII GSD (GSDVII) (Dunaway et al., 1988a;Tarui et al., 1965).  
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Figure 2.19 The genomic structure of PFKM and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
vii) Peroxisome proliferator-activated receptors (PPARs) 
PPARs are nuclear lipid-activated receptors that regulate numerous genes essential for lipid 
metabolism (Feige et al., 2006;Reviewed by Desvergne & Wahli, 1999).  
a) Peroxisome proliferator-activated receptor alpha  
PPARα is highly expressed in the heart where it regulates the transcriptional expression of various 
components of lipid and glucose metabolic pathways, including FA transport protein 1 (FATP1), 
FAT/CD36, CPT1b, PDK4, long chain acyl-CoA synthetase (LACS) and malonyl-CoA 
decarboxylase (MCD) (Reviewed by Rowe et al., 2010;Reviewed by Yang & Li, 2007).  
 
Figure 2.20 The genomic structure of PPARA and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
b) Peroxisome proliferator-activated receptor gamma  
Expression of the PPARγ isoform extends to cardiac tissue where it has been detected in the aorta, 
coronary arteries and left ventricles of healthy heart donors (Mehrabi et al., 2002). A recent study 
by Luo et al. 2010 aimed to characterise the function of PPARγ in the heart. The researchers 
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commented that the ligand binding profiles of the PPARs partially overlap which suggests that 
PPARγ may have cardiac functions similar to those of PPARα. Moreover, using a cardiomyocyte-
restricted PPARγ knockout mouse model, they established that it plays an essential role in fatty acid 
metabolism in the adult heart and so myocardial energetics and cardiac function. The PPARγ 
deficient hearts showed decreased levels of proteins essential for fatty acid uptake and oxidation 
which included CD36 and CPT-1. In addition, the PPARγ deficient hearts exhibited decreased fatty 
acid utilization and cardiac contraction. Most importantly, the deficient hearts showed a modest 
degree of cardiac hypertrophy relative to control hearts (Luo et al., 2010).  
 
Figure 2.21 The genomic structure of PPARG and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
viii) Peroxisome proliferator-activated receptor gamma coactivator-1α 
PCG-1α is abundantly expressed in the heart where it acts as coactivator for PPARα, allowing for 
initiation of target gene transcription (Finck, 2007). It similarly coactivates PPARγ in brown 
adipose tissue and may do the same in cardiomyocytes (Rowe et al., 2010;Puigserver et al., 
1998;Young et al., 2001). Moreover, PCG-1α is central to mitochondrial biogenesis in the heart, 
indirectly regulating mitochondrial transcription factor A (MTF-A).  
 
Figure 2.22 The genomic structure of PGC1A and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
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ix) AMP-activated protein kinase  
The mammalian AMPK complex is a heterotrimer (Davies et al., 1994) consisting of an α-catalytic 
subunit and 2 regulatory, β- and γ- subunits (Dolinsky & Dyck, 2006). A total of 7 subunit-
encoding genes exist, namely PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2 and 
PRKAG3 encoding 2 α-subunits (α1 and α2), 2 β-subunits (β1 and β2) and 3 γ-subunits (γ1, γ2, γ3), 
respectively (Refer to Table 2.3 for full gene names) (Hardie et al., 1998;Zhang et al., 2009). All 
isoforms show cardiac expression (Watkins H, personal communication). AMPK functions as a 
regulator of cellular energy homeostasis via its ability to sense the AMP:ATP ratio (Hardie & 
Carling, 1997). An increase in the latter, attributable to metabolic stresses that elevate ATP 
consumption, e.g. muscle contraction, or inhibit ATP synthesis, such as glucose deprivation, results 
in AMPK activation (Oliveira et al., 2003;Hardie et al., 2003). The kinase acts to restore the 
balance by promoting catabolic, ATP-generating processes including glucose uptake (Russell, III et 
al., 1999), glycolysis (Marsin et al., 2000), fatty acid uptake and oxidation (Kudo et al., 1995) and 
mitochondrial biogenesis (Zong et al., 2002). In addition, it inhibits anabolic, energy-consuming 
pathways, such as synthesis of fatty acids (Hardie & Pan, 2002), cholesterol (Zhou et al., 2001) and 
proteins (Horman et al., 2002), preventing further ATP depletion.  
In the heart, the kinase contributes to increased myocardial glucose uptake by promoting 
translocation of the transmembrane protein, GLUT4 (Russell, III et al., 1999), to the sarcolemma. 
Similarly, AMPK increases glycolysis via the activation of cardiac phosphofructokinase 2 (PFK2) 
(Marsin et al., 2000). The latter synthesises fructose 2,6-bisphosphate that in turn stimulates 
phosphofructokinase-1 (PFK1), the rate-limiting enzyme of glycolysis (Refer to Section 1.4.7) (Hue 
& Rider, 1987). AMPK and fatty acids synergistically induce PDK4 expression, subsequently 
reducing glucose oxidation in primary cardiomyocytes (Houten et al., 2009). It, furthermore, 
promotes fatty acid metabolism by improving myocardial uptake and usage of fatty acids. 
Lipoprotein lipase (LPL) present at the coronary lumen endothelium, facilitates uptake of fatty acids 
from circulation, whilst FAT/CD36 and CPT-1 allows for fatty acid transport across the 
sarcolemmal membrane and the outer mitochondrial membrane, respectively (Refer to Sections 
1.3.2.1 and 1.3.2.2) (Dyck & Lopaschuk, 2006;Harmon & Abumrad, 1993;McGarry & Brown, 
1997). CPT-1 function is inhibited by malonyl-CoA, converted from acetyl CoA by the acetyl-CoA 
carboxylase (ACC) enzyme. AMPK activation increases LPL activity (An et al., 2005), mediates 
FAT/CD36 translocation to the sarcolemma (Luiken et al., 2003) and inactivates ACC, relieving 
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CPT-1 inhibition (Kudo et al., 1996;Kudo et al., 1995). AMPK inhibits protein synthesis via 
inactivation of eukaryote elongation factor-2 (eEF2) and the target-of-rapamycin (TOR) pathway, 
responsible for peptide elongation and mRNA translation, respectively (Gwinn et al., 2008;Inoki et 
al., 2003;Horman et al., 2002). AMPK also affects mitochondrial biogenesis by activating PCG-1α 
(Refer to Section 1.4.6) (Ren et al., 2010). Mutations in the PRKAG2 gene have previously been 
linked to the development of an HCM phenocopy (Blair et al., 2001b).  
 
Figure 2.23 The genomic structure of PRKAA1 and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
 
Figure 2.24 The genomic structure of PRKAA2 and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
 
Figure 2.25 The genomic structure of PRKAB1 and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
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Figure 2.26 The genomic structure of PRKAB2 and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
 
Figure 2.27 The genomic structure of PRKAG1 and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
 
Figure 2.28 The genomic structure of PRKAG2 and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
 
Figure 2.29 The genomic structure of PRKAG3 and the physical locations of SNPs selected throughout 
this gene. Exons and introns are denoted by green and blue boxes, respectively. 
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2.4 ABI TaqMan® SNP genotyping 
The SNPs selected for investigation were genotyped within our pedigrees using ABI TaqMan® 
SNP Validated genotyping assays (Applied Biosystems, Foster City CA, USA). The allelic 
discrimination capacity of these assays relies on a PCR chemistry that combines primer/probe 
hybridisation and fluorophore-based detection. Each assay contains a set of primers for target 
sequence amplification, a pair of allele-specific probes that hybridise to the resulting amplicon, and 
a passive reference, ROX, for signal normalisation purposes. 
Individual probes, in turn, include a minor groove binder (MGB), which increases the probe melting 
temperature (Tm), and two dye attachments: a 5’-end fluorescent reporter dye that reflects allele-
specific amplification (VIC for Allele 1; FAM for Allele 2) and a 3’-end non-fluorescent quencher 
(NFQ) that interacts with the reporter dye, quenching the fluorescent signal. The MGB 
incorporation increases probe-template binding stability, resulting in greater Tm differences between 
matched and mismatched probes, and, consequently, enhanced discriminatory power.  
Signal generation occurs when the 5’-end reporter dye undergoes AmpliTaq Gold DNA polymerase 
5- exonuclease cleavage from the probe during PCR extension, thereby removing it from the 
inhibitory effect of the quencher, and allowing for fluorescence emission (Refer to Figure 2.30). 
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Figure 2.30 Overview of the ABI TaqMan® SNP Validated genotyping assay hybridisation- and 
fluorophore-based PCR chemistry that allows for allelic discrimination. (Taken from 
www3.appliedbiosystems.com/cms/groups/mcb_marketing/documents/generaldocuments/cms_040597.pdf) 
2.4.1 Real-time PCR amplification  
The 5 µl PCR amplification reaction volume consisted of 2.5 µl ABI TaqMan® Universal PCR 
Master Mix (including passive reference ROX (Perkin-Elmer)); 0.25 µl of a 20x TaqMan® SNP 
genotyping assay comprised of two primer/probe sets (Refer to Section 2.4); 20 ng genomic DNA 
and 1.25 µl DNase-free, sterile filtered water. Reactions for 330 samples and 54 non-template 
controls (NTCs), were prepared within 384-well microtiter plates by means of an Eppendorf 
epMotion 5070 (Eppendorf, Hamburg, Germany) automated pipetting tool. Subsequent thermal 
cycling was performed on an ABI Prism 7900HT Sequence Detection System (Applied Biosystems 
Inc, Foster City CA, USA), according to the following conditions: 2 min at 50°C, 10 min at 95°C, 
and 40 cycles of 15 sec at 92°C and 1 min 30 sec at 60°C each. 
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2.4.2 Allelic discrimination 
Allelic discrimination was achieved by means of the multicomponent algorithm within the 
Sequence Detection Software (SDS) v 2.3 that inferred the normalised allelic contribution per well 
from the end-point fluorescence measurements, as determined on an ABI Prism 7900HT Sequence 
Detection System (Applied Biosystems Inc, Foster City CA, USA). The SDS software 
automatically determines genotypes (set at 95% confidence level), and, in addition, graphs 
contrasting allele contributions onto allelic discrimination plots, allowing for image-based manual 
calling of genotypes. Furthermore, the 2-cluster calling option enabled analysis of assay results 
characterised by the presence of only two distinct clusters. Results were verified by visual 
inspection of the real-time PCR multicomponent analysis plots. 
2.5 PCR amplification 
Pedigree screening for the presence of a 25 bp deletion in the MYBPC3 gene was performed via 
PCR amplification using a deletion-flanking primer set synthesised at the Synthetic DNA 
Laboratory, Department of Molecular and Cell Biology, University of Cape Town (UCT), Cape 
Town, South Africa. The primer sequences were obtained from published literature (Dhandapany et 
al., 2009) and the relevant amplification conditions are detailed in Table 2.5. 
Table 2.5 Primer details and cycling conditions for screening of the 25 bp deletion in the 
MYBPC3 gene 
Primer Sequence Cycling conditions 
Forward 5’ GTT TCC AGC CTT GGG CAT AGT C 3’ Initial denaturation at 95°C for 2 min, 35 cycles of 
amplification at 95°C for 30 sec, 58°C for 30 sec and 
72°C for 30 sec, final elongation at 72°C for 2 min Reverse 5’ GAG GAC AAC GGA GCA AAG CCC 3’ 
Abbreviations: A-adenine; C-cytosine; G-guanine; min-minutes; sec-seconds; T-thymine 
The 50 µl reaction volume included 2× KapaTaq ReadyMix (Kapa Biosystems Inc, RSA), 7 pmol 
of each primer and 20 ng genomic DNA with the exclusion of the latter in the case of the NTC 
included as a measure for assessing contamination. Amplification was performed in a GeneAmp 
PCR System 2720 (Applied Biosystems Inc, Foster City CA, USA), whereafter PCR products were 
electrophoresed on a 2% agarose gel to verify product amplification and to allow for visual 
assessment of fragment size. 
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In addition, Dr Marshall Heradien previously performed cohort screening for a TNNT2 
insertion/deletion (I/D) polymorphism, rs4019985 (Heradien M, personal communication); these 
genotypes were also included in the statistical analysis performed in this study. The genotyping 
entailed fluorescent primer amplification and subsequent size determination on the ABI Prism 
3130xl Genetic Analyser.  
2.5.2 Agarose gel electrophoresis 
PCR products were electrophoresed on a 2% (w/v) horizontal agarose gel (Appendix I) to determine 
successful amplification. Aliquots of 5 µl of PCR product and 3 µl bromophenol blue loading dye 
(Appendix I) were mixed and pipetted into each well. In addition, a BenchTop pGEM® DNA 
Marker (Promega Corp, Madison Wisconsin, USA) was loaded to allow for determination of 
fragment size. Electrophoresis was performed at 120 V for an hour in 1× SB buffer solution 
(Appendix I). Post-electrophoresis visualisation was achieved by ultraviolet light transillumination 
on the Multigenius Bio Imaging System (Syngene, Cambridge, UK). 
2.6 Statistical analyses 
The statistical evaluations required the creation of a pedigree input file. This was achieved by 
capturing the genotypic and phenotypic data of the study participants onto family trees using the 
software program Cyrillic 2.1 (Cherwell Scientific, UK), whereafter it was exported in MLINK 
format and combined with the relevant echocardiographic and covariate data in an Excel 
spreadsheet.  
2.6.1 Descriptive Statistics 
Pedstats v 6.11 (Wigginton & Abecasis, 2005) allowed for validation of input files, including 
genetic marker data. It was used to test Hardy-Weinberg Equilibrium (HWE) amongst unrelated 
individuals from the cohort and perform Mendelian inheritance checks to identifying potential 
genotyping inconsistencies, which were subsequently resolved via sample re-typing. In addition, 
Pedstats v. 6.11 was employed to graphically summarise the distribution of the quantitative traits 
and covariates. Certain trait values are asymmetrically distributed and the data are therefore 
described in terms of the median and interquartile range (Refer to Table 3.1).  The interquartile 
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range is the pair of values (Q1 and Q3) within which the middle 50% of all the observations are 
located. All traits were quantile-normalised, thereby satisfying the underlying assumptions of the 
statistical analyses and ensuring the validity of results and conclusions (Pilia et al., 2006). Quantile 
normalisation retains the order of magnitude of the values, while making their distribution as close 
as possible to symmetric and bell-shaped; it is a useful approach when traditional forms of 
transformation do not result in a normal distribution. Haploview v.4.2 (Barrett et al., 2005) was 
used to calculate the minor allele frequencies (MAFs) for a set of unrelated study participants, as an 
estimate of SNP informativity within our HCM cohort.  
2.6.2 Linkage disequilibrium (LD) determination 
Linkage disequilibrium is defined as the occurrence of a combination of alleles in a population at a 
higher frequency than what is expected by random mating (Reviewed by Zondervan & Cardon, 
2004). The premise that certain markers are more frequently inherited with the effect allele due to 
the LD between them can be exploited to evaluate the contribution of a given gene to disease 
development and to determine the exact effect allele i.e. indirect association mapping. Estimation of 
LD therefore allows us to characterise the LD structure of our own unique study cohort comprised 
of South African HCM families from either Caucasian or Mixed Ancestry descent and, in turn, 
comment on the origin of a significant association signal i.e. whether the associated allele is in LD 
with, or is itself, deemed the effect allele. That is, we can consider a significant association result 
within the context of these estimates and, accordingly, prioritize SNPs for future functional analyses 
and propose avenues for potential fine mapping where relevant.  
There are a number of measures with which to describe the extent of LD amongst two markers, 
however, no one estimate is considered best. McVean (2007) noted that no single measure of LD 
can capture all information regarding the underlying processes. Similarly, Ardlie et al. (2002) 
explained that the various measures used to describe LD have ‘very different properties and 
measure different things’. A brief overview of the two most commonly used measures, the 
normalised disequilibrium coefficient (D’) and the square of the correlation coefficient (r2), is 
provided in the following paragraph (Reviewed by Zondervan & Cardon, 2004;McVean, 
2007;Ardlie et al., 2002).  
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A D’ measure is equal to 1 (complete LD/ no evidence of recombination) in instances where the 
rarer allele of a given marker is observed in combination with only one of the possible alleles of a 
second marker. D’ is below 1 only if all four possible haplotypes from a pair of SNPs were 
observed. However, in instances of rare alleles, the presence of all four possible allele combinations 
in the larger population may not be reflected in the smaller cohort. Moreover, D’ does not consider 
MAFs of individual markers and this may result in exaggerated estimates (McVean, 2007;Jarvik et 
al., 2003). The r2 estimate is a more stringent measure as it will only be equal to 1 (perfect LD) 
when the relevant alleles are also observed at identical frequencies i.e. if only two of the four 
possible allele combinations are observed (Pittman et al., 2005;Jarvik et al., 2003).  
It is important to consider that any estimates are cohort specific and they are therefore not exactly 
equal to the underlying population estimates. Rather, we can make predictions about the population 
from which our cohort stems by constructing 95% confidence intervals for both the aforementioned 
measures based on our cohort data. The interval is defined by a lower and upper bound between 
which we are 95% confident that the true estimate lies. Instead of reporting a cohort specific point 
estimate of D’ = 1, we can say that we are 95% certain that the true D’ value is greater than the 
lower confidence bound. Gabriel et al. (2002) elaborated on the use of D’ confidence bounds as a 
means of characterizing the LD between a set of markers. Indeed, Haploview v.4.2 (Barrett et al., 
2005) employs the Gabriel method as its default haplotype block generating algorithm which 
defines SNPs to be in strong LD only in instances where the  D’ upper confidence bound > 0.98 and 
the lower confidence bound > 0.70 (Gabriel et al., 2002). 
Using Haploview v.4.2 (Barrett et al., 2005), we opted to calculate pairwise LD statistics in terms 
of D’ for all pairs of SNPs in each gene included in this study. The software selects a group of 
maximally informative but unrelated individuals so as to provide an accurate estimate of LD not 
influenced by family-relatedness. Within the extended family context, as is the case for this study, 
several sets of equally valid, unrelated individuals may exist. The selection of different subsets 
might result in varying LD values estimated from the same pedigree data. Pair-wise analyses were 
thus repeated successively a total of 100 times and the D’ value most frequently observed, that is 
the mode, is reported in Chapter 3. Results were interpreted as follows: D’ values of 1 indicate 
complete LD; D’ values > 0.8 indicate strong LD, D’ values 0.2–0.8 classified as incomplete LD 
and D’ < 0.2 defined as negligible LD (Heward et al., 2007). Haploview v.4.2 (Barrett et al., 2005) 
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was also used to estimate pair-wise r2 values and the 95% confidence bounds for the D’ estimates, 
however, these analyses were not repeated as done for D’.  
2.6.3 Principal component score 
As previously described the HCM hypertrophy phenotype exhibits extreme variability in terms of 
degree and location. The resulting inter-individual variation hampers statistical analysis as no single 
measure can comprehensively capture hypertrophy. Echocardiographically derived LVM is 
commonly used as descriptor, but may not, due to the geometric assumptions underlying the 
calculation, accurately account for LV shape variability. PCA identifies similarities in patterns of 
phenotypic variation and it was therefore applied to the 16 transformed wall thickness 
measurements to define the mathematical combination thereof that accounts for the largest amount 
of variability in the data i.e. PC1. The latter, defined as the weighted sum of the 16 wall thickness 
measurements, thus serves as a single cohort-specific measure fit for association testing.  
To reiterate, variability defined here refers to differences in phenotype amongst study participants. 
The aim of the PCA analysis is to determine the extent to which individual measurements 
contribute to the phenotypic variability. These measurements are then combined mathematically in 
a way which reflects the weight of their individual contributions thereby providing a single score. A 
test of heritability determines if and to which extent this variability (for both individual measures 
and scores) can be ascribed to genetic factors (Refer to Section 2.6.5).  
2.6.4 Confounding variables 
Adjustment for confounding variables ensures that a significant association best reflects the 
relationship of interest i.e. between an investigated variant and phenotypic variation. The statistical 
models employed thus incorporated fixed effects for known covariates of hypertrophy namely age, 
sex, BSA, HR (as a proxy measure for tachycardia), mean arterial pressure (MAP) (as derived from 
systolic and diastolic BP), presence of hypertension (i.e., adjustment for anti-hypertensive therapy), 
ethnicity (as indication of recent population stratification) and both the individual carrier status and 
identity of the relevant HCM-causing founder mutation (mutation groups were treated as a factor 
with three categories). Inclusion of the latter served as adjustment for both the ancestral relatedness 
within each founder group and the potential contribution of the relevant founder mutation to the 
Stellenbosch University  http://scholar.sun.ac.za
  
63│Chapter 2 
trait variance. It is of specific relevance to the current study as the founder mutations are located 
within two of the candidate genes selected for investigation (R92WTNNT2, R403WMYH7, and 
A797TMYH7). The correction thus ensures that any significant associations identified for these genes 
would best reflect association with variants other than the founder mutations.  
2.6.5 Heritability 
The Abecasis pedigree-based QTDT (Abecasis et al., 2000) was used to estimate trait heritability, 
i.e. the degree to which additive genetic factors contribute to the phenotypic variation of a 
transformed, covariate-adjusted trait, to determine suitability for association testing. This was 
achieved by means of a variance components model that divides trait variance into environmental 
and additive genetic (polygenic) effects. The broad sense heritability is defined as the ratio of 
genetic variance to the total phenotypic variance.  
2.6.6 Single nucleotide polymorphism association 
Association testing was achieved by means of family-based statistical analyses, which allow for the 
inclusion of unaffected relatives as appropriately matched controls thereby reducing stratification. A 
significant association between a biallelic variant and a quantitative phenotype (p-value < 0.05) 
indicates an allele dosage effect interpreted as a significant difference in mean trait value between 
wild type homozygotes (no minor alleles) and heterozygotes (1 minor allele) and so too, in equal 
measure, between heterozygotes and minor homozygotes (2 minor alleles). The measure of 
difference in mean phenotype due to a given allele is termed the effect size. Association testing 
between individual variants and hypertrophy traits was performed in R using the lmekin function of 
the kinship package (Atkinson & Therneau, 2008). It entailed specialised mixed-effect modelling as 
it incorporated random effects, both family-and individual-specific, as well as fixed effects to adjust 
for known hypertrophy covariates and allow for additive allelic association testing between a single 
variant and single trait (polygenic variance component). Under an additive genetic model, SNPs 
were coded as ordinal variables of 0, 1 or 2 reflecting the number of minor allele copies.  
More specifically, modelling of family- and individual-specific random effects served as 
adjustments for possible intrafamilial clustering of traits and interindividual trait correlations owing 
to family or cryptic relatedness (Price et al., 2010). The first was achieved by inclusion of a family-
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membership indicator and the second was correlated according to the genetic relatedness between 
family members i.e. kinship coefficient. The latter, defined as the pedigree-based probability that 
two individuals share alleles identical by descent (IBD), was estimated with function makekinship 
in kinship. Given that the correlations in trait values between family members are taken into 
account, the models we used for inference ensure that larger families do not have disproportionately 
larger contributions to the estimated effects (van der Merwe L, personal communication). 
To facilitate interpretation, the results obtained for the SNP association analyses are presented 
graphically in Chapter 3 (Refer to Figure 3.3 as an example). The figures tabulate the original p-
values whilst plotting the corresponding negative logarithm base 10 (–log10) transformed p-values 
(–log10 [p-value]) on bar graphs. The log transformation compresses the scale of the relevant axis 
whilst maintaining the ratio between values; i.e. larger values are brought closer together whilst 
smaller values become more separated. The p-values are therefore expressed on a –log10 scale for 
ease of visualisation and comparison. Moreover, a red dashed horizontal line indicates the p-value 
significance threshold equal to 0.05. Bars which are located above this line therefore indicate 
significant p-values, i.e. p-values of less than 0.05. Moreover, the p-value significance increases 
with bar height above threshold.  
It is important to note that no formal correction was made for multiple testing given the lack of an 
appropriate method and the explorative nature of this genetic investigation. Briefly, the existing 
methods are only suited to the study of family trios and not extended pedigrees as investigated in 
the current study. Furthermore, they are either over-conservative or require prior knowledge of the 
hypothesis under investigation. A more detailed discussion of these reasons is provided in Section 
4.1.2. 
Furthermore, comparative analyses were done to determine whether the effect of the investigated 
variants varied amongst the three HCM founder mutation groups. Such HCM mutation-specific 
effects have been reported in the literature and were thus evaluated here by statistical pair-wise 
comparison of the three HCM founder mutation groups with regards to variant effect on phenotype. 
These tests for statistical interaction between the HCM mutation groups and the investigated variant 
are summarised with three p-values and their corresponding effect sizes (Refer to Section 3.4.5). 
The interpretation of a significant interaction result is demonstrated in Section 2.6.8. 
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2.6.7 Effect sizes 
As mentioned earlier, trait values were quantile-normalised to approximate normality, an important 
requirement for validity of the association model used. Hence, the derived effects sizes are in 
quantile-normalised units, which are not interpretable in terms of the original cardiac 
measurements. The untransformed, covariate-adjusted hypertrophy measures were therefore also 
analysed, as per the method detailed for modelling of the transformed data, in an attempt to estimate 
approximate effect sizes in the original units of measurement for all significant associations 
identified. An exception applies to estimation of effect sizes for PC1, as it is a composite score. 
Here, we estimated effect sizes based on modelling the mean of the 16 untransformed, covariate-
adjusted cardiac wall thickness measurements.  
2.6.8 Demonstrated interpretation of interaction 
As described in Section 2.6.6, comparative analyses were done with the aim of determining whether 
the effect of the investigated variants on hypertrophy traits varied amongst the three HCM founder 
mutation groups i.e. mutation group and variant interaction. One of the significant results obtained 
by comparative analysis is discussed in the subsequent paragraphs in order to demonstrate its 
interpretation. 
A significant interaction between HCM mutation group and the rs3729838 (TNNI3) variant was 
identified upon pair-wise comparison of the three HCM founder mutation groups, with respect to 
the effect of this SNP on mLVWT. The p-values for these between-group comparisons were as 
follows: R403WMYH7 and A797TMYH7 groups (p = 0.080); R92WTNNT2 and A797TMYH7 groups (p= 
0.482); R92WTNNT2 and R403WMYH7 groups (p = 0.022). This indicated a significant difference in 
the estimated variant effect, with the addition of a G-allele resulting in a 2.45 mm higher mLVWT 
in the R92WTNNT2 group compared to the R403WMYH7 group.  
Figure 2.31 illustrates the aforementioned significant interaction, in a plot of the estimated mLVWT 
values for 9 hypothetical ‘average’ individuals specific to the cohort, three per HCM founder 
mutation group, with each representing a possible rs3729838 genotype (CC, CG or GG). The 
demographics that define the ‘average’ individual are as follows: 41 years of age, Caucasian, male, 
no specific HCM mutation, treatment with anti-hypertensive medication, BSA of 1.93m2, MAP of 
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94 mm Hg, and HR of 69 beats per minute (bpm). The graph will adjust up or down when 
representing ‘real’ individuals as a reflection of the per-individual variation in hypertrophy 
covariate values; for instance, mutation carriers would be characterised by the addition of 4.98 units 
to the average values. However, the estimated difference in effect size amongst the HCM mutation 
groups is unvarying.  
The graph illustrates that the average effect of the TNNI3 gene variant on mLVWT, represented 
here as the addition of a G-allele, varies significantly relative to the specific HCM causal mutation 
present in a given individual. More specifically, each G-allele added will increase mLVWT in 
A797TMYH7 and R92WTNNT2 carriers by 1.70 mm and 1.53 mm, respectively, whilst decreasing 
mLVWT by 0.92 mm in R403WMYH7 carriers. The difference in variant effect was significant only 
for comparison of R403WMYH7 carriers to the R92WTNNT2 carriers. The effect of the two alleles at 
the locus corresponds in size, but is directionally opposite.  
 
Figure 2.31 Graph of estimated mLVWT by mutation group and rs3729838 genotype. 
2.6.9 Haplotype assignment and association analysis 
Simwalk v.2.91 (Sobel & Lange, 1996) was used to estimate the most probable, fully-typed 
maternal and paternal haplotype configuration for each individual in the pedigree. Each run of the 
software delivers a set of likely haplotypes. We arbitrarily selected 1.5% as our cut-off for 
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haplotype frequencies, as lower frequencies will not provide enough power to detect effects of 
biologically relevant sizes in our groups. Each effect size and group size provides a different power, 
of course. The selected frequency of 1.5% is arbitrary and conservative (van der Merwe L, personal 
communication). 
An additive model of association was fitted using the R function lmekin, exactly as described for 
SNP evaluations (Refer to Section 2.6.6) with the coding of 0, 1 or 2 here reflecting the number of 
copies of an inferred haplotype. Comparative (interaction) analyses were also performed to 
determine whether the effect of investigated haplotypes varied amongst the three HCM founder 
mutation groups. The p-values obtained for the haplotype association analyses; and the tests for 
statistical interaction between the HCM mutation groups and investigated haplotypes are presented 
in Chapter 3 (Refer to Section 3.4.5). The outline and interpretation of significant results is detailed 
in Section 2.6.6 and 2.6.8. The use of haplotype analyses allowed us to capture the variability 
throughout the investigated genes and to evaluate the effect of a single variant within the context of 
the entire gene, as the effect seen for a single variant by itself may be altered when considering it 
within the context of other variants within the total gene.  
2.6.10 Optimal selection 
We aimed to identify a subset of the variants investigated in this study that would collectively 
explain most of the variation in hypertrophy in the current cohort. To this end, we performed 
backwards stepwise-selection on the model for the PC1 trait with the goal of identifying a subset of 
variants that significantly affected the trait, independently of the eight hypertrophy covariates 
adjusted for throughout the study; and the other significant variants in the model. We focused on the 
composite score, PC1, as it is a weighted sum of the 16 wall thickness measurements that best 
reflected the ventricle-wide hypertrophy and so the variability in LVH in the present HCM cohort. 
Analyses were performed for the study participants with complete genotype and phenotype data. 
The model first comprised the hypertrophy covariates and a total of nine variants that associated 
significantly with at least one hypertrophy trait in the present cohort. Thereafter, we further reduced 
this subset of variants, by means of backward stepwise-selection, to a set of six markers that 
predicted an increase in at least one of the hypertrophy indices, independent of the hypertrophy 
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covariates and the other significant variants, i.e. three variants that did not significantly affect the 
hypertrophy trait following adjustment for the other significant variants in the model were removed. 
The six remaining markers were modelled on the quantile normalised traits and the untransformed 
trait data adjusted for the hypertrophy covariates and the other significant variants in the model, to 
obtain p-values and effect sizes, respectively. More specifically, as PC1 is a composite score, its 
estimated effect sizes are derived from the CWT score by modelling the mean of the 16 
untransformed, covariate-adjusted cardiac wall thickness measurements. 
All statistical analyses were designed and executed by Prof Lize van der Merwe (MRC Biostatistics 
Unit, South Africa), assisted by Ushma Galal and Renier van Rooyen. Also, the understanding and 
communication of the statistical concepts was facilitated by Prof Lize van der Merwe (van der 
Merwe L, personal communication).  
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CHAPTER THREE 
RESULTS 
3.1 Basic cohort characteristics 
The entire study cohort consisting of 388 participants underwent molecular genetic testing to 
determine their carrier status for each of the three HCM-causing founder mutations that segregate 
within the study cohort. None of the individuals were compound heterozygous for any of the 
founder mutations; i.e., individuals were either carriers of a single HCM-causing founder mutation, 
or non-carriers for all three mutations. 
In addition, 256 of these study individuals consented to clinical assessment. Table 3.1 details the 
basic cohort characteristics with participants grouped according to mutation carrier (MC) and non-
carrier (NC) status for each of the three HCM founder mutations. The data are described in terms of 
the median (interquartile range) as certain trait values are asymmetrically distributed.   
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
70│Chapter 3 
Table 3.1 Basic characteristics of the study cohort. Individuals are grouped according to the relevant HCM founder mutation and mutation status as 
either mutation carrier (MC) or non-carrier (NC). 
 
A797TMYH7 R92WTNNT2 R403WMYH7 
 
MC NC MC-NC† MC NC MC-NC† MC NC MC-NC† 
n 68 50  48 34  32 24  
Age 43.0 (26.8–56.8) 41.5 (29.3–53.0)  36.0 (21.0–47.0) 42.0 (25.5–49.0)  36.5 (25.0–46.8) 38.0 (31.3–50.8)  
BSA (m2) 1.90 (1.60–2.00) 1.90 (1.67–2.03)  1.70 (1.60–1.80) 1.80 (1.60–1.90)  1.80 (1.70–2.00) 1.95 (1.70–2.05)  
SBP (mm Hg) 120 (115–134) 120 (110–130)  115 (110–130) 120 (110–120)  120 (115–130) 120 (114–143)  
DBP (mm Hg) 80 (70–87) 80 (80–89)  73 (70–80) 80 (70–80)  80 (79–80) 80 (78–90)  
HR (bpm) 68 (60–75) 68 (62–76)  68 (61–76) 67 (60–73)  65 (60–76) 72 (65–84)  
Anti-hypertensive 
therapy 16 11  4 1  4 4  
LVM (g) 191 (135–-237) 135 (109–159) 58.6, p<0.001 146 (104–185) 116 (100–144) 19.5, p=0.039 170 (134–205) 154 (115–202) 26.2, p=0.021 
mIVST (mm) 14.5 (11.0–20.9) 10.5 (9.2–11.3) 5.7, p<0.001 14.0 (9.6–18.3) 10.0 (8.6–10.9) 3.9, p<0.001 13.6 (11.6–16.0) 11.0 (10.2–12.6) 3.7, p=0.004 
mLVWT (mm) 14.0 (11.0–20.7) 10.5 (9.5–11.3) 5.4, p<0.001 13.4 (9.9–18.1) 10.0 (9.2–10.9) 3.5, p=0.001 13.6 (11.6–17.8) 11.2 (10.2–12.4) 3.8, p=0.003 
mPWT (mm) 10.2 (9.1–11.8) 9.0 (8.3–10.0) 1.5, p<0.001 10.2 (8.1–11.5) 8.1 (7.5–9.1) 1.6, p<0.001 10.1 (9.1–11.5) 9.9 (8.8–10.4) 1.3, p=0.013 
CWT score 196 (151–239) 139 (127–148) 52.3, p<0.001 159 (131–192) 131 (117–142) 31.9, p<0.001 172 (148–190) 153 (136–166) 23.0, p=0.019 
PC1 2.12 (−0.14–4.88) −1.31 (-2.52–0.01) 3.3, p<0.001 0.86 (−2.62–2.72) −2.56 (−4.26–1.01) 2.0, p<0.001 1.42 (−0.34–2.42) 0.1 (−2.02–1.44) 1.4, p=0.032 
* Data summarised as median (interquartile range Q1–Q3); the interquartile range indicates the middle 50% of all the observations 
† Estimated difference between mutation-carriers and non-carriers per mutation group using raw data; p-values for tests of statistical differences using quantile normalised trait 
values. Joint models using all individuals were employed and adjusted for age, sex, BSA, MAP, HR, use of anti-hypertensive medication and ethnicity. 
Abbreviations: A-Alanine; bpm-beats per minute; BSA-body surface area; CWT score-cumulative wall thickness score; DBP-diastolic blood pressure; g-gram; HCM-hypertrophic 
cardiomyopathy; Hg-mercury; HR-heart rate; LVM-left ventricular mass; m2-per square meter; MC-HCM mutation carrier; mIVST-maximal interventricular septum thickness; 
mLVWT-maximal left ventricular wall thickness; mPWT-maximal posterior wall thickness; mm-millimetre; MYH7-Myosin heavy chain gene 7; NC-non-carrier; n-number of 
clinically evaluated participants; PC1-first principal component; Q1-first quartile; Q3-third quartile; R-Arginine; SBP-systolic blood pressure; T-Threonine; TNNT2-Troponin T 
gene 2, cardiac; W-Tryptophan
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3.2 Candidate gene selection and SNP prioritisation 
A comprehensive literature review allowed the identification of 26 candidate hypertrophy modifier 
genes selected for their contributions to sarcomere integrity and contractility and/or myocardial 
energetics, the disruption of which is known to contribute to the development of HCM. The SNPs 
investigated in the present study were selected with the aim of achieving 0.5 LDU even spacing 
throughout the candidate genes and were further prioritised according to ABI TaqMan® SNP 
Validated Genotyping Assay-availability and their MAFs. Table 3.2 lists the 26 candidate genes, the 
78 SNPs selected and their MAFs for the CEU and YRI populations (Refer to Section 2.3.2).  
Table 3.2 The SNPs chosen for investigation in this study and their minor allele frequencies 
(MAF) in the CEU and YRI populations 
Gene symbol Chromosome localisation SNP ID 
Nucleotide 
change 
MAF* 
CEU YRI 
Sarcomeric candidate modifier genes 
Thin filament components 
ACTC1 15q11-q14 rs1370154 T/C 0.258 (T) 0.133 (T) 
 
 rs2070664 T/C 0.500 (T) 0.267 (C) 
TNNT2 1q32 rs2365652 C/A 0.358 (C) 0.250 (A) 
 
 rs1892028 G/A 0.364 (G) 0.224 (A) 
 
 rs947485 A/G 0.356 (A) 0.242 (G) 
TNNI3 19q13.4 rs3729841 C/T 0.117 (T) 0.000 (T) 
 
 rs3729838 C/G 0.186 (C) 0.229 (G) 
 
 rs11667847 A/G - - 
TPM1 15q22 rs11071720 T/C 0.367 (T) 0.358 (C) 
 
 rs4238370 G/T 0.229 (T) 0.339 (T) 
 
 rs1071646 C/A 0.392 (C) 0.483 (C) 
 
 rs707602 T/C 0.136 (C) 0.117 (C) 
ACTN3 11q13-q14 rs1791690 G/A 0.433 (A) 0.280 (G) 
 
 rs2275998 C/T 0.175 (C) 0.292 (C) 
 
 rs1815739 C/T 0.458 (T) 0.100 (T) 
Thick filament components 
MYL3 3p21.3-p21.2 rs1531136 T/C 0.175 (T) 0.067 (C) 
 
 rs3792558 T/C 0.150 (T) 0.133 (C) 
MYH7 14q12 rs765019 C/T 0.108 (C) 0.212 (C) 
 
 rs2277475 T/A 0.333 (T) 0.233 (A) 
 
 rs1951154 G/A 0.308 (A) 0.025 (A) 
 
 rs2754163 C/T 0.300 (C) 0.308 (T) 
 
 rs2239578 G/A 0.442 (G) 0.342 (A) 
MYL2 12q23-q24.3 rs933296  C/A 0.354 (A) 0.071 (A) 
 
 rs4766517 C/G 0.449 (G) 0.142 (G) 
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Gene symbol Chromosome localisation SNP ID 
Nucleotide 
change 
MAF* 
CEU YRI 
Intermediate  filament components 
MYBPC3 11p11.2 rs4752825 G/A - - 
 
 rs1052373 C/T 0.254 (T) 0.500 (T) 
 
 rs10838696 G/A 0.367 (A) 0.000 (A) 
 
 rs11570058 G/A 0.098 (A) 0.042 (A) 
Energy metabolism candidate modifier genes 
Fatty acid metabolism components 
CD36 7q11.2 rs10268417 C/A 0.373 (A) 0.362 (C) 
 
 rs3211892 G/A 0.025 (A) 0.358 (A) 
 
 rs3173804 A/T 0.492 (A) 0.083 (A) 
CPT1B 22q13.33 rs470117 C/T 0.492 (C) 0.092 (T) 
 
 rs1557502 C/T 0.150 (T) 0.267 (C) 
PPARA 22q13.31 rs881740 G/A 0.092 (G) 0.317 (G) 
 
 rs4823613 A/G 0.300 (G) 0.380 (G) 
 
 rs4253776 G/A 0.150 (G) 0.467 (G) 
PPARG 3p25 rs12631028 C/T 0.211 (T) 0.259 (T) 
 
 rs12490265 G/A 0.350 (A) 0.025 (A) 
 
 rs2938392 G/A 0.467 (A) 0.108 (A) 
 
 rs1175540 C/A 0.342 (A) 0.225 (C) 
PGC1A 4p15.1 rs768695 A/G 0.433 (G) 0.483 (G) 
 
 rs4619879 C/A 0.450 (C) 0.467 (C) 
 
 rs11724368 A/T 0.217 (T) 0.042 (T) 
 
 rs13131226 C/T 0.316 (C) 0.481 (C) 
Glucose metabolism components 
ALDOA 16q22-q24 rs9928448 C/T 0.458 (T) 0.400 (T) 
 
 rs11860935 C/T 0.110 (T) 0.147 (T) 
PFKM 12q13.3 rs1859445 A/C 0.300 (C) 0.150 (C) 
 
 rs10875749 A/T 0.392 (T) 0.108 (T) 
PDK4 7q21.3 rs2073978 C/T 0.442 (C) 0.417 (T) 
 
 rs2301630 T/C 0.467 (T) 0.314 (C) 
Creatine kinase energy shuttle components 
CKM 19q13.2-q13.3 rs8111989 T/C 0.258 (C) 0.475 (T) 
 
 rs7260463 G/T 0.283 (T) 0.421 (G) 
 
 rs1133190 G/A 0.350 (A) 0.225 (G) 
 
 rs344816 T/A 0.417 (T) 0.050 (A) 
CKB 14q32 rs1803283 C/T 0.351 (C) 0.364 (T) 
 
 rs2071407 T/C 0.283 (T) 0.448 (T) 
 
 rs1136165 T/G - - 
Cellular energy homeostasis 
PRKAA1 5p12 rs12517210 T/C 0.392 (C) 0.167 (C) 
 
 rs11747210 T/G 0.345 (G) 0.181 (G) 
 
 rs466108 C/A 0.333 (A) 0.400 (A) 
PRKAA2 1p31 rs1124900 G/T 0.433 (G) 0.356 (G) 
 
 rs2796495 C/T 0.433 (T) 0.492 (T) 
 
 rs932447 T/C 0.383 (C) 0.288 (C) 
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Gene symbol Chromosome localisation SNP ID 
Nucleotide 
change 
MAF* 
CEU YRI 
PRKAB1 12q24.1 rs6490267 G/T 0.367 (T) 0.442 (T) 
 
 rs278143 A/G 0.342 (G) 0.442(G) 
 
 rs10849690 C/G - 0.009 (G) 
 
 rs278149 T/G 0.333 (T) 0.483 (T) 
 
 rs4213 T/G 0.342 (G) 0.458 (G) 
PRKAB2 1q21.1 rs6937 T/C 0.133 (C) 0.092 (C) 
 
 rs1348316 G/A 0.442 (G) 0.195 (A) 
PRKAG1 12q12-q14 rs10875910 G/C 0.283 (C) 0.075 (C) 
 
 rs2117029 A/T 0.342 (A) 0.459 (T) 
PRKAG2 7q36.1 rs8961 C/T 0.367 (T) 0.167 (C) 
 
 rs2727537 G/A 0.342 (G) 0.358 (A) 
 
 rs6464170 G/C 0.267 (G) 0.508 (C) 
 
 rs13240743 C/G 0.373 (G) 0.425 (G) 
PRKAG3 2q35 rs1000935 G/T 0.000 (G) 0.333 (T) 
 
 rs16859382 C/T 0.000 (C) 0.192 (T) 
* Minor allele indicated in brackets  
Abbreviations: A-adenine; ACTC1-Actin, alpha, cardiac muscle 1; ACTN3-Actinin, alpha 3; ALDOA-Aldolase A, 
fructose-bisphosphate; C-cytosine; CD36-CD36 antigen, thrombospondin receptor; CEU-Central European; CKB-
Creatine kinase, brain; CKM-Creatine kinase, muscle; CTP1B-Carnitine palmitoyltransferase 1B, muscle; G-guanine; 
MAF-minor allele frequency; MYBPC3-Myosin binding protein C, cardiac; MYH7-Mysoin heavy chain 7, cardiac 
muscle, beta; MYL2-Myosin light chain 2, regulatory cardiac, slow; MYL3-Myosin light chain 3, alkali, ventricular, 
skeletal slow; PDK4-Pyruvate dehydrogenase kinase, isozyme 4; PFKM-Phosphofructokinase, muscle; SNP-single 
nucleotide polymorphism; T-thymine; TNNI3-Troponin I type 3, cardiac; TNNT2-Troponin T type 2, cardiac; TPM1-
Tropomyosin 1; PPARA-Peroxisome proliferator-activated receptor alpha; PPARG-Peroxisome proliferator-activated 
receptor gamma; PGC1A-Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha; PRKAA1-Protein 
kinase, AMP-activated, alpha 1 catalytic subunit; PRKAA2-Protein kinase, AMP-activated, alpha 2 catalytic subunit; 
PRKAB1-Protein kinase, AMP-activated, beta 1 non-catalytic subunit; PRKAB2-Protein kinase, AMP-activated, beta 2 
non-catalytic subunit; PRKAG1-Protein kinase, AMP-activated, gamma 1 non-catalytic subunit; PRKAG2-Protein 
kinase, AMP-activated gamma 2 non-catalytic subunit; PRKAG3-Protein kinase, AMP-activated, gamma 3 non-
catalytic subunit; YRI-Yoruba 
 
3.3 Genotyping results 
3.3.1 TaqMan® allelic discrimination 
The ABI TaqMan® SNP validated genotyping that encompassed real-time PCR amplification and 
allelic discrimination, was successfully completed for all the polymorphisms selected for 
investigation. Poor amplification was initially achieved for a total of six of the investigated variants. 
The reactions were repeated a number of times and as a result insufficient assay volumes hampered 
successful re-typing. This is reflected by the overall genotyping success rate which ranged from 71-
90% (success rate of the six assays ranged from 71-79%). The genotyping success rate, excluding 
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the six assays, ranged from 80-90%. Figure 3.1 represents an allelic discrimination plot for the 
CD36 gene polymorphism, rs10268417, graphed by the SDS software as contrasting normalised 
allele contributions.  
 
Figure 3.1 The CD36 rs10268417 genotypes. Genotyping was determined by end point analyses and 
graphed by the SDS software as contrasting allele contributions. Blue squares indicate individuals 
homozygous for allele Y; red squares signify individuals homozygous for the X allele; green blocks 
represent heterozygous individuals; black squares denote non-template controls (NTCs); black crosses 
indicate undetermined samples that either did not cluster tightly or clustered with the NTC samples. Allele 
X: A; Allele Y: C 
3.3.2 PCR amplification 
Successful PCR amplification was achieved for the screening of the 25 bp, MYBPC3 gene deletion.  
The absence of contamination was confirmed by the observed non-amplification of negative 
controls. Figure 3.2 is a representation of the PCR results obtained, with the entire cohort proving to 
be homozygous wild-type (WT) (fragment sizes: WT 403 bp; mutant 378 bp).  
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Figure 3.2 PCR amplification of the 25bp deletion in the MYBPC3 gene. Representative 2% agarose gel 
of fragment sizes generated via PCR, indicating individual genotypes for the MYBPC3 deletion. Lane 1: 
Molecular weight marker; Lanes 2–8: individual sample amplification (lane 2 denotes unsuccessful 
amplification resolved via subsequent re-typing); Lane 9: negative control. 
All genotype results determined by end-point analyses or by visualization of PCR fragments, 
together with the established phenotype information, were then integrated into a database for further 
statistical evaluations.  
3.4 Statistical analyses 
3.4.1 Descriptive statistics 
The Pedstats software v 6.11 (Wigginton & Abecasis, 2005) was used to perform HWE testing 
amongst unrelated individuals from the cohort with the exact test p-values obtained reported in 
Table 3.3. Three of the investigated SNPs were excluded from further statistical analyses as the 
heterozygosity in one (rs3729841) was too low to be informative, whilst the genotype frequencies 
of the other two (rs3211892 and rs8961) departed from HWE at the p-value < 0.01 level. Moreover, 
the genotyping results obtained for the rs3729841 SNP indicated that the majority of individuals 
were homozygous for the C-allele, whilst three individuals proved to be heterozygous and a further 
five individuals homozygous for the T-allele.  
Haploview v.4.1 was used to calculate MAFs from a set of unrelated study individuals; estimates of 
SNP informativity within our HCM cohort are included in Table 3.3. Also, the SNP MAFs for the 
CEU and YRI populations are again provided for ease of comparison. A total of 59 of the 78 SNPs 
1 2 3 4 5 6 8 9 7 
460 bp 
396 bp 
350 bp 
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selected for investigation shared a minor allele with at least one of the HapMap reference 
populations of which the MAFs did not differ by > 0.2 as indicated by the purple highlighting. Blue 
highlighting indicates instances in which the same minor allele is shared but the difference in the 
frequencies is > 0.2. The corresponding allele frequencies suggest that the CEU and YRI reference 
populations provide accurate estimates of the LD structure of our own unique study cohort. As 
mentioned in Chapter 2, this was also clear from previous association studies from our own 
laboratory. However, it should be noted that five of the SNPs investigated had different minor 
alleles relative to the reference populations: ALDOA, rs9928448; PFKM, rs1859445; CKB, 
rs2071407; PRKAA1, rs11747210; PRKAA2, rs2796495. 
Table 3.3 Cohort-specific descriptives: Hardy-Weinberg equilibrium test p-values and minor 
allele frequencies for the SNPs investigated 
Candidate 
gene 
Chromosome 
locus SNP ID HWE p-value 
MAF 
Study 
cohort CEU YRI 
Sarcomeric candidate modifier genes 
Thin filament components 
ACTC1 15q11-q14 rs1370154 1.000 0.302 (T) 0.258 (T) 0.133 (T) 
 
 rs2070664 1.000 0.256 (C) 0.500 (T) 0.267 (C) 
TNNT2 1q32 rs2365652 0.200 0.497 (A) 0.358 (C) 0.250 (A) 
 
 rs1892028 0.220 0.490 (A) 0.364 (G) 0.224 (A) 
 
 rs947485 0.350 0.494 (G) 0.356 (A) 0.242 (G) 
TNNI3 19q13.4 rs3729841 - 0.009 (T) 0.117 (T) 0.000 (T) 
 
 rs3729838 0.550 0.445 (G) 0.186 (C) 0.229 (G) 
 
 rs11667847 0.270 0.239 (G) - - 
TPM1 15q22 rs11071720 0.080 0.470 (C) 0.367 (T) 0.358 (C) 
 
 rs4238370 0.360 0.332 (T) 0.229 (T) 0.339 (T) 
 
 rs1071646 1.000 0.374 (C) 0.392 (C) 0.483 (C) 
 
 rs707602 1.000 0.054 (C) 0.136 (C) 0.117 (C) 
ACTN3 11q13-q14 rs1791690 1.000 0.422 (A) 0.433 (A) 0.280 (G) 
 
 rs2275998 0.400 0.298 (C) 0.175 (C) 0.292 (C) 
 
 rs1815739 0.690 0.315 (T) 0.458 (T) 0.100 (T) 
Thick filament components 
MYL3 3p21.3-p21.2 rs1531136 0.100 0.489 (T) 0.175 (T) 0.067 (C) 
 
 rs3792558 0.340 0.454 (T) 0.150 (T) 0.133 (C) 
MYH7 14q12 rs765019 0.550 0.142 (C) 0.108 (C) 0.212 (C) 
 
 rs2277475 0.040 0.242 (T) 0.333 (T) 0.233 (A) 
 
 rs1951154 0.720 0.296 (A) 0.308 (A) 0.025 (A) 
 
 rs2754163 0.060 0.299 (C) 0.300 (C) 0.308 (T) 
 
 rs2239578 0.730 0.416 (G) 0.442 (G) 0.342 (A) 
MYL2 12q23-q24.3 rs933296 0.170 0.201 (A) 0.354 (A) 0.071 (A) 
 
 rs4766517 1.000 0.357 (G) 0.449 (G) 0.142 (G) 
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Candidate 
gene 
Chromosome 
locus SNP ID HWE p-value 
MAF 
Study 
cohort CEU YRI 
Intermediate filament components 
MYBPC3 11p11.2 rs4752825 1.000 0.472 (A) - - 
 
 rs1052373 1.000 0.468 (T) 0.254 (T) 0.500 (T) 
 
 rs10838696 0.160 0.186 (A) 0.367 (A) 0.000 (A) 
 
 rs11570058 1.000 0.113 (A) 0.098 (A) 0.042 (A) 
Energy metabolism candidate modifier genes 
Fatty acid metabolism components 
CD36 7q11.2 rs10268417 0.750 0.385 (A) 0.373 (A) 0.362 (C) 
 
 rs3211892 0.002* 0.068 (A) 0.025 (A) 0.358 (A) 
 
 rs3173804 0.520 0.453 (A) 0.492 (A) 0.083 (A) 
CPT1B 22q13.33 rs470117 1.000 0.240 (T) 0.492 (C) 0.092 (T) 
 
 rs1557502 0.090 0.410 (T) 0.150 (T) 0.267 (C) 
PPARA 22q13.31 rs881740 0.020 0.194 (G) 0.092 (G) 0.317 (G) 
 
 rs4823613 0.460 0.289 (G) 0.300 (G) 0.380 (G) 
 
 rs4253776 1.000 0.274 (G) 0.150 (G) 0.467 (G) 
PPARG 3p25 rs12631028 0.730 0.305 (T) 0.211 (T) 0.259 (T) 
 
 rs12490265 0.530 0.235 (A) 0.350 (A) 0.025 (A) 
 
 rs2938392 0.110 0.448 (A) 0.467 (A) 0.108 (A) 
 
 rs1175540 0.740 0.430 (A) 0.342 (A) 0.225 (C) 
PGC1A 4p15.1 rs768695 0.530 0.448 (G) 0.433 (G) 0.483 (G) 
 
 rs4619879 1.000 0.488 (C) 0.450 (C) 0.467 (C) 
 
 rs11724368 0.400 0.230 (T) 0.217 (T) 0.042 (T) 
 
 rs13131226 0.320 0.427 (C) 0.316 (C) 0.481 (C) 
Glucose metabolism components 
ALDOA 16q22-q24 rs9928448 0.760 0.500 (C) 0.458 (T) 0.400 (T) 
 
 rs11860935 1.000 0.088 (T) 0.110 (T) 0.147 (T) 
PFKM 12q13.3 rs1859445 0.340 0.456 (A) 0.300 (C) 0.150 (C) 
 
 rs10875749 1.000 0.221 (T) 0.392 (T) 0.108 (T) 
PDK4 7q21.3 rs2073978 1.000 0.379 (T) 0.442 (C) 0.417 (T) 
 
 rs2301630 0.510 0.446 (C) 0.467 (T) 0.314 (C) 
Creatine kinase energy shuttle components 
CKM 19q13.2-q13.3 rs8111989 1.000 0.373 (C) 0.258 (C) 0.475 (T) 
 
 rs7260463 0.180 0.380 (T) 0.283 (T) 0.421 (G) 
 
 rs1133190 1.000 0.477 (A) 0.350 (A) 0.225 (G) 
 
 rs344816 0.100 0.296 (T) 0.417 (T) 0.050 (A) 
CKB 14q32 rs1803283 0.200 0.497 (T) 0.351 (C) 0.364 (T) 
 
 rs2071407 0.120 0.406 (C) 0.283 (T) 0.448 (T) 
 
 rs1136165 0.110 0.424 (G) - - 
Cellular energy homeostasis 
PRKAA1 5p12 rs12517210 0.450 0.267 (C) 0.392 (C) 0.167 (C) 
 
 rs11747210 0.290 0.261 (T) 0.345 (G) 0.181 (G) 
 
 rs466108 0.720 0.369 (A) 0.333 (A) 0.400 (A) 
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Candidate 
gene 
Chromosome 
locus SNP ID HWE p-value 
MAF 
Study 
cohort CEU YRI 
PRKAA2 1p31 rs1124900 0.370 0.459 (G) 0.433 (G) 0.356 (G) 
 
 rs2796495 0.020 0.425 (C) 0.433 (T) 0.492 (T) 
 
 rs 932447 1.000 0.356 (C) 0.383 (C) 0.288 (C) 
PRKAB1 12q24.1 rs6490267 1.000 0.266 (T) 0.367 (T) 0.442 (T) 
 
 rs278143 1.000 0.236 (G) 0.342 (G) 0.442(G) 
 
 rs10849690 0.630 0.135 (G) - 0.009 (G) 
 
 rs278149 1.000 0.278 (T) 0.333 (T) 0.483 (T) 
 
 rs4213 1.000 0.269 (G) 0.342 (G) 0.458 (G) 
PRKAB2 1q21.1 rs6937 1.000 0.096 (C) 0.133 (C) 0.092 (C) 
 
 rs1348316 0.340 0.450 (G) 0.442 (G) 0.195 (A) 
PRKAG1 12q12-q14 rs10875910 1.000 0.343 (C) 0.283 (C) 0.075 (C) 
 
 rs2117029 0.520 0.442 (T) 0.342 (A) 0.459 (T) 
PRKAG2 7q36.1 rs8961 0.004* 0.480 (C) 0.367 (T) 0.167 (C) 
 
 rs2727537 0.230 0.461 (A) 0.342 (G) 0.358 (A) 
 
 rs6464170 0.420 0.266 (G) 0.267 (G) 0.508 (C) 
 
 rs13240743 0.490 0.303 (G) 0.373 (G) 0.425 (G) 
PRKAG3 2q35 rs1000935 1.000 0.261 (G) 0.000 (G) 0.333 (T) 
 
 rs16859382 1.000 0.261 (C) 0.000 (C) 0.192 (T) 
*Genotyping frequencies departed from HWE at the p-value < 0.01 level 
Abbreviations: ACTC1-Actin, alpha, cardiac muscle 1; ALDOA-Aldolase A, fructose-bisphosphate; CD36-CD36 
antigen, thrombospondin receptor; CKB-Creatine kinase, brain; CKM-Creatine kinase, muscle; CTP1B-Carnitine 
palmitoyltransferase 1B, muscle; HWE-Hardy-Weinberg equilibrium; MAF-minor allele frequency; MYBPC3-Myosin 
binding protein C, cardiac; MYH7-Mysoin heavy chain 7, cardiac muscle, beta; MYL2-Myosin light chain 2, regulatory 
cardiac, slow; MYL3-Myosin light chain 3, alkali, ventricular, skeletal slow; PDK4-Pyruvate dehydrogenase kinase, 
isozyme 4; PFKM-Phosphofructokinase, muscle; SNP-single nucleotide polymorphism; TNNI3-Troponin I type 3, 
cardiac; TNNT2-Troponin T type 2, cardiac; TPM1-Tropomyosin 1; p-short arm of chromosome; p-value-probability; 
PPARA-Peroxisome proliferator-activated receptor alpha; PPARG-Peroxisome proliferator-activated receptor gamma; 
PPARGC1A-Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha; PRKAA1-Protein kinase, AMP-
activated, alpha 1 catalytic subunit; PRKAA2-Protein kinase, AMP-activated, alpha 2 catalytic subunit; PRKAB1-
Protein kinase, AMP-activated, beta 1 non-catalytic subunit; PRKAB2-Protein kinase, AMP-activated, beta 2 non-
catalytic subunit; PRKAG1-Protein kinase, AMP-activated, gamma 1 non-catalytic subunit; PRKAG2-Protein kinase, 
AMP-activated gamma 2 non-catalytic subunit; PRKAG3-Protein kinase, AMP-activated, gamma 3 non-catalytic 
subunit; q-long arm of chromosome 
 
3.4.2 LD assessment 
As previously described, Haploview v.4.2 (Barrett et al., 2005) was used to estimate pair-wise LD 
for all SNPs included in this study in terms of D’ point estimates, r2 values and D’ confidence 
bounds. The D’ evaluations were repeated a total of 100 times with the mode of the observed point 
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estimates reported here. The r2 values and D’ confidence bounds were estimated only once and 
these values are provided in brackets. 
Complete LD (D’=1) was observed for all the SNPs investigated within the genes TNNT2; 
PRKAG3 (rs1000935/rs16859382: r2=1.00; 0.90-1.00), MYL3 (rs1531136/rs3792558: r2=0.783; 
0.87-1.00), PRKAA1, ACTC1 (rs1370154/rs2070664: r2=0.139; 0.39-1.00), ALDOA 
(rs9928448/rs11860935: r2=0.094; 0.14-0.99), TNNI3 (rs3729838/rs11667847: r2=0.403, 0.80-
1.00) and CPT1B (rs470117/rs1557502: r2=0.202; 0.67-1.00). The LD structures of the genes 
covered by 3 or more SNPs, including the aforementioned TNNT2 and PRKAA1 genes, have been 
visually depicted in Tables 3.4 through 3.18 with the r2 and D’ confidence bounds indicated in 
brackets and blue font. The LD structures of the remaining, 2-SNP-covered genes, ranged from 
strong to negligible: PFKM (rs10875749 and rs1859445: D’= 0.00; r2=0.026; 0.05-0.70), MYL2 
(rs4766517 and rs933296: D’= 0.55; r2=0.161; 0.31-0.75), PRKAB2 (rs1348316 and rs6937: D’= 
0.65; r2=0.063; 0.11-0.91), PDK4 (rs2301630 and rs2073978: D’= 0.85; r2=0.0020; 0.00-0.31) and 
PRKAG1 (rs2117029 and rs10875910: D’= 0.95; r2=0.696; 0.78-0.99).  
LD assessment showed that the R92WTNNT2 founder mutation was in complete LD with all other 
TNNT2 SNPs. Similarly, the R403WMYH7 and A797TMYH7 founder mutations indicated complete LD 
with a number of MYH7 SNPs (Refer to Table 3.17). However, it is important to again note that the 
statistical evaluations corrected for the contribution of individual founder mutations to trait variance 
and any significant associations identified are, therefore, independent of founder mutation effect 
(Refer to Section 2.6.4).  
Table 3.4 Pair-wise LD structure for PRKAA2. Complete LD was observed between rs932447 and both 
rs1124900 and rs2796495 (D’= 1), whilst strong LD was observed between rs1124900 and rs2796495       
(D’= 0.95).  
PRKAA2 
 rs1124900 rs2796495 rs932447 
rs932447 1.00 
(0.755; 0.86-1.00) 
1.00 
(0.505; 0.82 -1.00) 
 
rs2796495 0.95 
(0.479; 0.64-0.93) 
  
rs1124900    
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Table 3.5 Pair-wise LD structure for TNNT2. Complete pair-wise LD (D’=1) was observed amongst all 
the TNNT2 gene variants including the R92W founder mutation and the rs4019985 insertion/deletion 
polymorphism. 
TN
N
T2
 
 rs947485 rs4019985 rs1892028 R92W rs2365652 
rs2365652 1.00 
(1.00; 0.93-1.00) 
1.00 
(0.902; 0.88-1.00) 
1.00 
(1.00; 0.93-1.00) 
1.00 
(0.036; 0.10-0.90) 
 
R92W 1.00 
(0.056; 0.18-0.93) 
1.00 
(0.063; 0.20-1.00) 
1.00 
(0.063; 0.19-0.93) 
  
rs1892028 1.00 
(1.00; 0.93-1.00) 
1.00 
(0.897; 0.88-1.00) 
  
 
rs4019985 1.00 
(0.902; 0.88-1.00) 
   
 
rs947485      
 
Table 3.6 Pair-wise LD structure for PPARG. SNPs rs2938392 and rs1175540, as well as rs12490265 and 
rs2938392, were in complete LD (D’= 1) whereas SNPs rs1175540 and rs12490265 were in strong LD 
(D’=0.80). Evidence for incomplete LD was found between SNPs rs12631028 and rs2938392 (D’= 0.45) as 
well as rs12631028 and rs12490265 (D’= 0.75), whilst negligible LD was observed between rs12631028 and 
rs1175540 (D’=0.10).  
PPARG 
 rs1175540 rs2938392 rs12490265 r12631028 
rs12631028 
 
0.10 
(0.015; 0.01-0.48) 
0.45 
(0.044; 0.08-0.69) 
0.75 
(0.017; 0.04-0.80) 
 
rs12490265 
 
0.80 
(0.170; 0.39-0.88) 
1.00 
(0.180; 0.63-1.00) 
  
rs2938392 
 
1.00 
(0.532; 0.83-1.00) 
   
rs1175540     
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Table 3.7 Pair-wise LD structure for PGC1A. The PGC1A gene polymorphisms showed little pair-wise 
LD with the highest D’ value of 0.25, observed for SNP pair rs11724368 and rs13131226, indicating 
incomplete LD.  
PGC1A 
 rs13131226 rs11724368 rs4619879 rs768695 
rs768695 
 
0.02  
(0.0060; 0.0-0.38) 
0.20  
(0.0010; 0.0-0.48) 
0.10 
(0.0020; 0.0-0.33) 
 
rs4619879 
 
0.05  
(0.012; 0.01-0.40) 
0.05  
(0.011; 0.02-0.57) 
  
rs11724368 
 
0.25 
(0.07; 0.1-0.70) 
  
 
rs13131226     
 
Table 3.8 Pair-wise LD structure for PRKAA1. Complete LD (D’=1) was observed for all pairs of SNPs 
investigated in the PRKAA1 gene. 
PRKAA1 
 rs466108 rs11747210 rs12517210 
rs12517210 1.00 
(0.244; 0.65-1.00) 
1.00 
(1.00; 0.91-1.00) 
 
rs11747210 1.00 
(0.244; 0.65-1.00) 
  
rs466108    
 
Table 3.9 Pair-wise LD structure for CD36. The pair-wise D’ prime estimates determined for the CD36 
gene polymorphisms ranged from 0.15 to 0.22 thus indicating negligible to incomplete LD. 
CD36 
 rs3173804 rs3211892 rs10268417 
rs10268417 0.22 
(0.034; 0.02-0.56) 
0.15 
(0.00; 0.01 -0.72) 
 
rs3211892 0.19 
(0.023; 0.02-0.56) 
  
rs3173804    
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Table 3.10 Pair-wise LD structure for PRKAG2. The pair-wise D’ prime values observed for the PRKAG2 
gene polymorphisms ranged from 0.05 to 0.55, indicating negligible to incomplete LD.  
PRKAG2 
 rs13240743 rs6464170 rs2727537 rs8961 
rs8961 0.55 
(0.141; 0.21-0.84) 
0.05 
(0.076; 0.08-0.74) 
0.05 
(0.011; 0.00-0.35) 
 
rs2727537 0.15 
(0.016; 0.02-0.47) 
0.30 
(0.019; 0.03-0.56) 
  
rs6464170 0.20 
(0.0010; 0.01-0.65) 
  
 
rs13240743     
 
Table 3.11 Pair-wise LD structure for MYBPC3. Complete LD (D’= 1.00) was observed for all pairs of 
polymorphisms investigated in the MYBPC3 gene, with the exception of the rs10838696 and rs11570058 
SNP pair with a D’ prime value of 0.95, indicating strong LD. 
MYBPC3 
 rs11570058 rs10838696 rs1052373 rs4752825 
rs4752825 1.00 
(0.105; 0.37-1.00) 
1.00 
(0.145; 0.39-1.00) 
1.00 
(1.00; 0.93-1.00) 
 
rs1052373 1.00 
(0.106; 0.38-1.00) 
1.00 
(0.163; 0.45-1.00) 
  
rs10838696 0.95 
(0.017; 0.09-0.99) 
   
rs11570058     
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Table 3.12 Pair-wise LD structure for ACTN3. SNPs rs1791690 and rs2275998, as well as rs2275998 and 
rs1815739, were in complete LD (D’= 1), whilst evidence for strong LD was found between SNPs 
rs1791690 and rs1815739 (D’= 0.60). 
ACTN3 
 rs1815739 rs2275998 rs1791690 
rs1791690 0.60 
(0.139; 0.21- 0.68) 
1.00 
(0.287; 0.71-1.00) 
 
rs2275998 1.00 
(0.116; 0.41-1.00) 
  
rs1815739    
 
Table 3.13 Pair-wise LD structure for PRKAB1. Overall, significant pair-wise LD, ranging from strong         
(D’= 0.90) to complete (D’= 1.00), was observed for the PRKAB1 gene polymorphisms investigated. 
PRKAB1 
 rs4213 rs278149 rs10849690 rs278143 rs6490267 
rs6490267 0.95 
(0.954;  
0.90-1.00) 
0.93 
(0.769;  
0.80-0.99) 
1.00 
(0.508;  
0.80-1.00) 
0.95 
(0.956;  
0.91-1.00) 
 
rs278143 1.00 
(1.00;  
0.93-1.00) 
0.95 
(0.81;  
0.81-0.99) 
1.00 
(0.535;  
0.81-1.00) 
 
 
rs10849690 1.00 
(0.509;  
0.78-1.00) 
0.90 
(0.46;  
0.66-0.98) 
  
 
rs278149 0.98 
(0.848;  
0.81-0.99) 
   
 
rs4213      
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Table 3.14 Pair-wise LD structure for MYH7. The pair-wise LD observed for the MYH7 gene variants, 
including the A797T and R403W founder mutations, varied from negligible (D’= 0.13) to complete (D’= 
1.00). 
M
YH
7 
 rs2239578 R403W rs2754163 rs1951154 A797T rs2277475 rs765019 
rs765019 0.25 
(0.036; 
0.06-0.71) 
1.00 
(0.0030; 
0.04-0.97) 
0.76 
(0.209; 
0.44-0.96) 
0.90 
(0.049; 
0.13-0.99) 
1.00 
(0.0020; 
0.03-0.85) 
0.58 
(0.118; 
0.16-0.76) 
 
rs2277475 
 
0.20 
(0.064; 
0.08-0.60) 
1.00 
(0.0090; 
0.06-0.98) 
0.90 
(0.575; 
0.75-0.99) 
0.75 
(0.117; 
0.48-1.00) 
1.00 
(0.024; 
0.07-0.89) 
 
 
A797T 
 
0.55 
(0.032; 
0.06-0.81) 
1.00 
(0.0050; 
0.04-0.97) 
1.00 
(0.057; 
0.15-0.92) 
0.83 
(0.269; 
0.35-0.88) 
  
 
rs1951154 
 
1.00 
(0.221; 
0.63-1.00) 
1.00 
(0.0070; 
0.05-0.98) 
1.00 
(0.175; 
0.63-1.00) 
   
 
rs2754163 
 
0.13 
(0.0050; 
0.00-0.32) 
1.00 
(0.012; 
0.06-0.98) 
    
 
R403W 1.00 
(0.0010; 
0.02-0.83) 
     
 
rs2239578        
 
Table 3.15 Pair-wise LD structure for CKB. SNPs rs1803283 and rs1136165 (D’= 0.35), as well as 
rs1803283 and rs2071407 (D’= 0.75), showed incomplete LD. Evidence for strong LD was found between 
SNPs rs2071407 and rs1136165 (D’= 0.84). 
CKB 
 rs1136165 rs2071407 rs1803283 
rs1803283 0.35 
(0.146; 0.18-0.58) 
0.75  
(0.359; 0.52-0.88) 
 
rs2071407 0.84 
(0.618; 0.72-0.97) 
 
 
rs1136165    
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Table 3.16 Pair-wise LD structure for TPM1. The pair-wise LD observed for the TPM1 gene variants 
ranged from negligible (D’= 0.10) to complete (D’= 1.00). 
TPM1 
 rs707602 rs1071646 rs4238370 rs11071720 
rs11071720 0.10 
(0.07; 0.09-0.99) 
0.13 
(0.00; 0.00-0.44) 
0.30 
(0..0010; 0.00-0.40) 
 
rs4238370 0.50 
(0.018; 0.04-0.97) 
0.65 
(0238; 0.34-0.78) 
 
 
rs1071646 1.00 
(0.179; 0.48-1.00) 
 
 
 
rs707602     
 
Table 3.17 Pair-wise LD structure for CKM. Pair-wise LD observed for the CKM gene variants ranging 
from negligible (D’= 0.00) to strong (D’= 0.88). 
CKM 
 rs344816 rs1133190 rs7260463 rs8111989 
rs8111989 0.35 
(0.041; 0.05-0.42) 
0.45 
(0.052; 0.05-0.56) 
0.88 
(0.754; 0.74-0.94) 
 
rs7260463 0.35 
(0.043; 0.05-0.41) 
0.25 
(0.03; 0.03-0.50) 
 
 
rs1133190 0.00 
(0.0010; 0.00-0.33) 
 
 
 
rs344816     
 
Table 3.18 Pair-wise LD structure for PPARA. SNPs rs881740 and rs4253776 (D’= 0.30), as well as 
rs4823613 and rs4253776 (D’= 0.60), showed incomplete LD, whilst negligible LD was observed for SNP 
pair rs881740 and rs4823613 (D’= 0.00). 
PPARA 
 rs4253776 rs4823613 rs881740 
rs881740 0.30 
(0.012; 0.01-0.48) 
0.00 
(0.021; 0.03-0.66) 
 
rs4823613 0.60 
(0.221; 0.35-0.83) 
 
 
rs4253776    
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3.4.3 Principal component analysis 
PCA was applied to the 16 transformed wall thickness measurements to define the mathematical 
combination, or weighted average, of these measurements that best captures the variability in left 
ventricular wall thickness measurements; that is, a single score that best reflects cohort-specific 
hypertrophy, as distributed throughout the left ventricle. A score, PC1, accounting for 75% of the 
overall variability in hypertrophy was identified, and its weighted composition is detailed in Table 
3.19. 
Table 3.19 The PC1 score defined in terms of its weighted composition: the weight of each 
wall thickness measurement 
Wall thickness measurement Weight contribution to PC1 
pIVS at mitral valve 0.253 
aIVS at mitral valve 0.261 
AW at mitral valve 0.256 
LW at mitral valve 0.249 
IW at mitral valve 0.221 
PW at mitral valve 0.221 
pIVS at papillary muscle 0.262 
aIVS at papillary muscle 0.269 
AW at papillary muscle 0.267 
LW at papillary muscle 0.254 
IW at papillary muscle 0.234 
PW at papillary muscle 0.238 
IVS at apex 0.263 
AW at apex 0.259 
LW at apex 0.239 
PW at apex 0.248 
Abbreviations: aIVS-anterior interventricular septum thickness; AW-anterior wall thickness; IVS-interventricular 
septum thickness; IW- inferior wall thickness; LW-lateral wall thickness; PC1-first principal component; pIVS-
posterior interventricular septum thickness; PW-posterior wall thickness 
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3.4.4 Heritability 
The respective contributions of environmental and genetic factors (heritability) to the phenotypic 
variability of the traits investigated were determined as detailed in Section 2.6.5. These estimates 
are reported in Table 3.20 along with the p-values for each test of heritability. All six hypertrophy 
traits indicated a considerable genetic component after adjustment for known hypertrophy 
covariates described in Section 2.6.4.  
Table 3.20 The environmental and heritability estimates detailed as estimated percentage 
contribution to trait variance as well as the p-values for heritability 
Hypertrophy trait Environmental (%) Heritability (%) p-value 
LVMecho 41 59 < 0.0001 
mIVST 56 44 < 0.0001 
mLVWT 44 55 0.0001 
mPWT 44 56 0.0002 
CWTscore 59 41 0.0018 
PC1 48 52 0.0009 
Abbreviations: CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-maximal 
interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal posterior wall 
thickness; PC1-first principal component 
3.4.5 Association and interaction analyses 
The results obtained for the association and interaction analyses are detailed per gene and in order 
of function, i.e. sarcomeric genes and genes relating to myocardial energetics (as per Section 2.3.3). 
Moreover, the original p-values for the tests of association are tabulated, whilst bar graphs plot the 
corresponding –log10 transformed p-values against the relevant SNP- or haplotype-trait 
combination. A red dashed horizontal line indicates the p-value significance threshold equal to 0.05. 
Bars that intersect this line, therefore, indicate significant p-values (p-value < 0.05). The higher the 
bar, the smaller the p-value. The values reported reflect association that is independent of 
hypertrophy confounders, as well as independent of both carrier status and identity of the relevant 
HCM-causing founder mutations. 
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The p-values obtained for the interaction analyses, i.e. whether the effect of the investigated 
variants/haplotypes on individual hypertrophy traits varied amongst the three HCM founder 
mutation groups, are tabulated per pairwise-comparison of the three HCM founder mutation groups 
with respect to each SNP- or haplotype-trait evaluation. The interpretation of a significant 
interaction result has been demonstrated in Section 2.6.8. The graphs indicate the strength of the 
associations whereas characterisation of the significant results in terms of effect (protective or 
exacerbating) and effect size is done in the text. More specifically, in instances of significant single 
SNP associations the in-text descriptions are done in terms of the minor allele, which is also 
indicated on the graphs along with up and down arrows representing exacerbating and 
cardioprotective effects, respectively. Similarly, arrows are indicated on the graphs of significantly 
associated haplotypes to illustrate their directional effect. 
3.4.5.1 ACTC1  
The p-values for the association between the ACTC1 SNPs and hypertrophy traits are given in 
Figure 3.3; and the p-values for pair-wise differences between mutation groups in the association 
between the ACTC1 SNPs and hypertrophy traits are given in Table 3.21. No statistically 
significant single SNP effect or difference in SNP effect amongst the three HCM founder mutation 
groups was observed.  
The p-values for the association between ACTC1 haplotypes and hypertrophy traits are graphically 
represented in Figure 3.4. The p-values for pair-wise comparison between mutation groups in the 
association between ACTC1 haplotypes and hypertrophy traits are given in Table 3.22. The effect 
of the CC haplotype, identified in 23% of the cohort, was an estimated decrease of 0.51 mm in 
LVM (p = 0.013). The CT haplotype, present in 37% of the cohort, was associated with increases in 
LVM (p = 0.004) and mIVST (p = 0.039) of 1.55 mm and 1.05 mm, respectively. No significant 
difference in haplotype effect was observed amongst the mutation groups.  
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Figure 3.3 The p-values for tests of association between single SNPs in ACTC1 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.21 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in ACTC1. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs1370154 0.937 0.239 0.294 0.540 0.832 0.473 0.544 0.617 0.339 0.162 0.443 0.530 0.542 0.741 0.404 0.547 0.659 0.358 
rs2070664 0.730 0.906 0.691 0.376 0.935 0.408 0.339 0.948 0.383 0.668 0.652 0.984 0.908 0.750 0.862 0.912 0.994 0.919 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.4 The p-values for tests of association between ACTC1 haplotypes and individual hypertrophy 
traits. The original p-values are given in the data table, whilst the graph represents the corresponding –log10 
transformed values. The red dashed horizontal line indicates the p-value significance threshold equal to 0.05. 
Bars located above this line, therefore, indicate significant p-values (p-values<0.05). The p-value 
significance increases with bar height above threshold. The observed haplotype frequencies are indicated in 
brackets. 
Table 3.22 The p-values obtained for the analysis of interaction between mutation group and 
ACTC1 haplotypes. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
13
70
15
4 
rs
20
70
66
4 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W  
vs 
R403W 
C C 0.824 0.804 0.686 0.461 0.718 0.335 0.475 0.646 0.305 0.816 0.832 0.701 0.715 0.399 0.741 0.773 0.561 0.845 
C T 0.793 0.410 0.330 0.097 0.998 0.123 0.110 0.764 0.081 0.159 0.380 0.566 0.686 0.404 0.270 0.748 0.432 0.324 
T T 0.906 0.337 0.499 0.651 0.683 0.459 0.519 0.467 0.236 0.302 0.852 0.417 0.511 0.604 0.294 0.601 0.445 0.262 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
 
 
┌  ↑  ┐ ┌  ↓  ┐ 
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3.4.5.2 MYH7  
Figure 3.5 graphically represents the p-values for association between the MYH7 SNPs and 
hypertrophy traits. The rs2277475 SNP had a statistically significant effect on mLVWT                
(p = 0.016), the CWT score (p = 0.026) and PC1 (p = 0.045). More specifically, the effect of the T-
allele was an estimated decrease of 1.19 mm in mLVWT, 8.64 mm in the CWT score and 0.54 in 
PC1. Table 3.23 details the p-values for pair-wise differences between mutation groups in the 
association between MYH7 SNPs and hypertrophy traits. The rs2277475 SNP also indicated a 
significant difference in SNP effect amongst the HCM founder mutation groups. The effect of the 
T-allele was higher in the R403WMYH7 group compared to the A797TMYH7 group with 18.2 mm on 
the CWT score (p = 0.032) and 1.14 on PC1 (p = 0.034). Its effect was lower in the R92WTNNT2 
group relative to the R403WMYH7 group with 24.8 mm on the CWT score (p = 0.013) and 1.55 on 
PC1 (p = 0.009). 
Figure 3.6 graphically represents the p-values for association between MYH7 haplotypes and 
hypertrophy traits. No statistically significant haplotype effect was observed. Table 3.24 details the 
p-values for pair-wise comparison between mutation groups in the association between MYH7 
haplotypes and hypertrophy traits. Significant differences in haplotype effect were observed 
between the mutation groups for haplotypes TTGCG and TAGCA. The effect of the first, observed 
in 7% of the cohort, was lower in the R92WTNNT2 group relative to the R403WMYH7 group with 1.84 
on PC1 (p = 0.039). Conversely the effect of the second, observed in 2% of the cohort, was higher 
in the R92WTNNT2 group relative to the R403WMYH7 group: 58.4 g on LVM (p = 0.028), 36.7 mm on 
the CWT score (p = 0.023) and 2.29 on PC1 (p = 0.019). 
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Figure 3.5 The p-values for tests of association between single SNPs in MYH7 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.23 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in MYH7. Significant results are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs765019 0.872 0.937 0.929 0.381 0.174 0.799 0.589 0.314 0.763 0.552 0.967 0.553 0.432 0.399 0.935 0.547 0.598 0.876 
rs2277475 0.900 0.648 0.628 0.117 0.468 0.347 0.305 0.679 0.190 0.607 0.251 0.160 0.032 0.570 0.013 0.034 0.466 0.009 
rs1951154 0.561 0.938 0.656 0.333 0.535 0.717 0.345 0.682 0.614 0.656 0.654 0.957 0.133 0.631 0.335 0.261 0.706 0.479 
rs2754163 0.666 0.649 0.986 0.441 0.358 0.948 0.672 0.927 0.624 0.726 0.933 0.676 0.364 0.938 0.417 0.322 0.948 0.366 
rs2239578 0.958 0.329 0.425 0.316 0.178 0.887 0.404 0.159 0.704 0.514 0.784 0.366 0.613 0.184 0.514 0.783 0.175 0.358 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
┌  T↓  ┐     
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Figure 3.6 The p-values for tests of association between MYH7 haplotypes and individual hypertrophy 
traits. The original p-values are given in the data table, whilst the graph represents the corresponding –log10 
transformed values. The red dashed horizontal line indicates the p-value significance threshold equal to 0.05. 
Bars located above this line, therefore, indicate significant p-values (p-values<0.05). The p-value 
significance increases with bar height above threshold. The observed haplotype frequencies are indicated in 
brackets. 
Table 3.24 The p-values obtained for the analysis of interaction between mutation group and 
MYH7 haplotypes. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
76
50
19
 
rs
22
77
47
5  
rs
19
51
15
4  
rs
27
54
16
3  
rs
22
39
57
8  
R403W 
vs  
A797T 
R92W 
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W 
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W 
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W 
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W 
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W 
vs 
A797T 
R92W  
vs  
R403W 
C T G C G 0.881 0.263 0.380 0.714 0.517 0.814 0.651 0.568 0.931 0.626 0.100 0.304 0.954 0.278 0.367 0.682 0.110 0.304 
T A A T A 0.573 0.978 0.635 0.739 0.360 0.325 0.676 0.306 0.257 0.855 0.887 0.970 0.298 0.266 0.086 0.496 0.274 0.159 
T A G T A 0.414 0.740 0.562 0.758 0.619 0.910 0.524 0.867 0.593 0.105 0.254 0.471 0.112 0.673 0.173 0.116 0.748 0.152 
T A G T G 0.998 0.804 0.819 0.352 0.654 0.568 0.879 0.987 0.860 0.465 0.784 0.606 0.551 0.979 0.533 0.702 0.978 0.659 
T T G C A** 0.839 - - 0.337 - - 0.882 - - 0.714 - - 0.634 - - 0.491 - - 
T T G C G 0.637 0.919 0.641 0.980 0.437 0.396 0.428 0.069 0.271 0.809 0.545 0.324 0.606 0.305 0.060 0.512 0.302 0.039 
T A G C G 0.908 0.422 0.457 0.653 0.838 0.763 0.461 0.787 0.588 0.141 0.940 0.149 0.395 0.694 0.577 0.424 0.906 0.473 
T A G C A** - - 0.028 - - 0.109 - - 0.107 - - 0.106 - - 0.023 - - 0.019 
** absence of p-values indicates unequal distribution of haplotypes in the three HCM mutation groups resulting in 
stratified groups of small size with insufficient statistical power for testing 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
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3.4.5.3 TNNT2 
The p-values for the association between the TNNT2 SNPs and hypertrophy traits are given in 
Figure 3.7; and the p-values for pair-wise comparison between mutation groups in the association 
of TNNT2 SNPs and hypertrophy traits are given in Table 3.25. No statistically significant single 
SNP effect was observed. The effect of the rs2365652 SNP varied significantly amongst the HCM 
founder mutation groups. The effect of the A-allele was estimated to be higher in the R92WTNNT2 
group relative to the A797TMYH7 group with 2.30 mm on mIVST (p = 0.049).   
Figure 3.8 graphically represents the p-values for association between TNNT2 haplotypes and 
hypertrophy traits. No statistically significant haplotype effect was observed. Table 3.26 details the 
p-values for pair-wise differences between mutation groups in the association between TNNT2 
haplotypes and hypertrophy traits. The AAIG and CGIA haplotypes indicated significant 
differences in haplotype effect amongst the three mutation groups. The effect of the first was higher 
on LVM (23.5 g; p = 0.028) in the R403WMYH7 group compared to the A797TMYH7 group. The effect 
of the second was lower on mIVST (12.57 mm; p = 0.008), mLVWT (11.34 mm; p = 0.034) and the 
CWT score (89.4 mm; p = 0.034) in the R403WMYH7 group relative to the A797TMYH7 group.  
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Figure 3.7 The p-values for tests of association between single SNPs in TNNT2 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.25 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in TNNT2. Significant results are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs 
A797T 
R92W 
vs  
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs  
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs 
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs  
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs  
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs  
A797T 
R92W 
vs 
R403W 
rs2365652 0.899 0.054 0.117 0.147 0.049 0.701 0.423 0.589 0.788 0.547 0.507 0.983 0.450 0.212 0.723 0.580 0.182 0.535 
rs1892028 0.892 0.138 0.250 0.122 0.101 0.999 0.362 0.795 0.545 0.911 0.617 0.745 0.395 0.311 0.966 0.463 0.237 0.769 
rs4019985 0.779 0.106 0.254 0.165 0.255 0.737 0.236 0.623 0.481 0.636 0.251 0.588 0.200 0.374 0.628 0.341 0.387 0.854 
rs947485 0.879 0.083 0.178 0.090 0.094 0.908 0.294 0.727 0.508 0.899 0.587 0.729 0.314 0.220 0.941 0.425 0.175 0.703 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.8 The p-values for tests of association between TNNT2 haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.26 The p-values obtained for the analysis of interaction between mutation group and 
TNNT2 haplotypes. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
23
65
65
2  
rs
18
92
02
8  
rs
40
19
98
5  
rs
94
74
85
 
R403W 
vs 
 A797T 
R92W 
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W 
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W 
vs 
A797T 
R92W  
vs 
R403W 
A A I G 0.028 0.152 0.448 0.212 0.912 0.178 0.462 0.738 0.288 0.376 0.546 0.782 0.200 0.824 0.326 0.176 0.600 0.452 
C G D A 0.090 0.096 0.920 0.128 0.822 0.110 0.324 0.602 0.158 0.282 0.866 0.414 0.092 0.988 0.140 0.070 0.708 0.226 
C G I A 0.374 0.616 0.584 0.008 0.136 0.116 0.034 0.382 0.110 0.180 0.224 0.724 0.034 0.242 0.208 0.076 0.248 0.382 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; D-deletion; G-
Guanine*; I-insertion; LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-
maximal left ventricular wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-
Arginine; SNP-single nucleotide polymorphism; T-Threonine; vs-versus; W-Tryptophan 
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3.4.5.4 TNNI3 
The p-values for the association between the TNNI3 SNPs and hypertrophy traits; and the p-values 
for pair-wise differences between mutation groups in the association between TNNI3 SNPs and 
hypertrophy traits are given in Figure 3.9 and Table 3.27, respectively. No statistically significant 
single SNP effect was observed. However, the effects of SNPs rs3729838 and rs11667847 varied 
amongst the three HCM founder mutation groups. The effect of the G-allele of rs3729838 was 
higher on mLVWT (2.45 mm; p = 0.021), whilst the effect of the G-allele of rs11667847 was lower 
on LVM (34.3 g; p = 0.046) in the R92WTNNT2 group compared to the R403WMYH7 group. 
The p-values for the association between the TNNI3 haplotypes and hypertrophy traits are 
graphically represented in Figure 3.10. The p-values for pair-wise comparison between mutation 
groups in the association between TNNI3 haplotypes and hypertrophy traits are given in Table 
3.28. No statistically significant haplotype effect was observed. However, the CA and GA 
haplotypes, observed in 54% and 21% of the cohort, respectively, showed significant differences in 
haplotype effect amongst the HCM founder mutation groups. The effect of the first was lower on 
mLVWT (1.97 mm; p = 0.037) in the R92WTNNT2 group compared to the R403WMYH7 group. The 
effect of the second was higher on mIVST (3.7 mm; p = 0.032) and mLVWT (3.46 mm; p = 0.009) 
in the R92WTNNT2 group relative to the R403WMYH7 group; and lower on mLVWT                       
(4.47 mm; p = 0.045) in the R403WMYH7 group compared to the A797TMYH7 group.  
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Figure 3.9 The p-values for tests of association between single SNPs in TNNI3 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.27 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in TNNI3. Significant  are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs3729838 0.783 0.284 0.456 0.274 0.743 0.182 0.080 0.482 0.021 0.326 0.746 0.531 0.180 0.821 0.140 0.395 0.828 0.315 
rs11667847 0.552 0.219 0.046 0.512 0.981 0.454 0.764 0.748 0.982 0.704 0.704 0.409 0.894 0.949 0.936 0.906 0.907 0.996 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.10 The p-values for tests of association between TNNI3 haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.28 The p-values obtained for the analysis of interaction between mutation group and 
TNNI3 haplotypes. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
37
29
83
8  
rs
11
66
78
47
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
C A 0.782 0.288 0.495 0.546 0.529 0.266 0.330 0.183 0.037 0.493 0.916 0.463 0.407 0.732 0.273 0.687 0.673 0.450 
G A 0.484 0.870 0.404 0.110 0.495 0.032 0.045 0.464 0.009 0.539 0.207 0.627 0.198 0.911 0.232 0.322 0.839 0.414 
G G 0.630 0.253 0.073 0.660 0.832 0.467 0.889 0.773 0.873 0.836 0.743 0.561 0.864 0.805 0.941 0.886 0.987 0.854 
Abbreviations: A-Adenine*, A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
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3.4.5.5 TPM1 
Figure 3.11 graphically represents the p-values for the association between the TPM1 SNPs and 
hypertrophy traits. The effect of the C-allele of the rs11071720 variant was an estimated 0.49 mm 
decrease in mPWT (p = 0.008). The C-allele of the rs1071646 variant was associated with an 
increase in all measures: 17.3 g in LVM (p = 0.006), 2.02 mm in mIVST (p = 0.002), 1.75 mm in 
mLVWT (p = 0.005), 0.59 in mPWT (p = 0.004), 17.68 mm in the CWT score (p < 0.001) and 1.10 
in PC1 (p < 0.001). The effect of the C-allele of the rs707602 variant was an estimated increase of 
1.0 mm in mLVWT (p = 0.031) and 0.83 mm in mPWT (p = 0.023). 
Table 3.29 details the p-values for pair-wise differences between mutation groups in the 
association between the TPM1 SNPs and hypertrophy traits. The rs11071720 SNP also indicated 
significant differences in SNP effect amongst the HCM founder mutation groups. The effect of the 
C-allele was higher in the R92WTNNT2 group relative to the A797TMYH7 group with 2.65 mm on 
mIVST (p = 0.024). The effect of the T-allele of the rs4238370 variant was lower in the R92WTNNT2 
group compared to the A797TMYH7 group: 48.1 g on LVM (p = 0.045), 3.84 mm on mIVST (p = 
0.022), 4.84 mm on mLVWT (p = 0.016), 45.6 mm on the CWT score (p = 0.003) and 2.85 on PC1 
(p = 0.004). Also, its effect was lower in the R403WMYH7 group relative to the A797TMYH7 group: 
3.99 mm on mIVST (p = 0.019), 35.8 mm on the CWT score (p = 0.011) and 2.23 on the PC1 
measure (p = 0.019). 
Figure 3.12 graphically represents the p-values for the association between TPM1 haplotypes and 
hypertrophy traits with evidence of statistically significant haplotype effects for haplotypes CGAT, 
CTCT and CGCT. The effect of the first, present in 27% of the cohort, was an estimated decrease of 
18.1 g in LVM (p = 0.004), 0.78 mm in mPWT (p = 0.001), 9 mm in the CWT score (p = 0.042) 
and 0.56 in PC1 (p = 0.006). The second, observed in 6% of the cohort, was associated with an 
estimated increase of 3.21 mm in mIVST (p = 0.012), 3.13 mm in mLVWT (p = 0.022), 30.2 mm in 
the CWT score (p = 0.004) and 1.89 in PC1 (p = 0.006). The final haplotype, identified in 3% of the 
cohort, was associated with an increase of 47.9 g in LVM (p = 0.004). 
Table 3.30 details the p-values for pair-wise differences between mutation groups in the 
association between TPM1 haplotypes and hypertrophy traits. The CGAT haplotype that showed a 
significant haplotype effect as well as the TGCT haplotype indicated significant differences in 
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haplotype effect amongst the HCM founder mutation groups. The effect of the CGAT haplotype 
was higher on mIVST (2.98 mm; p = 0.040) and the CWT score (18.4 mm; p = 0.046) in the 
R92WTNNT2 group relative to the R403WMYH7 group. Also, its effect was higher in the R403WMYH7 
group compared to the A797TMYH7 group:  3.88 mm on mIVST (p = 0.010) and 28.5 mm on the 
CWT score (p = 0.020) and 1.78 on PC1 (p = 0.040). The effect of the TGCT haplotype was lower 
on LVM in the R92WTNNT2 group compared to the A797TMYH7 group (105 g; p = 0.014); and higher 
on LVM in R92WTNNT2 group compared to the R403WMYH7 group (105.5 g; p = 0.018).  
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Figure 3.11 The p-values for tests of association between single SNPs in TPM1 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.29 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in TPM1. Significant results are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs11071720 0.921 0.422 0.429 0.211 0.024 0.464 0.605 0.165 0.479 0.879 0.988 0.872 0.303 0.103 0.694 0.443 0.141 0.608 
rs4238370 0.118 0.045 0.527 0.019 0.022 0.789 0.082 0.016 0.370 0.162 0.189 0.931 0.011 0.003 0.473 0.019 0.004 0.432 
rs1071646 0.571 0.647 0.389 0.447 0.662 0.843 0.459 0.617 0.913 0.310 0.271 0.841 0.214 0.253 0.932 0.217 0.185 0.798 
rs707602 0.489 0.063 0.510 0.257 0.288 0.806 0.430 0.502 0.833 0.695 0.354 0.773 0.451 0.393 0.938 0.416 0.274 0.976 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
┌  C↓  ┐     ┌  C↑  ┐     ┌  C↑  ┐     
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Figure 3.12 The p-values for tests of association between TPM1 haplotypes and individual hypertrophy 
traits. The original p-values are given in the data table, whilst the graph represents the corresponding –log10 
transformed values. The red dashed horizontal line indicates the p-value significance threshold equal to 0.05. 
Bars located above this line, therefore, indicate significant p-values (p-values<0.05). The p-value 
significance increases with bar height above threshold. The observed haplotype frequencies are indicated in 
brackets. 
Table 3.30 The p-values obtained for the analysis of interaction between mutation group and 
TPM1 haplotypes. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
11
07
17
20
 
rs
42
38
37
0  
rs
10
71
64
6  
rs
70
76
02
 R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
C G A T 0.182 0.568 0.440 0.010 0.576 0.040 0.060 0.802 0.100 0.182 0.774 0.300 0.020 0.786 0.046 0.040 0.760 0.088 
C G C C** - - - - - - - - - - - - - - - - - - 
C T C T** - - - - - - - - - - - - - - - - - - 
T G A T 0.188 0.726 0.390 0.350 0.974 0.416 0.544 0.778 0.784 0.420 0.704 0.728 0.792 0.978 0.834 0.756 0.798 0.980 
T T C T 0.846 0.936 0.880 0.186 0.750 0.210 0.138 0.526 0.254 0.468 0.770 0.568 0.094 0.274 0.346 0.142 0.210 0.594 
C G C T** - - - - - - - - - - - - - - - - - - 
T G C T 0.908 0.014 0.018 0.538 0.094 0.252 0.984 0.280 0.288 0.724 0.178 0.296 0.590 0.078 0.160 0.732 0.114 0.176 
** absence of p-values indicates unequal distribution of haplotypes in the three HCM mutation groups resulting in 
stratified groups of small size with insufficient statistical power for testing 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
┌  ↓  ┐    ┌  ↑  ┐    ┌  ↑  ┐    
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3.4.5.6 MYL2 
Figure 3.13 graphically represents the p-values for the association between the MYL2 SNPs and 
hypertrophy traits. A statistically significant SNP effect was observed for rs933296. The effect of 
the A-allele was an estimated decrease of 13.6 g in LVM (p = 0.018), 9.57 mm in the CWT score   
(p = 0.049) and 0.60 in PC1 (p = 0.032). Table 3.31 details the p-values for pair-wise comparison 
between mutation groups in the association between MYL2 SNPs and hypertrophy traits. No 
significant difference in variant effect was observed amongst the three mutation groups. 
Figure 3.14 graphically represents the p-values for the association between MYL2 haplotypes and 
hypertrophy traits. Evidence of statistically significant haplotype effects were identified for 
haplotypes AC an AG, present in 2% and 20% of the cohort, respectively. The effect of the AC 
haplotype was an estimated decrease of 25.1 g in LVM (p = 0.031). The effect of the AG haplotype 
was an estimated 0.60 decrease in PC1 (p = 0.042). Table 3.32 details the p-values for pair-wise 
differences between mutation groups in the association between MYL2 haplotypes and 
hypertrophy traits with no evidence of significant differences in haplotype effect amongst the three 
HCM founder mutation groups. 
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Figure 3.13 The p-values for tests of association between single SNPs in MYL2 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.31 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in MYL2. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs933296 0.644 0.537 0.966 0.717 0.381 0.274 0.530 0.548 0.258 0.221 0.489 0.077 0.341 0.337 0.085 0.314 0.257 0.056 
rs4766517 0.780 0.312 0.580 0.710 0.786 0.876 0.728 0.687 0.984 0.212 0.680 0.348 0.362 0.615 0.597 0.256 0.715 0.383 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
 
 
 
 
 
┌     A↓    ┐     
Stellenbosch University  http://scholar.sun.ac.za
  
106│Chapter 3 
 
Figure 3.14 The p-values for tests of association between MYL2 haplotypes and individual hypertrophy 
traits. The original p-values are given in the data table, whilst the graph represents the corresponding –log10 
transformed values. The red dashed horizontal line indicates the p-value significance threshold equal to 0.05. 
Bars located above this line, therefore, indicate significant p-values (p-values<0.05). The p-value 
significance increases with bar height above threshold. The observed haplotype frequencies are indicated in 
brackets. 
Table 3.32 The p-values obtained for the analysis of interaction between mutation group and 
MYL2 haplotypes. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
93
32
96
 
rs
47
66
51
7 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
A C 0.826 0.564 0.728 0.804 0.403 0.362 0.513 0.677 0.389 0.791 0.851 0.721 0.676 0.780 0.564 0.627 0.918 0.628 
A G 0.622 0.304 0.269 0.601 0.962 0.638 0.545 0.731 0.712 0.356 0.819 0.309 0.274 0.475 0.515 0.390 0.402 0.726 
C C 0.546 0.864 0.693 0.571 0.579 0.331 0.682 0.898 0.634 0.114 0.757 0.250 0.830 0.750 0.941 0.877 0.879 0.990 
C G 0.385 0.123 0.541 0.533 0.233 0.623 0.379 0.289 0.885 0.346 0.588 0.181 0.162 0.294 0.713 0.150 0.118 0.945 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; vs-versus; W-Tryptophan 
 
 
 
┌  ↓  ┐ ┌  ↓  ┐ 
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3.4.5.7 MYL3 
Figure 3.15 graphically represents the p-values for the association between the MYL3 SNPs and 
hypertrophy traits. Table 3.33 details the p-values for the pair-wise differences between mutation 
groups in the association of MYL3 SNPs and hypertrophy traits. No statistically significant single 
SNP effect or difference in SNP effect amongst the three HCM founder mutation groups was 
observed.  
Figure 3.16 graphically represents the p-values for the association between MYL3 haplotypes and 
hypertrophy traits. Significant haplotype effects were identified for haplotypes CC and TC. The 
effect of the first, observed in 49% of the cohort, was an estimated decrease of 8 g in LVM             
(p = 0.014), 0.32 mm in mPWT (p = 0.026), 3.7 mm in the CWT score (0.042) and 0.23 in PC1      
(p = 0.030). The effect of the second haplotype, present in 3% of the cohort, was an estimated 
increase of 25.6 mm in the CWT score (p = 0.018) and 1.6 in PC1 (p = 0.035). Table 3.34 details 
the p-values for pair-wise differences between mutation groups in the association of MYL3 
haplotypes and hypertrophy traits. No statistically significant difference in haplotype effect was 
observed amongst the three HCM founder mutation groups. 
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Figure 3.15 The p-values for tests of association between single SNPs in MYL3 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.33 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in MYL3. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
rs1531136 0.644 0.537 0.966 0.717 0.381 0.274 0.530 0.548 0.258 0.221 0.489 0.077 0.341 0.337 0.085 0.314 0.257 0.056 
rs3792558 0.780 0.312 0.580 0.710 0.786 0.876 0.728 0.687 0.984 0.212 0.680 0.348 0.362 0.615 0.597 0.256 0.715 0.383 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.16 The p-values for tests of association between MYL3 haplotypes and individual hypertrophy 
traits. The original p-values are given in the data table, whilst the graph represents the corresponding –log10 
transformed values. The red dashed horizontal line indicates the p-value significance threshold equal to 0.05. 
Bars located above this line, therefore, indicate significant p-values (p-values<0.05). The p-value 
significance increases with bar height above threshold. The observed haplotype frequencies are indicated in 
brackets. 
Table 3.34 The p-values obtained for the analysis of interaction between mutation group and 
single haplotypes in MYL3. 
Haplotype* LVM  mIVST  mLVWT  mPWT  CWT score  PC1  
rs
15
31
13
6  
rs
37
92
55
8  R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
C C 0.267 0.717 0.163 0.494 0.612 0.749 0.290 0.467 0.587 0.206 0.280 0.619 0.261 0.685 0.390 0.271 0.676 0.408 
T C 0.589 0.932 0.534 0.562 0.633 0.351 0.071 0.989 0.063 0.143 0.519 0.248 0.186 0.532 0.080 0.587 0.692 0.422 
T T 0.797 0.912 0.715 0.666 0.400 0.775 0.869 0.824 0.979 0.617 0.439 0.236 0.517 0.896 0.433 0.410 0.736 0.253 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; LVM-left ventricular mass; 
mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-
maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; 
T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
 
 
 
┌  ↓  ┐ ┌  ↑  ┐ 
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3.4.5.8 MYBPC3 
Figure 3.17 graphically represents the p-values for the association between the MYBPC3 SNPs and 
hypertrophy traits with no evidence of statistically significant SNP effects. Table 3.35 details the p-
values for the pair-wise comparison between mutation groups in the association of MYBPC3 SNPs 
and hypertrophy traits. The effect of the A-allele of rs4752825 and the T-allele of rs1052373 was 
higher on LVM in the R92WTNNT2 group compared to A797TMYH7 group (22.6 g; p = 0.020 and  
22.5 g; p = 0.019).  
Figure 3.18 graphically represents the p-values for the association between MYBPC3 haplotypes 
and hypertrophy traits. The effect of the ATGG haplotype, identified in 25% of the cohort, was an 
estimated decrease of 0.51 mm in mPWT (p = 0.026). Table 3.36 details the p-values for pair-wise 
comparison between mutation groups in the association of MYBPC3 haplotypes and hypertrophy 
traits. The effect of the ATGA haplotype, observed in 10% of the cohort, was higher on LVM     
(65.1 g; p = 0.002), mPWT (1.66 mm; p = 0.032), the CWT score (8.6 mm; p = 0.038) and PC1 
(0.54; p = 0.048) in the R403WMYH7 group compared to the A797TMYH7 group. Its effect was also 
higher on LVM (29.9 g, p = 0.046) and mPWT (1.25 mm; p = 0.046) in the R92WTNNT2 group 
relative to the R403WMYH7 group. Finally, its effect was lower on PC1 (0.05; p < 0.001) in the 
R92WTNNT2 group compared to the A797TMYH7 group. The effect of the GCGG haplotype, observed 
in 37% of the cohort, was lower on the LVM measure (36.8 g; p = 0.002) in the R403WMYH7 group 
compared to the A797TMYH7 group. Also, its effect was lower on LVM (30.9 g; p = 0.008), mPWT 
(1.13 mm; p = 0.012) and PC1 (1.10; p = 0.042) in the R92WTNNT2 group relative to the R403WMYH7 
group. 
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Figure 3.17 The p-values for tests of association between single SNPs in MYBPC3 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.35 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in MYBPC3. Significant results are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs4752825 0.266 0.020 0.447 0.313 0.255 0.941 0.359 0.413 0.809 0.297 0.980 0.326 0.532 0.561 0.883 0.413 0.643 0.665 
rs1052373 0.147 0.019 0.650 0.210 0.221 0.805 0.267 0.371 0.711 0.214 0.686 0.376 0.400 0.520 0.752 0.336 0.543 0.643 
rs10838696 0.393 0.997 0.464 0.811 0.925 0.777 0.536 0.578 0.319 0.368 0.925 0.394 0.364 0.745 0.604 0.254 0.663 0.529 
rs11570058 0.140 0.062 0.422 0.220 0.313 0.875 0.597 0.575 0.846 0.177 0.306 0.936 0.254 0.240 0.742 0.303 0.295 0.779 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.18 The p-values for tests of association between MYBPC3 haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.36 The p-values obtained for the analysis of interaction between mutation group and 
individual haplotypes in MYBPC3. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
47
52
82
5  
rs
10
52
37
3  
rs
10
83
86
96
 
rs
11
57
00
58
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
A T G A 0.002 0.800 0.046 0.100 0.474 0.120 0.306 0.524 0.468 0.032 0.382 0.046 0.038 0.262 0.158 0.048 0.000 0.158 
A T G G 0.192 0.794 0.926 0.782 0.994 0.838 0.706 0.986 0.764 0.314 0.622 0.776 0.738 0.710 0.532 0.760 0.262 0.582 
G C A G 0.988 0.736 0.160 0.936 0.760 0.840 0.806 0.640 0.474 0.860 0.488 0.400 0.294 0.978 0.306 0.268 0.344 0.182 
G C G G 0.002 0.954 0.008 0.130 0.794 0.094 0.206 0.526 0.064 0.260 0.140 0.012 0.074 0.888 0.076 0.060 0.276 0.042 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
 
 
┌    ↓    ┐ 
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3.4.5.9 ACTN3 
The p-values for the association between the ACTN3 SNPs and hypertrophy traits; and the            
p-values for pair-wise differences between mutation groups in the association between the ACTN3 
SNPs and hypertrophy traits are given in Figure 3.19 and Table 3.37, respectively. No statistically 
significant single SNP effect or difference in SNP effect was observed amongst the three HCM 
founder mutation groups.  
Figure 3.20 graphically represents the p-values for the association between ACTN3 haplotypes and 
hypertrophy traits with no evidence of statistically significant haplotype effects. Table 3.38 details 
the p-values for pair-wise comparison between mutation groups in the association between ACTN3 
haplotypes and hypertrophy traits. The effect of the GCC haplotype, present in 23% of the cohort, 
was lower on the PC1 measure (1.02; p = 0.040) in the R92WTNNT2 group compared to the 
R403WMYH7 group. 
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Figure 3.19 The p-values for tests of association between single SNPs in ACTN3 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.37 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in ACTN3. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs1791690 0.455 0.337 0.928 0.983 0.638 0.679 0.960 0.774 0.773 0.337 0.696 0.556 0.360 0.915 0.430 0.249 0.794 0.373 
rs2275998 0.617 0.197 0.412 0.935 0.496 0.544 0.858 0.541 0.654 0.675 0.536 0.295 0.956 0.304 0.270 0.986 0.188 0.186 
rs1815739 0.838 0.230 0.710 0.872 0.815 0.962 0.911 0.921 0.951 0.815 0.677 0.974 0.608 0.512 0.859 0.431 0.331 0.772 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.20 The p-values for tests of association between ACTN3 haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.38 The p-values obtained for the analysis of interaction between mutation group and 
ACTN3 haplotypes. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
17
91
69
0 
rs
22
75
99
8 
rs
18
15
73
9 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs  
R403W 
A T C 0.285 0.439 0.715 0.820 0.368 0.334 0.973 0.564 0.605 0.492 0.581 0.850 0.350 0.999 0.366 0.266 0.849 0.358 
G C C 0.961 0.149 0.116 0.927 0.112 0.121 0.885 0.325 0.376 0.642 0.361 0.157 0.795 0.144 0.075 0.805 0.083 0.040 
G T T 0.877 0.261 0.634 0.987 0.557 0.737 0.885 0.967 0.905 0.914 0.830 0.990 0.682 0.536 0.958 0.534 0.392 0.899 
A T T** 0.281 0.769 0.272 0.662 0.405 0.396 0.970 0.473 0.658 - 0.436 0.585 - 0.733 - - 0.909 - 
G T C** - 0.358 - - 0.876 - - 0.474 - - 0.541 - - 0.758 - - 0.966 - 
** absence of p-values indicates unequal distribution of haplotypes in the three HCM mutation groups resulting in 
stratified groups of small size with insufficient statistical power for testing 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
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3.4.5.10 CD36 
Figure 3.21 graphically represents the p-values for the association between the CD36 SNPs and 
hypertrophy traits. No statistically significant SNP effect was observed. Table 3.39 details the     p-
values for pair-wise comparison between mutation groups in the association of CD36 SNPs and 
individual hypertrophy traits. The effect of the A-allele of rs10268417 was lower on mPWT       
(1.29 mm; p = 0.007), the CWT score (20.7 mm; p = 0.041) and PC1 (1.29; p = 0.022) in the 
R92WTNNT2 group relative to the A797TMYH7 group.  
Figure 3.22 graphically represents the p-values for the association between CD36 haplotypes and 
hypertrophy traits. The effect of the CGT haplotype, present in 37% of the cohort, was an estimated 
decrease of 0.58 mm in mPWT (p = 0.020), 8.6 mm in the CWT score (p = 0.020) and 0.54 in PC1 
(p = 0.007). Table 3.40 details the p-values for pair-wise differences between mutation groups in 
the association of CD36 haplotypes and hypertrophy traits. The effect of the AGT haplotype, 
present in 11% of the cohort, was lower on mPWT (1.99 mm; p = 0.008), the CWT score           
(41.6 mm; p = 0.008) and PC1 (2.6; p = 0.005) in the R92WTNNT2 group compared to the 
A797TMYH7 group. Also, its effect was lower on the CWT score (42.5 mm; p = 0.047) and PC1 
(2.66; p = 0.019) in the R403WMYH7 group relative to the A797TMYH7 group. The effect of the CGT 
haplotype, observed in 37% of the cohort, was higher on mIVST in the R403WMYH7 group than in 
the A797TMYH7 group (2.2 mm; p = 0.022). 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
117│Chapter 3 
 
Figure 3.21 The p-values for tests of association between single SNPs in CD36 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.39 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in CD36. Significant results are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs10268417 0.505 0.309 0.821 0.096 0.309 0.481 0.283 0.264 0.944 0.274 0.007 0.227 0.224 0.041 0.618 0.188 0.022 0.542 
rs3211892 0.984 0.537 0.567 0.825 0.847 0.641 0.740 0.304 0.550 0.446 0.355 0.066 0.909 0.341 0.283 0.799 0.295 0.180 
rs3173804 0.765 0.620 0.891 0.494 0.742 0.712 0.779 0.974 0.771 0.642 0.511 0.906 0.805 0.896 0.731 0.635 0.957 0.620 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.22 The p-values for tests of association between CD36 haplotypes and individual hypertrophy 
traits. The original p-values are given in the data table, whilst the graph represents the corresponding –log10 
transformed values. The red dashed horizontal line indicates the p-value significance threshold equal to 0.05. 
Bars located above this line, therefore, indicate significant p-values (p-values<0.05). The p-value 
significance increases with bar height above threshold. The observed haplotype frequencies are indicated in 
brackets. 
Table 3.40 The p-values obtained for the analysis of interaction between mutation group and 
individual haplotypes in CD36. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
10
26
84
17
 
rs
32
11
89
2  
rs
31
73
80
4  R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs  
R403W 
A G T 0.613 0.226 0.600 0.133 0.117 0.818 0.310 0.087 0.680 0.406 0.008 0.147 0.047 0.008 0.956 0.019 0.005 0.841 
C G A 0.891 0.544 0.522 0.554 0.645 0.820 0.622 0.424 0.874 0.253 0.162 0.999 0.972 0.879 0.871 0.801 0.886 0.893 
A G A 0.899 0.421 0.542 0.384 0.548 0.882 0.557 0.622 0.987 0.456 0.105 0.392 0.986 0.252 0.326 0.866 0.190 0.214 
C G T 0.327 0.976 0.391 0.022 0.410 0.174 0.138 0.337 0.606 0.520 0.586 0.298 0.092 0.231 0.597 0.097 0.329 0.488 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
 
 
┌  ↓  ┐ 
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3.4.5.11 CPT1B 
Figure 3.23 graphically represents the p-values for the association between the three CPT1B SNPs 
and hypertrophy traits. The effect of the T-allele of rs1557502 is an estimated increase of 0.54 mm 
in mPWT (p = 0.028). Table 3.41 details the p-values for pair-wise differences between mutation 
groups in the association of CPT1B SNPs and hypertrophy traits. No significant difference in SNP 
effect was observed between the HCM founder mutation groups. 
Figure 3.24 graphically represents the p-values for the association between CPT1B haplotypes and 
hypertrophy traits with no evidence of statistically significant haplotype effects. Table 3.42 details 
the p-values for pair-wise comparison between mutation groups in the association of CPT1B 
haplotypes and hypertrophy traits. The effect of the CC haplotype, present in 36% of the cohort, 
was estimated to be lower in the R403WMYH7 group compared to the A797TMYH7 group:                
1.8 mm on mIVST (p = 0.021), 0.83 mm on mPWT (p = 0.028), 18.3 mm on the CWT score           
(p = 0.034) and 1.14 on the PC1 measure (p = 0.016). Also, its effect was higher in the R92WTNNT2 
group relative to the R403WMYH7 group: 3 mm on mIVST (p = 0.024), 2.41 mm on mLVWT           
(p = 0.039), 25.8 mm on the CWT score (p = 0.025) and 1.61 on the PC1 measure (p = 0.014). The 
effect of the CT haplotype, present in 38% of the cohort, was lower on mLVWT                         
(3.11 mm; p = 0.034) in the R92WTNNT2 group relative to the A797TMYH7 group. In addition, its 
effect was lower in the R92WTNNT2 group compared to the R403WMYH7 group: 0.95 mm on mPWT 
(p = 0.040), 18.2 mm on the CWT score (p = 0.039) and 1.14 on the PC1 measure (p = 0.025). 
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Figure 3.23 The p-values for tests of association between single SNPs in CPT1B and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.41 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in CPT1B.  
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs470117 0.670 0.720 0.903 0.099 0.119 0.730 0.248 0.434 0.644 0.534 0.769 0.440 0.544 0.603 0.860 0.572 0.691 0.821 
rs1557502 0.951 0.920 0.982 0.736 0.627 0.449 0.733 0.172 0.421 0.652 0.660 0.413 0.428 0.598 0.223 0.272 0.787 0.186 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
┌        T↑        ┐     
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Figure 3.24 The p-values for tests of association between CPT1B haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.42 The p-values obtained for the analysis of interaction between mutation group and 
CPT1B haplotypes. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
47
01
17
 
rs
15
57
50
2  
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
C C 0.136 0.799 0.135 0.021 0.750 0.024 0.116 0.369 0.039 0.028 0.971 0.053 0.034 0.577 0.025 0.016 0.608 0.014 
C T 0.674 0.365 0.196 0.938 0.078 0.128 0.709 0.034 0.128 0.538 0.120 0.040 0.394 0.182 0.039 0.254 0.235 0.025 
T C 0.260 0.491 0.136 0.143 0.736 0.125 0.189 0.892 0.207 0.400 0.338 0.152 0.333 0.787 0.289 0.307 0.665 0.221 
** absence of p-values indicates unequal distribution of haplotypes in the three HCM mutation groups resulting in 
stratified groups of small size with insufficient statistical power for testing 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
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3.4.5.12 PDK4 
Figure 3.25 graphically represents the p-values for the association between the PDK4 SNPs and 
hypertrophy traits with no evidence of statistically significant SNP effects. Table 3.43 details the p-
values for pair-wise differences between mutation groups in the association of PDK4 SNPs and 
hypertrophy traits. The effect of the T-allele of rs2073978 was higher on LVM (30.2 g; p = 0.034), 
the CWT score (30.7 mm; p = 0.016) and PC1 (1.92; p = 0.019) in the R403WMYH7 group relative to 
the A797TMYH7 group. In addition, its effect was lower on LVM (38.4 g; p = 0.018) in the 
R92WTNNT2 group compared to the R403WMYH7 group. 
Figure 3.26 graphically represents the p-values for the association between PDK4 haplotypes and 
hypertrophy traits. The effect of the CT haplotype, observed in 46% of the cohort, was an estimated 
1.42 mm increase in mIVST (p = 0.037). Table 3.44 details the p-values for pair-wise comparison 
between mutation groups in the association between PDK4 haplotypes and hypertrophy traits. The 
CT haplotype also indicated significant differences in haplotype effect amongst the three mutation 
groups. Its effect was estimated to be lower on mIVST (3.2 mm; p = 0.028), mLVWT (3.62 mm;    
p = 0.025), the CWT score (31.9 mm; p = 0.008) and PC1 (1.99; p = 0.011) in the R403WMYH7 
group relative to the A797TMYH7 group. 
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Figure 3.25 The p-values for tests of association between single SNPs in PDK4 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.43 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in PDK4. Significant results are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W 
 vs 
R403W 
rs2073978 0.034 0.611 0.018 0.055 0.351 0.273 0.075 0.550 0.226 0.155 0.309 0.557 0.016 0.173 0.180 0.019 0.180 0.193 
rs2301630 0.060 0.419 0.209 0.192 0.785 0.284 0.088 0.706 0.165 0.137 0.214 0.591 0.118 0.453 0.325 0.176 0.310 0.565 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
124│Chapter 3 
 
 
Figure 3.26 The p-values for tests of association between PDK4 haplotypes and individual hypertrophy 
traits. The original p-values are given in the data table, whilst the graph represents the corresponding –log10 
transformed values. The red dashed horizontal line indicates the p-value significance threshold equal to 0.05. 
Bars located above this line, therefore, indicate significant p-values (p-values<0.05). The p-value 
significance increases with bar height above threshold. The observed haplotype frequencies are indicated in 
brackets. 
Table 3.44 The p-values obtained for the analysis of interaction between mutation group and 
PDK4 haplotypes. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
20
73
97
8 
rs
23
01
63
0 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
C C 0.426 0.261 0.995 0.629 0.351 0.283 0.426 0.810 0.373 0.095 0.530 0.263 0.374 0.851 0.335 0.282 0.954 0.326 
C T 0.091 0.760 0.165 0.028 0.240 0.247 0.025 0.366 0.155 0.105 0.108 0.827 0.008 0.064 0.250 0.011 0.068 0.286 
T C 0.171 0.901 0.219 0.446 0.661 0.658 0.238 0.904 0.293 0.645 0.605 0.919 0.252 0.640 0.422 0.394 0.556 0.660 
T T 0.787 0.595 0.459 0.269 0.601 0.541 0.479 0.810 0.633 0.704 0.667 0.453 0.165 0.431 0.491 0.138 0.630 0.289 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; LVM-left 
ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular wall 
thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
 
 
┌  ↑  ┐ 
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3.4.5.13 CKM 
Figure 3.27 graphically represents the p-values for the association between the CKM SNPs and 
hypertrophy traits. The effect of the T-allele of rs7260463 was an estimated 0.24 mm decrease in 
mPWT (p = 0.049). Table 3.45 details the p-values for pair-wise differences between mutation 
groups in the association of CKM SNPs and hypertrophy traits. The effect of the T-allele of 
rs344816 was lower on mLVWT in the R92WTNNT2 group relative to both the A797TMYH7                
(p = 0.003, 4.21 mm) and R403WMYH7 (p = 0.015, 3.42 mm) groups. 
Figure 3.28 graphically represents the p-values for the association between CKM haplotypes and 
hypertrophy traits. The effect of the CTAT haplotype, present in 4% of the cohort, was an 
estimated increase of 3.20 mm in mIVST (p = 0.018), 2.72 mm in mLVWT (p = 0.046) and      1.37 
in PC1 (p = 0.047). The TTGA haplotype, observed in 3% of the cohort, was significantly 
associated with a decrease of 27.4 g in LVM (p = 0.039). The effect of the CTGT haplotype, 
identified in 10% of the cohort, was an estimated decrease of 17.6 g in LVM (p = 0.035) and         
7.9 mm in the CWT score (p = 0.039). Table 3.46 details the p-values for pair-wise comparison 
between mutation groups in the association of CKM haplotypes and hypertrophy traits. The TTGA 
and CTGT haplotypes also showed significant differences in haplotype effect amongst the founder 
mutation groups. The effect of the first was higher on LVM in the R403WMYH7 group relative to 
both the A797TMYH7 (96.4 g; p = 0.035) and R92WTNNT2 groups (120.3 g; p = 0.013). In addition, its 
effect was higher on PC1 (3.97; p = 0.048) in the R92WTNNT2 group compared to the R403WMYH7 
group. The effect of the second was lower on mLVWT (5.1 mm; p = 0.002) and the CWT score 
(32.1 mm; p = 0.018) in the R92WTNNT2 group relative to the A797TMYH7 group. Also, the effect of 
the CTGA haplotype, identified in 9% of the cohort, was higher on mLVWT in the R92WTNNT2 
group relative to both the A797TMYH7 (p = 0.048, 4.53 mm) and R403WMYH7 (p = 0.042, 3.70 mm) 
groups. 
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Figure 3.27 The p-values for tests of association between single SNPs in CKM and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.45 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in CKM. Significant results are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs8111989 0.468 0.603 0.801 0.478 0.786 0.647 0.321 0.914 0.389 0.879 0.941 0.934 0.614 0.791 0.476 0.763 0.733 0.560 
rs7260463 0.252 0.718 0.159 0.848 0.274 0.289 0.652 0.892 0.587 0.344 0.331 0.887 0.510 0.765 0.687 0.431 0.674 0.666 
rs1133190 0.991 0.852 0.880 0.884 0.744 0.912 0.915 0.619 0.791 0.397 0.816 0.548 0.517 0.686 0.771 0.508 0.557 0.867 
rs344816 0.924 0.254 0.328 0.602 0.293 0.199 0.959 0.003 0.015 0.611 0.967 0.628 0.564 0.118 0.082 0.428 0.301 0.133 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
┌  T↓  ┐     
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Figure 3.28 The p-values for tests of association between CKM haplotypes and individual hypertrophy 
traits. The original p-values are given in the data table, whilst the graph represents the corresponding –log10 
transformed values. The red dashed horizontal line indicates the p-value significance threshold equal to 0.05. 
Bars located above this line, therefore, indicate significant p-values (p-values<0.05). The p-value 
significance increases with bar height above threshold. The observed haplotype frequencies are indicated in 
brackets. 
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Table 3.46 The p-values obtained for the analysis of interaction between mutation group and 
CKM haplotypes. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
81
11
98
9  
rs
72
60
46
3  
rs
11
33
19
0  
rs
34
48
16
 R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
C G G A 0.098 0.741 0.096 0.572 0.863 0.387 0.131 0.233 0.649 0.270 0.466 0.618 0.602 0.753 0.766 0.657 0.830 0.757 
C G G T** - - 0.222 - - 0.096 - - 0.083 - - 0.410 - - 0.092 - - 0.114 
C T A A 0.656 0.354 0.558 0.720 0.814 0.644 0.511 0.628 0.365 0.502 0.606 0.346 0.562 0.775 0.505 0.798 0.827 0.704 
C T A T 0.972 0.279 0.240 0.350 0.801 0.420 0.199 0.573 0.376 0.152 0.967 0.111 0.171 0.798 0.178 0.194 0.925 0.096 
C T G A 0.172 0.740 0.072 0.922 0.150 0.112 0.970 0.048 0.042 0.584 0.944 0.511 0.517 0.102 0.208 0.445 0.134 0.356 
T G A A 0.361 0.920 0.432 0.805 0.703 0.910 0.821 0.941 0.775 0.957 0.830 0.804 0.830 0.807 0.993 0.817 0.920 0.890 
T G A T 0.192 0.334 0.908 0.473 0.924 0.654 0.423 0.584 0.911 0.546 0.590 0.981 0.945 0.923 0.892 0.777 0.811 0.996 
T G G A 0.520 0.080 0.062 0.108 0.961 0.165 0.378 0.522 0.207 0.166 0.588 0.102 0.176 0.641 0.121 0.208 0.661 0.148 
T T G A 0.035 0.725 0.013 0.205 0.684 0.119 0.290 0.301 0.072 0.205 0.889 0.159 0.150 0.556 0.052 0.135 0.588 0.048 
C T G T** - 0.143 - - 0.080 - - 0.002 - - 0.303 - - 0.018 - - 0.053 - 
T G G T** - 0.450 - - 0.447 - - 0.284 - - 0.556 - - 0.482 - - 0.535 - 
** absence of p-values indicates unequal distribution of haplotypes in the three HCM mutation groups resulting in 
stratified groups of small size with insufficient statistical power for testing 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
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3.4.5.14 CKB 
Figure 3.29 graphically represents the p-values for the association between the CKB SNPs and 
hypertrophy traits with no evidence of statistically significant SNP effects. Table 3.47 details the   
p-values for pair-wise differences between mutation groups in the association between CKB SNPs 
and hypertrophy traits. No significant difference in SNP effect was observed amongst the three 
HCM founder mutation groups. 
Figure 3.30 graphically represents the p-values for the association between CKB haplotypes and 
hypertrophy traits with no evidence of statistically significant haplotype effects. Table 3.48 details 
the p-values for pair-wise comparison between mutation groups in the association between CKB 
haplotypes and hypertrophy traits. The effect of the CCT haplotype, present in 3% of the cohort, 
was higher on LVM (86.5 g; p = 0.032) in the R92WTNNT2 group relative to the R403WMYH7 group. 
The effect of the CTT haplotype, observed in 17% of the cohort, was lower on LVM (65.1 g; p = 
0.032) in the R92WTNNT2 group relative to the R403WMYH7 group. Also, its effect was higher on 
LVM (62.9 g; p = 0.032) in the R403WMYH7 group compared to the A797TMYH7 group. The effect of 
the TCG haplotype, present in 6% of the cohort, was lower on the CWT score (59.4 mm; p = 0.032) 
in the R403WMYH7 group than the A797TMYH7 group. 
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Figure 3.29 The p-values for tests of association between single SNPs in CKB and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.47 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in CKB. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs1803283 0.623 0.729 0.878 0.544 0.217 0.635 0.479 0.243 0.747 0.129 0.656 0.312 0.106 0.174 0.687 0.161 0.231 0.742 
rs2071407 0.725 0.380 0.287 0.712 0.873 0.841 0.967 0.793 0.852 0.701 0.675 0.999 0.659 0.531 0.907 0.761 0.431 0.699 
rs1136165 0.949 0.477 0.520 0.513 0.736 0.744 0.616 0.884 0.560 0.746 0.819 0.911 0.891 0.830 0.961 0.984 0.735 0.762 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.30 The p-values for tests of association between CKB haplotypes and individual hypertrophy 
traits. The original p-values are given in the data table, whilst the graph represents the corresponding –log10 
transformed values. The red dashed horizontal line indicates the p-value significance threshold equal to 0.05. 
Bars located above this line, therefore, indicate significant p-values (p-values<0.05). The p-value 
significance increases with bar height above threshold. The observed haplotype frequencies are indicated in 
brackets. 
Table 3.48 The p-values obtained for the analysis of interaction between mutation group and 
CKB haplotypes. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
18
03
28
3  
rs
20
71
40
7  
rs
11
36
16
5  
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
C C G 0.702 0.980 0.717 0.899 0.612 0.579 0.641 0.837 0.814 0.422 0.990 0.470 0.171 0.580 0.428 0.263 0.678 0.498 
C C T 0.119 0.495 0.032 0.180 0.868 0.130 0.339 0.826 0.421 0.673 0.888 0.742 0.232 0.858 0.181 0.466 0.621 0.294 
C T T 0.032 0.900 0.032 0.220 0.231 0.575 0.415 0.504 0.663 0.342 0.775 0.285 0.183 0.529 0.319 0.145 0.661 0.224 
T C G 0.905 0.326 0.312 0.088 0.562 0.347 0.070 0.689 0.226 0.344 0.544 0.794 0.038 0.811 0.099 0.055 0.983 0.081 
T T G** - 0.411 - - 0.991 - - 0.705 - - 0.894 - - 0.639 - - 0.904 - 
T T T 0.606 0.344 0.747 0.932 0.295 0.429 0.781 0.263 0.490 0.321 0.529 0.665 0.431 0.269 0.902 0.470 0.212 0.754 
** absence of p-values indicates unequal distribution of haplotypes in the three HCM mutation groups resulting in 
stratified groups of small size with insufficient statistical power for testing 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; LVM-left 
ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular wall 
thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
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3.4.5.15 ALDOA 
Figure 3.31 graphically represents the p-values for the association between the ALDOA SNPs and 
hypertrophy traits. The effect of the T-allele of rs11860935 was an estimated decrease of 1.88 mm 
in mIVST (p = 0.043). Table 3.49 details the p-values for pair-wise differences between mutation 
groups in the association of ALDOA SNPs and hypertrophy traits. The effect of the C-allele of 
rs9928448 was lower on mIVST (2.29 mm; p = 0.026), the CWT score (23.2 mm; p = 0.036) and 
PC1 (1.45; p = 0.029) in the R92WTNNT2 group compared to the A797TMYH7 group. 
Figure 3.32 graphically represents the p-values for the association between ALDOA haplotypes and 
hypertrophy traits with no evidence of statistically significant haplotype effects. Table 3.50 details 
the p-values for pair-wise differences between mutation groups in the association of ALDOA 
haplotypes and hypertrophy traits. The effect of the CC haplotype, present in 37% of the cohort, 
was lower on mIVST (2.7 mm; p = 0.015) and mLVWT (2.65 mm; p = 0.026) in the R92WTNNT2 
group compared to the R403WMYH7 group. 
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Figure 3.31 The p-values for tests of association between single SNPs in ALDOA and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.49 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in ALDOA. Significant results are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs9928448 0.637 0.129 0.429 0.381 0.026 0.324 0.550 0.134 0.501 0.163 0.181 0.831 0.510 0.036 0.279 0.466 0.029 0.273 
rs11860935 0.702 0.481 0.792 0.587 0.613 0.958 0.711 0.414 0.707 0.232 0.422 0.702 0.763 0.739 0.998 0.555 0.574 0.942 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
 
┌       T↓       ┐     
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Figure 3.32 The p-values for tests of association between ALDOA haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.50 The p-values obtained for the analysis of interaction between mutation group and 
ALDOA haplotypes. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
99
28
44
8  
rs
11
86
09
35
 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
C C 0.985 0.486 0.531 0.326 0.015 0.244 0.365 0.026 0.269 0.649 0.253 0.580 0.451 0.086 0.429 0.567 0.124 0.420 
C T 0.541 0.490 0.919 0.789 0.864 0.944 0.995 0.730 0.754 0.284 0.228 0.862 0.668 0.480 0.801 0.455 0.286 0.768 
T C 0.496 0.406 0.969 0.288 0.182 0.939 0.341 0.316 0.940 0.330 0.889 0.420 0.303 0.199 0.949 0.298 0.183 0.925 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; LVM-left 
ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular wall 
thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
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3.4.5.16 PFKM 
Figure 3.33 graphically represents the p-values for the association between the PFKM SNPs and 
hypertrophy traits with no evidence of statistically significant SNP effects. Table 3.51 details the   
p-values for pair-wise comparison between the mutation groups in the association between PFKM 
SNPs and hypertrophy traits. The effect of the T-allele of rs10875749 was higher on mIVST     
(2.56 mm; p = 0.033) in the R92WTNNT2 group relative to A797TMYH7 group. Also, its effect was 
higher in the R92WTNNT2 group compared to the R403WMYH7 group on mIVST (2.87 mm; p = 
0.005), mLVWT (2.08 mm; p = 0.013), the CWT score (22.9 mm; p = 0.010) and PC1 (1.43; p = 
0.006). Finally, its effect was lower on PC1 (0.92; p = 0.030) in the R403WMYH7 group compared to 
the A797TMYH7 group. 
Figure 3.34 graphically represents the p-values for the association between PFKM haplotypes and 
hypertrophy traits. The effect of the AT haplotype, identified in 12% of the cohort, was an 
estimated increase of 1.03 mm in mIVST (p = 0.042). Table 3.52 details the p-values for pair-wise 
comparison between mutation groups in the association between PFKM haplotypes and 
hypertrophy traits. The effect of the AA haplotype, observed in 35% of the cohort, was higher on 
mPWT in the R403WMYH7 group relative to the A797TMYH7 group (0.88 mm; p = 0.048). The effect 
of the AT haplotype, identified in 12% of the cohort, was lower in the R403WMYH7 group relative to 
the A797TMYH7 group: 3.1 mm on mIVST (p = 0.043), 31.6 mm on the CWT score (p = 0.022) and 
1.98 on PC1 (p = 0.012). The effect of the CA haplotype, present in 38% of the cohort, was lower in 
the R92WTNNT2 group compared to the A797TMYH7 group on mPWT (1.54 mm; p = 0.002), the CWT 
score (22.1 mm; p = 0.030) and PC1 (1.38; p = 0.014). Also, its effect was lower in the R92WTNNT2 
group relative to the R403WMYH7 group on PC1 (1.05; p = 0.046). The effect of the CT haplotype, 
observed in 10% of the cohort, was higher in the R92WTNNT2 group compared to the A797TMYH7 
group: 3.7 mm on mIVST (p = 0.004), 3.03 mm on mLVWT (p = 0.036) and 1.32 mm on mPWT   
(p = 0.045). 
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Figure 3.33 The p-values for tests of association between single SNPs in PFKM and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.51 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in PFKM. Significant results are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W 
 vs 
R403W 
rs1859445 0.595 0.570 0.329 0.738 0.582 0.900 0.903 0.724 0.866 0.163 0.280 0.625 0.949 0.567 0.599 0.820 0.409 0.656 
rs10875749 0.352 0.300 0.066 0.362 0.033 0.005 0.394 0.070 0.013 0.328 0.374 0.084 0.058 0.407 0.010 0.030 0.481 0.006 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.34 The p-values for tests of association between PFKM haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.52 The p-values obtained for the analysis of interaction between mutation group and 
PFKM haplotypes. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
18
59
44
5  
rs
10
87
57
49
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
A A 0.736 0.325 0.586 0.576 0.759 0.439 0.530 0.931 0.518 0.048 0.097 0.675 0.169 0.283 0.721 0.087 0.167 0.684 
A T 0.218 0.656 0.125 0.043 0.829 0.106 0.095 0.898 0.167 0.088 0.097 0.991 0.022 0.600 0.096 0.012 0.414 0.106 
C A 0.705 0.061 0.056 1.000 0.062 0.123 0.838 0.068 0.187 0.215 0.002 0.165 0.936 0.030 0.065 0.998 0.014 0.046 
C T 0.484 0.241 0.866 0.500 0.004 0.129 0.732 0.036 0.219 0.771 0.045 0.226 0.827 0.128 0.318 0.963 0.120 0.232 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; LVM-left 
ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular wall 
thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
 
 
┌  ↑  ┐ 
Stellenbosch University  http://scholar.sun.ac.za
  
138│Chapter 3 
3.4.5.17 PPARA 
Figure 3.35 graphically represents the p-values for the association between the PPARA SNPs and 
hypertrophy traits with no evidence of statistically significant SNP effects. Table 3.53 details the   
p-values for pair-wise differences between mutation groups in the association between the PPARA 
SNPs and hypertrophy traits. No significant difference in SNP effect was observed amongst the 
three HCM founder mutation groups. 
Figure 3.36 graphically represents the p-values for the association between PPARA haplotypes and 
hypertrophy traits. The effect of the GAA haplotype, present in 10% of the cohort, was an 
estimated increase of 30.1 g in LVM (p = 0.043), 3.01 mm in mIVST (p = 0.006), 3.40 mm in 
mLVWT (p = 0.001), 21.0 mm in CWT score (p = 0.012) and 1.31 in PC1 (p = 0.019). The GGG 
haplotype, identified in 2% of the cohort, was associated with decreases of 49.1 g in LVM              
(p = 0.015), 3.09 mm in mIVST (p = 0.045) and 1.14 mm in mPWT (p = 0.046). Table 3.54 details 
the p-values for pair-wise comparison between mutation groups in the association of PPARA 
haplotypes and hypertrophy traits. The GGG haplotype also showed a significant difference in 
haplotype effect amongst the founder mutation groups. Its effect was estimated to be lower on 
mPWT (2.13 mm; p = 0.047) in the R403WMYH7 group relative to the A797TMYH7 group. The effect 
of the AAA haplotype, indentified in 48% of the cohort, was lower on LVM (21.9 g; p = 0.043) in 
the R92WTNNT2 group compared to the R403WMYH7 group.  
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Figure 3.35 The p-values for tests of association between single SNPs in PPARA and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.53 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in PPARA. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
 vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
 vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
 vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
 vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
 vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
 vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs881740 0.234 0.967 0.240 0.518 0.898 0.474 0.319 0.753 0.456 0.181 0.794 0.268 0.581 0.868 0.678 0.281 0.784 0.399 
rs4823613 0.789 0.098 0.084 0.425 0.430 0.173 0.499 0.274 0.123 0.239 0.781 0.227 0.704 0.308 0.208 0.740 0.270 0.195 
rs4253776 0.331 0.169 0.760 0.551 0.332 0.764 0.590 0.310 0.692 0.908 0.452 0.425 0.485 0.236 0.701 0.536 0.214 0.605 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.36 The p-values for tests of association between PPARA haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.54 The p-values obtained for the analysis of interaction between mutation group and 
PPARA haplotypes. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
88
17
40
 
rs
48
23
61
3  
rs
42
53
77
6  R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
A A A 0.331 0.249 0.043 0.487 0.732 0.317 0.608 0.606 0.323 0.834 0.207 0.181 0.922 0.342 0.337 0.745 0.312 0.211 
A A G 0.755 0.615 0.463 0.792 0.909 0.730 0.780 0.839 0.660 0.480 0.469 0.977 0.248 0.451 0.648 0.258 0.378 0.746 
A G A 0.258 0.997 0.376 0.345 0.749 0.306 0.531 0.911 0.561 0.910 0.730 0.694 0.630 0.736 0.508 0.596 0.494 0.316 
A G G 0.245 0.137 0.777 0.910 0.589 0.718 0.875 0.378 0.540 0.844 0.865 0.984 0.920 0.570 0.700 0.766 0.630 0.890 
G A G 0.402 0.444 0.648 0.287 0.114 0.845 0.313 0.337 0.600 0.373 0.691 0.453 0.493 0.862 0.351 0.387 1.000 0.310 
G A A 0.277 0.818 0.267 0.777 0.959 0.777 0.254 0.902 0.336 0.545 0.461 0.328 0.339 0.855 0.445 0.907 0.945 0.884 
G G A 0.717 0.150 0.255 0.640 0.737 0.974 0.926 0.902 0.862 0.746 0.518 0.414 0.706 0.891 0.909 0.637 0.797 0.948 
G G G 0.280 0.123 0.473 0.305 0.822 0.615 0.197 - - 0.047 - - 0.247 - - 0.148 - - 
** absence of p-values indicates unequal distribution of haplotypes in the three HCM mutation groups resulting in 
stratified groups of small size with insufficient statistical power for testing 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
┌  ↑  ┐ ┌  ↓  ┐ 
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3.4.5.18 PPARG 
Figure 3.37 graphically represents the p-values for the association between the four PPARG SNPs 
and hypertrophy traits. No statistically significant SNP effects were observed. Table 3.55 details 
the p-values for pair-wise comparison between mutation groups in the association between 
PPARG SNPs and hypertrophy traits. The effect of the T-allele of rs12631028 was higher on 
mLVWT (1.71 mm; p = 0.040) in the R92WTNNT2 group compared to the A797TMYH7 group.  
Figure 3.38 graphically represents the p-values for the association between PPARG haplotypes and 
hypertrophy traits with evidence of statistically significant haplotype effects for haplotypes CAGA, 
CGGC and CAGC. The effect of the first, present in 15% of the cohort, was an estimated decrease 
of 22.8 g in LVM (p = 0.004). The second, observed in 4% of the cohort, was associated with an 
estimated increase of 27.1 g in LVM (p = 0.026), 2.55 mm in mIVST (p = 0.034), 2.73 mm in 
mLVWT (p = 0.042), 23.7 mm in the CWT score (p = 0.022) and 1.48 in PC1 (p = 0.042). The final 
haplotype, present in 4% of the cohort, was associated with an estimated decrease of 0.97 mm in 
mPWT (p = 0.030).  
Table 3.56 details the p-values for pair-wise comparison between mutation groups in the 
association of PPARG haplotypes and hypertrophy traits. Haplotypes CAGA and CAGC that 
showed significant haplotype effects as well as haplotypes TGAC and TGGA indicated significant 
differences in haplotype effect amongst the HCM founder mutation groups. The effect of the 
CAGA haplotype was lower on mIVST (4.98 mm, p = 0.002) and mLVWT (4.83, p < 0.001) in the 
R92WTNNT2 group compared to the A797TMYH7 group. Also, its effect was lower on mLVWT (2.85 
mm, p = 0.026) in the R403WMYH7 group relative to the A797TMYH7 group. The effect of the TGAC 
haplotype was higher on mPWT (2.52 mm, p = 0.012) and PC1 (0.53, p = 0.004) in the R92WTNNT2 
group compared to the A797TMYH7 group. The effects of both the TGGA and CAGC haplotypes 
were lower on PC1 (0.12, p = 0.004; 0.94, p = 0.044) in the R92WTNNT2 group compared to the 
A797TMYH7 group. 
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Figure 3.37 The p-values for tests of association between single SNPs in PPARG and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.55 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in PPARG. Significant results are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
rs12631028 0.082 0.238 0.515 0.486 0.247 0.737 0.228 0.040 0.520 0.272 0.148 0.848 0.094 0.073 0.956 0.079 0.082 0.859 
rs12490265 0.447 0.846 0.594 0.188 0.572 0.093 0.675 0.145 0.103 0.657 0.243 0.162 0.899 0.447 0.448 0.932 0.663 0.656 
rs2938392 0.316 0.461 0.686 0.925 0.934 0.877 0.858 0.544 0.762 0.426 0.341 0.973 0.968 0.436 0.562 0.951 0.438 0.579 
rs1175540 0.146 0.760 0.250 0.796 0.681 0.569 0.839 0.244 0.257 0.954 0.692 0.713 0.519 0.408 0.198 0.412 0.545 0.202 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.38 The p-values for tests of association between PPARG haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
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Table 3.56 The p-values obtained for the analysis of interaction between mutation group and 
single haplotypes in PPARG. Significant results are indicated in bold red font. 
Haplotype* LVM  mIVST  mLVWT  mPWT  CWT score  PC1  
rs
12
63
10
28
 
rs
12
49
02
65
 
rs
29
38
39
2  
rs
11
75
54
0  R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
C A G A 0.360 0.142 0.694 0.148 0.002 0.166 0.026 0.000 0.422 0.330 0.256 0.998 0.172 0.102 0.920 0.342 0.276 0.984 
C G A A** - - - - - - - - - - - - - - - - - - 
C G A C 0.540 0.764 0.760 0.578 0.800 0.428 0.980 0.398 0.384 0.974 0.526 0.506 0.838 0.376 0.488 0.890 0.610 0.706 
C G G A 0.244 0.662 0.588 0.890 0.566 0.492 0.384 0.844 0.586 0.772 0.320 0.216 0.260 0.680 0.616 0.202 0.698 0.516 
C G G C 0.258 0.486 0.080 0.684 0.660 0.398 0.664 0.964 0.696 0.310 0.960 0.296 0.212 0.742 0.378 0.224 0.734 0.132 
T A G A** - - - - - - - - - - - - - - - - - - 
T G A C 0.856 0.932 0.874 0.518 0.942 0.516 0.306 0.860 0.460 0.184 0.012 0.222 0.440 0.598 0.864 0.402 0.004 0.918 
T G G A 0.718 0.764 0.194 0.760 0.548 0.364 0.240 0.414 0.604 0.900 0.494 0.422 0.728 0.790 0.500 0.904 0.004 0.342 
T G G C** - - - - - - - - - - - - - - - - - - 
C A G C 0.718 0.764 0.194 0.760 0.548 0.364 0.240 0.414 0.604 0.900 0.494 0.422 0.756 0.602 0.742 0.614 0.044 0.846 
** absence of p-values indicates unequal distribution of haplotypes in the three HCM mutation groups resulting in 
stratified groups of small size with insufficient statistical power for testing 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
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3.4.5.19 PGC1A 
The p-values for the association between the PGC1A SNPs and hypertrophy traits; and the p-
values for pair-wise differences between mutation groups in the association between PGC1A SNPs 
and hypertrophy traits are given in Figure 3.39 and Table 3.57, respectively. No statistically 
significant single SNP effect or difference in SNP effect amongst the three HCM founder mutation 
groups was observed.  
Figure 3.40 graphically represents the p-values for the association between PGC1A haplotypes and 
hypertrophy traits. The effect of the GATT haplotype was an estimated increase of 2.92 mm in 
mIVST (p = 0.043). Table 3.58 details the p-values for pair-wise differences between mutation 
groups in the association between PGC1A haplotypes and hypertrophy traits. The effect of the 
GAAC haplotype, identified in 6% of the cohort, was higher on LVM (103.3 g; p = 0.002), mIVST 
(7 mm; p = 0.019), mLVWT (7.26 mm; p = 0.016), the CWT score (65.4 mm; p = 0.009) and PC1 
(4.09; p = 0.030) in the R92WTNNT2 group compared to the A797TMYH7 group. Also, its effect was 
higher in the R92WTNNT2 group relative to the R403WMYH7 group: 82 g on LVM (p = 0.012), 5.4 mm 
on mIVST (p = 0.028), 5.84 mm on mLVWT (p = 0.020), 54.1 mm on the CWT score (p = 0.018) 
and 3.38 on PC1 (p = 0.047). The effect of the GATC haplotype, present in 5% of the cohort, was 
higher on the CWT score (36 mm; p = 0.038) in the R92WTNNT2 group compared to the A797TMYH7 
group. The effect of the GCAC haplotype, identified in 9% of the cohort, was lower in the 
R92WTNNT2 group relative to the R403WMYH7 group: 48 g on LVM (p = 0.018), 26.9 mm on the 
CWT score (p = 0.048) and 1.68 on PC1 (p = 0.037). 
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Figure 3.39 The p-values for tests of association between single SNPs in PGC1A and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.57 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in PGC1A. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
rs768695 0.662 0.745 0.895 0.504 0.969 0.504 0.358 0.886 0.321 0.669 0.613 0.977 0.825 0.769 0.962 0.712 0.919 0.786 
rs4619879 0.352 0.547 0.705 0.557 0.315 0.782 0.587 0.468 0.918 0.528 0.417 0.940 0.855 0.225 0.427 0.804 0.300 0.286 
rs11724368 0.931 0.706 0.743 0.767 0.476 0.456 0.627 0.828 0.745 0.634 0.634 0.875 0.930 0.975 0.917 0.830 0.995 0.839 
rs13131226 0.375 0.185 0.746 0.461 0.163 0.611 0.908 0.272 0.300 0.764 0.491 0.764 0.709 0.196 0.473 0.604 0.220 0.597 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.40 The p-values for tests of association between PGC1A haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
 
 
 
 
 
 
 
┌  ↑  ┐ 
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Table 3.58 The p-values obtained for the analysis of interaction between mutation group and 
single haplotypes in PGC1A. Significant results are indicated in bold red font. 
Haplotype* LVM  mIVST  mLVWT  mPWT  CWT score  PC1  
rs
76
86
95
 
rs
46
19
87
9  
rs
11
72
43
68
 
rs
13
13
12
26
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
A A A C 0.116 0.116 0.913 0.619 0.408 0.733 0.328 0.236 0.859 0.853 0.933 0.898 0.552 0.344 0.719 0.527 0.373 0.807 
A A A T 0.732 0.541 0.798 0.714 0.932 0.801 0.473 0.867 0.417 0.542 0.141 0.412 0.969 0.568 0.547 0.849 0.402 0.310 
A A T T** - 0.298 - - 0.967 - - 0.937 - - 0.713 - - 0.487 - - 0.524 - 
A C A C 0.066 0.180 0.615 0.732 0.854 0.875 0.285 0.450 0.782 0.358 0.242 0.749 0.072 0.185 0.739 0.063 0.205 0.644 
A C T C 0.814 0.378 0.413 0.343 0.825 0.400 0.182 0.490 0.340 0.129 0.771 0.078 - 0.524 - - 0.545 - 
G A A C 0.339 0.002 0.012 0.827 0.019 0.028 0.920 0.016 0.020 0.699 0.225 0.325 0.683 0.009 0.018 0.753 0.030 0.047 
G A A T 0.568 0.348 0.812 0.629 0.165 0.512 0.531 0.373 0.871 0.608 0.277 0.694 0.994 0.303 0.446 0.924 0.275 0.379 
G A T C 0.759 0.615 0.528 0.264 0.076 0.956 0.379 0.250 0.911 0.791 0.411 0.783 0.555 0.038 0.430 0.571 0.050 0.461 
G A T T 0.948 0.754 0.920 0.496 0.663 0.658 0.497 0.193 0.971 0.211 0.061 0.805 0.717 0.259 0.788 0.676 0.278 0.850 
G C A T 0.790 0.359 0.729 0.870 0.470 0.751 0.948 0.204 0.442 0.853 0.943 0.898 0.780 0.264 0.654 0.823 0.447 0.783 
A C A T 0.341 0.438 0.706 0.842 0.159 0.387 0.421 0.709 0.272 0.634 0.607 0.916 0.664 0.595 0.406 0.529 0.649 0.327 
A C T T 0.673 0.890 0.744 0.932 0.541 0.468 0.652 0.748 0.887 0.314 0.612 0.544 0.931 0.744 0.816 0.878 0.906 0.780 
G C A C 0.443 0.097 0.018 0.997 0.191 0.190 0.959 0.169 0.188 0.325 0.792 0.227 0.460 0.195 0.048 0.267 0.296 0.037 
** absence of p-values indicates unequal distribution of haplotypes in the three HCM mutation groups resulting in 
stratified groups of small size with insufficient statistical power for testing 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
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3.4.5.20 PRKAA1 
Figure 3.41 graphically represents the p-values for the association between the PRKAA1 SNPs and 
hypertrophy traits. No statistically significant SNP effects were observed. Table 3.59 details the  
p-values for pair-wise comparison between mutation groups in the association between PRKAA1 
SNPs and hypertrophy traits. The effect of the C-allele of rs12517210 and the G-allele of 
rs11747210 (the minor allele of the rs11747210 SNP is the T allele) was higher on LVM in the 
R92WTNNT2 group relative to the A797TMYH7 group          
(26.9 g, p = 0.025; 26.7 g, p = 0.023). Also, their effects were higher in the R403WMYH7 group 
compared to the A797TMYH7 group on the CWT score (18.7 mm, p = 0.026; 17.9 mm, p = 0.047) 
and PC1 (1.17, p = 0.024; 1.12, p = 0.042). The effect of the A-allele of rs466108 was higher on 
mPWT (1.52 mm; p = 0.027) in the R403WMYH7 group compared to the A797TMYH7 group.  
Figure 3.42 graphically represents the p-values for the association between PRKAA1 haplotypes 
and hypertrophy traits with no evidence of statistically significant haplotype effects. Table 3.60 
details the p-values for pair-wise differences between mutation groups in the association between 
PRKAA1 haplotypes and hypertrophy traits. The effect of haplotype CGC, observed in 31% of the 
cohort, was higher on LVM in the R92WTNNT2 group compared to the A797TMYH7 group  
(21.7 g; p = 0.045). Conversely, the effect of haplotype TTC, also observed in 31% of the cohort, 
was lower on LVM in the R92WTNNT2 group compared to the A797TMYH7 group (36.4 g; p = 0.016).   
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Figure 3.41 The p-values for tests of association between single SNPs in PRKAA1 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.59 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in PRKAA1. Significant results are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs 
A797T 
R92W 
vs 
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs 
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs 
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs 
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs 
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs 
A797T 
R92W 
vs 
R403W 
rs12517210 0.143 0.025 0.532 0.077 0.090 0.913 0.164 0.200 0.911 0.646 0.364 0.716 0.026 0.074 0.611 0.024 0.085 0.559 
rs11747210 0.189 0.023 0.448 0.127 0.091 0.937 0.252 0.214 0.958 0.792 0.373 0.613 0.047 0.066 0.786 0.042 0.056 0.800 
rs466108 0.327 0.748 0.444 0.338 0.589 0.550 0.199 0.405 0.462 0.027 0.693 0.053 0.474 0.281 0.947 0.302 0.197 0.800 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.42 The p-values for tests of association between PRKAA1 haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.60 The p-values obtained for the analysis of interaction between mutation group and 
single haplotypes in PRKAA1. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
12
51
72
10
 
rs
11
74
72
10
 
rs
46
61
08
 R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W 
 vs 
R403W 
C G C 0.140 0.045 0.717 0.180 0.230 0.853 0.272 0.494 0.699 0.804 0.629 0.859 0.055 0.136 0.601 0.054 0.142 0.583 
T T A 0.540 0.701 0.389 0.348 0.891 0.400 0.194 0.538 0.366 0.054 0.557 0.121 0.393 0.560 0.599 0.257 0.442 0.483 
T T C 0.326 0.016 0.202 0.376 0.067 0.422 0.750 0.385 0.625 0.299 0.298 0.050 0.301 0.170 0.874 0.490 0.242 0.743 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
152│Chapter 3 
3.4.5.21 PRKAA2  
The p-values for the association between the PRKAA2 SNPs and hypertrophy traits; and the  
p-values for pair-wise differences between mutation groups in the association between PRKAA2 
SNPs and hypertrophy traits are given in Figure 3.43 and Table 3.61, respectively. No statistically 
significant single SNP effect or difference in SNP effect amongst the three HCM founder mutation 
groups was observed.  
The p-values for the association between PRKAA2 haplotypes and hypertrophy traits are 
graphically represented in Figure 3.44. The p-values for pair-wise comparison between mutation 
groups in the association of PRKAA2 haplotypes and hypertrophy traits are provided in Table 3.62. 
The effect of the TTT haplotype, observed in 14% of the study cohort, was an estimated increase of 
0.45 in PC1 (p = 0.043). No statistically significant difference in haplotype effect was observed 
amongst the three HCM founder mutation groups. 
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Figure 3.43 The p-values for tests of association between single SNPs in PRKAA2 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.61 The p-values obtained for the analysis of interaction between HCM founder 
mutation group and single SNPs in PRKAA2. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W 
 vs 
A797T 
R92W  
vs  
R403W 
rs1124900 0.852 0.617 0.822 0.983 0.950 0.976 0.992 0.703 0.758 0.679 0.435 0.330 0.952 0.263 0.337 0.820 0.261 0.486 
rs2796495 0.783 0.629 0.884 0.618 0.296 0.685 0.927 0.907 0.853 0.503 0.742 0.717 0.567 0.781 0.749 0.675 0.531 0.893 
rs932447 0.817 0.754 0.642 0.914 0.756 0.876 0.853 0.920 0.803 0.676 0.707 0.499 0.868 0.285 0.454 0.691 0.319 0.637 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
Stellenbosch University  http://scholar.sun.ac.za
  
154│Chapter 3 
 
Figure 3.44 The p-values for the tests of association between PRKAA2 haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.62 The p-values obtained for the analysis of interaction between mutation group and 
PRKAA2 haplotypes. 
Haplotype* LVM  mIVST  mLVWT  mPWT  CWT score  PC1  
rs
11
24
90
0 
rs
27
96
49
5 
rs
93
24
47
 
R403W 
vs  
A797T  
R92W 
vs 
A797T
R92W  
vs 
R403W  
R403W 
vs  
A797T  
R92W 
vs 
A797T
R92W  
vs 
R403W  
R403W 
vs  
A797T  
R92W 
vs 
A797T
R92W  
vs 
R403W  
R403W 
vs  
A797T  
R92W 
vs 
A797T
R92W  
vs 
R403W  
R403W 
vs  
A797T  
R92W 
vs 
A797T
R92W  
vs 
R403W  
R403W 
vs  
A797T  
R92W 
vs 
A797T 
R92W  
vs 
R403W  
G C T 0.289 0.387 0.717 0.409 0.437 0.941 0.648 0.652 0.994 0.451 0.525 0.828 0.392 0.476 0.784 0.408 0.451 0.899 
C T C 0.851 0.381 0.599 0.883 0.724 0.890 0.734 0.811 0.896 0.720 0.677 0.510 0.655 0.126 0.416 0.533 0.133 0.532 
T C T 0.424 0.993 0.453 0.558 0.501 0.975 0.773 0.940 0.741 0.096 0.843 0.154 0.321 0.844 0.414 0.351 0.594 0.623 
T T T 0.547 0.943 0.533 0.502 0.145 0.114 0.510 0.602 0.330 0.402 0.814 0.520 0.413 0.134 0.104 0.616 0.115 0.172 
G T T 0.866 0.535 0.632 0.424 0.416 0.874 0.750 0.784 0.993 0.848 0.147 0.109 0.627 0.426 0.699 0.824 0.277 0.362 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; LVM-left 
ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular wall 
thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
 
┌  ↑  ┐ 
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3.4.5.22 PRKAB1 
Figure 3.45 graphically represents the p-values for the association between the PRKAB1 SNPs and 
hypertrophy traits with no evidence of statistically significant SNP effects. Table 3.63 details the 
p-values for pair-wise comparison between mutation groups in the association between the 
PRKAB1 SNPs and hypertrophy traits. The effect of the T-allele of rs278149 was higher on the 
CWT score (25 mm; p = 0.041) and PC1 (1.56; p = 0.025) in the R92WTNNT2 group compared to the 
A797TMYH7 group. 
Figure 3.46 graphically represents the p-values for the association between PRKAB1 haplotypes 
and hypertrophy traits with evidence of statistically significant haplotype effects for the TGGTG 
haplotype, present in 14% of the cohort. Its effect was an estimated decrease of 18.3 g in LVM (p = 
0.010). Table 3.64 details the p-values for pair-wise differences between mutation groups in the 
association of PRKAB1 haplotypes and hypertrophy traits. The TGGTG haplotype that showed a 
significant haplotype effect as well as the GACGT haplotype indicated significant differences in 
haplotype effect amongst the HCM founder mutation groups. The effect of the TGGTG haplotype 
was higher on LVM (41.6 g; p = 0.020) in the R92WTNNT2 group compared to the A797TMYH7 group. 
The effect of the GACGT haplotype, present in 68% of the cohort, was lower on mPWT (1.21 mm; 
p = 0.004) in the R403WMYH7 group compared to the A797TMYH7 group.  
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Figure 3.45 The p-values for tests of association between single SNPs in PRKAB1 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.63 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in PRKAB1. Significant results are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
rs6490267 0.555 0.142 0.093 0.949 0.372 0.440 0.729 0.108 0.311 0.446 0.139 0.576 0.863 0.093 0.118 0.991 0.082 0.147 
rs278143 0.587 0.112 0.080 0.951 0.273 0.348 0.747 0.078 0.245 0.461 0.123 0.528 0.803 0.078 0.089 0.953 0.070 0.115 
rs10849690 0.935 0.082 0.115 0.992 0.292 0.356 0.963 0.207 0.252 0.755 0.940 0.766 0.476 0.262 0.122 0.575 0.245 0.142 
rs278149 0.493 0.068 0.347 0.316 0.102 0.606 0.289 0.118 0.689 0.151 0.066 0.722 0.522 0.041 0.226 0.368 0.025 0.244 
rs4213 0.516 0.284 0.151 0.939 0.625 0.643 0.741 0.169 0.400 0.495 0.104 0.459 0.824 0.150 0.156 0.959 0.129 0.182 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.46 The p-values for tests of association between PRKAB1 haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.64 The p-values obtained for the analysis of interaction between mutation group and 
PRKAB1 haplotypes. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
64
90
26
7  
rs
27
81
43
 
rs
10
84
96
90
 
rs
27
81
49
 
rs
42
13
 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W 
vs  
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W 
 vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs  
A797T 
R92W 
 vs 
R403W 
G A C G T 0.410 0.178 0.554 0.102 0.602 0.358 0.154 0.844 0.148 0.004 0.086 0.520 0.164 0.354 0.786 0.090 0.260 0.736 
T G C T G 0.618 0.894 0.602 0.762 0.902 0.912 0.612 0.820 0.538 0.116 0.406 0.700 0.496 0.972 0.560 0.310 0.854 0.524 
T G G T G 0.058 0.020 0.774 0.238 0.178 0.774 0.366 0.376 0.714 0.730 0.152 0.340 0.326 0.136 0.824 0.302 0.200 0.958 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
 
 
┌      ↓      ┐ 
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3.4.5.23 PRKAB2 
Figure 3.47 graphically represents the p-values for the association between the PRKAB2 SNPs and 
hypertrophy traits. The effect of the G-allele of rs1348316 was an estimated increase of 0.36 mm in 
mPWT (p = 0.049). Table 3.65 details the p-values for pair-wise differences between mutation 
groups in the association between PRKAB2 SNPs and hypertrophy traits. No statistically 
significant difference in SNP effect was observed amongst the three HCM founder mutation groups. 
The p-values for the association between the PRKAB2 haplotypes and hypertrophy traits; and the 
p-values for pair-wise differences between mutation groups in the association between the 
PRKAB2 haplotypes and hypertrophy traits are given in Figure 3.48 and Table 3.66, respectively. 
No statistically significant haplotype effect or difference in haplotype effect amongst the three 
HCM founder mutation groups was observed.  
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Figure 3.47 The p-values for tests of association between single SNPs in PRKAB2 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.65 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in PRKAB2. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs 
A797T 
R92W 
vs 
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs 
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs 
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs 
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs 
A797T 
R92W 
vs 
R403W 
R403W 
vs 
A797T 
R92W 
vs 
A797T 
R92W 
vs 
R403W 
rs6937 0.576 0.393 0.883 0.446 0.647 0.585 0.393 0.652 0.523 0.877 0.853 0.805 0.646 0.578 0.851 0.554 0.326 0.914 
rs1348316 0.481 0.586 0.909 0.739 0.898 0.865 0.800 0.679 0.875 0.800 0.733 0.603 0.808 0.966 0.861 0.854 0.738 0.891 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
┌       G↑       ┐     
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Figure 3.48 The p-values for tests of association between PRKAB2 haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.66 The p-values obtained for the analysis of interaction between mutation group and 
PRKAB2 haplotypes. 
Haplotype* LVM  mIVST  mLVWT  mPWT  CWT score  PC1  
rs
69
37
 
rs
13
48
31
6  
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W 
 vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W 
 vs 
R403W 
C A 0.817 0.209 0.803 0.991 0.554 0.834 0.984 0.606 0.828 0.631 0.860 0.676 0.979 0.626 0.871 0.937 0.411 0.810 
T A 0.317 0.330 0.906 0.940 0.868 0.942 0.826 0.600 0.796 0.615 0.806 0.479 0.807 0.920 0.730 0.927 0.939 0.869 
T G 0.230 0.936 0.342 0.839 0.472 0.637 0.753 0.307 0.513 0.408 0.233 0.078 0.989 0.479 0.520 0.939 0.294 0.316 
C G 0.773 0.759 0.614 0.519 0.737 0.388 0.339 0.660 0.210 0.801 0.552 0.492 0.533 0.871 0.627 0.469 0.682 0.699 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
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3.4.5.24 PRKAG1 
The p-values for the association between the PRKAG1 SNPs and hypertrophy traits; and the         
p-values for pair-wise differences between mutation groups in the association between PRKAG1 
SNPs and hypertrophy traits are given in Figure 3.49 and Table 3.67, respectively. No statistically 
significant single SNP effect or difference in SNP effect amongst the three HCM founder mutation 
groups was observed.  
The p-values for the association between the PRKAG1 haplotypes and hypertrophy traits are given 
in Figure 3.50; and the p-values for pair-wise comparisons between mutation groups in the 
association between PRKAG1 haplotypes and hypertrophy traits are given in Table 3.68. No 
statistically significant haplotype effect or difference in haplotype effect amongst the HCM founder 
mutation groups was observed.  
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Figure 3.49 The p-values for tests of association between single SNPs in PRKAG1 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.67 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in PRKAG1. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs10875910 0.736 0.693 0.535 0.998 0.881 0.904 0.641 0.643 0.948 0.642 0.690 0.458 0.962 0.973 0.985 0.852 0.833 0.989 
rs2117029 0.445 0.845 0.387 0.663 0.316 0.205 0.271 0.997 0.317 0.416 0.761 0.316 0.446 0.722 0.305 0.413 0.786 0.315 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.50 The p-values for tests of association between PRKAG1 haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.68 The p-values obtained for the analysis of interaction between mutation group and 
PRKAG1 haplotypes. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
10
87
59
10
 
rs
21
17
02
9  R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
C T 0.571 0.878 0.678 0.982 0.922 0.959 0.517 0.648 0.788 0.505 0.678 0.351 0.659 0.760 0.837 0.543 0.669 0.780 
G A 0.412 0.639 0.717 0.524 0.875 0.476 0.197 0.463 0.575 0.343 0.284 0.978 0.402 0.598 0.737 0.369 0.490 0.799 
G T 0.527 0.852 0.632 0.898 0.106 0.067 0.688 0.469 0.178 0.722 0.977 0.720 0.951 0.377 0.248 0.965 0.366 0.246 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
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3.4.5.25 PRKAG2 
Figure 3.51 graphically represents the p-values for the association between the PRKAG2 SNPs and 
hypertrophy traits with no evidence of statistically significant SNP effects. Table 3.69 details the p-
values for pair-wise differences between mutation groups in the association between PRKAG2 
SNPs and hypertrophy traits. The effect of the C-allele of rs8961 was higher on LVM (23.8 g; p = 
0.047) in the R92WTNNT2 group relative to the A797TMYH7 group. Also, its effect was higher in the 
R403WMYH7 group compared to the A797TMYH7 group: 3.25 mm on mIVST (p = 0.033), 3.23 mm on 
mLVWT (p = 0.023) and 24.0 mm on the CWT score (p = 0.043). The effect of the G-allele of the 
rs6464170 variant was higher on mIVST (3.09 mm; p = 0.023) in the R92WTNNT2 group compared 
to the A797TMYH7 group. The effect of the G-allele of the rs13240743 variant was lower in the 
R92WTNNT2 group relative to the A797TMYH7 group on LVM (15.4 g; p = 0.012), mPWT (0.77 mm; 
p = 0.039), the CWT score (13.3 mm; p = 0.042) and PC1 (0.83; p = 0.023). In addition, its effect 
was lower on LVM (44.7 g; p = 0.004), mIVST (3.63 mm; p = 0.038) and mLVWT (3.30 mm; p = 
0.049) in the R92WTNNT2 group compared to the R403WMYH7 group.  
Figure 3.52 graphically represents the p-values for the association between PRKAG2 haplotypes 
and hypertrophy traits. The effect of the CACC haplotype, observed in 10% of the cohort, was an 
estimated increase of 1.48 mm in mIVST (p = 0.044). The TGGG haplotype, observed in 7% of the 
cohort, was associated with a decrease in mLVWT of 2.03 mm (p = 0.014). Table 3.70 details the 
p-values for pair-wise comparison between mutation groups in the association of PRKAG2 
haplotypes and hypertrophy traits. The effect of the CGCC haplotype, observed in 11% of the 
cohort, was higher on LVM (42.6 g; p = 0.047) in the R403WMYH7 group relative to the A797TMYH7 
group. Also, its effect was higher in the R92WTNNT2 group compared to the A797TMYH7 group: 57.3 
g on LVM (p = 0.001), 4.4 mm on mIVST (p = 0.008), 3.76 mm on mLVWT (p = 0.021), 30.1 mm 
on the CWT score (p = 0.012) and 1.88 on PC1 (p = 0.015). The effect of the CGCG haplotype, 
observed in 5% of the cohort, was lower in the R92WTNNT2 group compared to the R403WMYH7 
group: 90 g on LVM (p = 0.021), 7.6 mm on mIVST (p = 0.033), 7.6 mm on mLVWT (p = 0.017), 
92.3 mm on the CWT score (p = 0.018) and 5.77 on PC1 (p = 0.020). In addition, its effect was 
lower in the R92WTNNT2 group relative to the A797TMYH7 group: 1.72 mm on mPWT (p = 0.013) and 
0.68 on PC1 (p = 0.049). The effect of the CGGC haplotype, present in 7% of the cohort, was lower 
on mIVST in the R92WTNNT2 group than the A797TMYH7 group (7.3 mm; p = 0.028). The effect of 
Stellenbosch University  http://scholar.sun.ac.za
  
165│Chapter 3 
the TAGC haplotype, observed in 4% of the cohort, was lower in the R403WMYH7 group compared 
to the A797TMYH7 group: 7.4 mm on mIVST (p = 0.040) and 7.18 mm on mLVWT (p = 0.048). 
 
Figure 3.51 The p-values for tests of association between single SNPs in PRKAG2 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.69 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in PRKAG2. Significant results are indicated in bold red font. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
rs8961 0.097 0.047 0.908 0.033 0.076 0.602 0.023 0.062 0.627 0.200 0.546 0.482 0.043 0.062 0.733 0.146 0.152 0.869 
rs2727537 0.109 0.350 0.472 0.245 0.861 0.240 0.574 0.579 0.352 0.936 0.654 0.794 0.951 0.673 0.708 0.784 0.773 0.638 
rs6464170 0.133 0.313 0.623 0.067 0.023 0.643 0.091 0.190 0.703 0.059 0.109 0.773 0.100 0.077 0.878 0.162 0.071 0.665 
rs13240743 0.338 0.012 0.004 0.453 0.077 0.038 0.320 0.180 0.049 0.913 0.039 0.131 0.630 0.042 0.052 0.831 0.023 0.061 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.52 The p-values for tests of association between PRKAG2 haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
 
 
 
 
 
 
┌  ↑  ┐ ┌  ↓  ┐
Stellenbosch University  http://scholar.sun.ac.za
  
167│Chapter 3 
Table 3.70 The p-values obtained for the analysis of interaction between mutation group and 
individual haplotypes in PRKAG2. Significant results are indicated in bold red font. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
89
61
 
rs
27
27
53
7  
rs
64
64
17
0  
rs
13
24
07
43
 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs  
A797T 
R92W  
vs 
A797T 
R92W  
vs  
R403W 
C A C C 0.616 0.225 0.707 0.908 0.227 0.353 0.949 0.894 0.971 0.817 0.388 0.704 0.977 0.385 0.571 0.962 0.270 0.478 
C A C G 0.617 0.931 0.691 0.530 0.510 0.920 0.131 0.231 0.558 0.155 0.784 0.257 0.143 0.522 0.313 0.382 0.637 0.586 
C G C C 0.047 0.001 0.584 0.195 0.008 0.496 0.501 0.021 0.281 0.260 0.059 0.767 0.906 0.012 0.128 0.970 0.015 0.101 
C G C G 0.214 0.106 0.021 0.142 0.348 0.033 0.180 0.112 0.017 0.742 0.013 0.220 0.111 0.141 0.018 0.195 0.049 0.020 
C G G C 0.364 0.458 0.987 0.214 0.028 0.159 0.580 0.140 0.222 0.429 0.522 0.992 0.339 0.112 0.325 0.398 0.131 0.319 
T A C C 0.575 0.776 0.815 0.873 0.818 0.966 0.976 0.797 0.833 0.810 0.624 0.585 0.707 0.595 0.497 0.529 0.730 0.453 
T A C G** - 0.473 - - 0.666 - 
 
0.686 - - 0.878 - - 0.994 - - 0.919 - 
T A G C 0.289 0.626 0.392 0.040 0.126 0.401 0.048 0.145 0.411 0.598 0.846 0.626 0.333 0.283 0.946 0.742 0.512 0.685 
T G C C 0.726 0.749 0.507 0.812 0.566 0.444 0.697 0.907 0.788 0.943 0.941 0.890 0.969 0.467 0.459 0.834 0.521 0.406 
T G C G 0.152 0.732 0.182 0.633 0.542 0.230 0.583 0.523 0.192 0.689 0.830 0.804 0.875 0.967 0.882 0.716 0.710 0.947 
T G G C 0.341 0.205 0.444 0.468 0.279 0.383 0.686 0.350 0.199 0.307 0.202 0.536 0.413 0.185 0.230 0.380 0.173 0.254 
C A G G** - 0.765 - - 0.553 - - 0.858 - - 0.305 - - 0.605 - - 0.463 - 
T G G G 0.557 0.180 0.304 0.614 0.169 0.287 0.843 0.278 0.222 0.293 0.314 0.911 0.549 0.145 0.262 0.498 0.121 0.255 
** absence of p-values indicates unequal distribution of haplotypes in the three HCM mutation groups resulting in 
stratified groups of small size with insufficient statistical power for testing 
Abbreviations: A-Adenine*; A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; 
LVM-left ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular 
wall thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
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3.4.5.26 PRKAG3 
The p-values for the association between the PRKAG3 SNPs and hypertrophy traits; and the          
p-values for pair-wise comparison between mutation groups in the association between PRKAA2 
SNPs and hypertrophy traits are given in Figure 3.53 and Table 3.71, respectively. No statistically 
significant single SNP effect or difference in SNP effect amongst the three HCM founder mutation 
groups was observed.  
Figure 3.54 graphically represents the p-values for the association between PRKAG3 haplotypes 
and hypertrophy traits. The effect of the TT haplotype, observed in 74% of the cohort, was an 
estimated decrease of 13.4 g in LVM (p = 0.031). Table 3.72 details the p-values for pair-wise 
differences between mutation groups in the association between PRKAG3 haplotypes and 
hypertrophy traits. No statistically significant difference in haplotype effect was observed amongst 
the three HCM founder mutation groups. 
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Figure 3.53 The p-values for tests of association between single SNPs in PRKAG3 and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. 
Table 3.71 The p-values obtained for the analysis of interaction between mutation group and 
single SNPs in PRKAG3. 
SNP ID LVM mIVST mLVWT mPWT CWT score PC1 
 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
rs1000935 0.911 0.641 0.670 0.592 0.804 0.722 0.927 0.864 0.749 0.705 0.814 0.859 0.945 0.760 0.625 0.852 0.871 0.647 
rs16859382 0.932 0.733 0.759 0.599 0.740 0.801 0.883 0.908 0.747 0.630 0.814 0.755 0.928 0.742 0.585 0.822 0.840 0.575 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; LVM-left ventricular mass; mIVST-
maximal interventricular septum thickness; mLVWT-maximal left ventricular wall thickness; mPWT-maximal 
posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single nucleotide polymorphism; T-
Threonine; vs-versus; W-Tryptophan 
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Figure 3.54 The p-values for tests of association between PRKAG3 haplotypes and individual 
hypertrophy traits. The original p-values are given in the data table, whilst the graph represents the 
corresponding –log10 transformed values. The red dashed horizontal line indicates the p-value significance 
threshold equal to 0.05. Bars located above this line, therefore, indicate significant p-values (p-values<0.05). 
The p-value significance increases with bar height above threshold. The observed haplotype frequencies are 
indicated in brackets. 
Table 3.72 The p-values obtained for the analysis of interaction between mutation group and 
haplotypes in PRKAG3. 
Haplotype* LVM mIVST mLVWT mPWT CWT score PC1 
rs
10
00
93
5  
rs
16
85
93
82
 
R403W 
vs 
 A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs  
A797T 
R92W  
vs 
R403W 
R403W 
vs 
 A797T 
R92W  
vs 
A797T 
R92W  
vs 
R403W 
G C 0.975 0.490 0.425 0.447 0.734 0.604 0.855 0.874 0.673 0.441 0.670 0.663 0.893 0.860 0.683 0.770 0.996 0.692 
T T 0.719 0.777 0.909 0.988 0.793 0.801 0.912 0.524 0.564 0.735 0.710 0.450 0.970 0.811 0.807 0.990 0.884 0.845 
Abbreviations: A-Alanine; CWT score-cumulative wall thickness score; C-Cytosine*; G-Guanine*; LVM-left 
ventricular mass; mIVST-maximal interventricular septum thickness; mLVWT-maximal left ventricular wall 
thickness; mPWT-maximal posterior wall thickness; PC1-principal component score; R-Arginine; SNP-single 
nucleotide polymorphism; T-Threonine; T-Thymine*; vs-versus; W-Tryptophan 
 
 
 
┌        ↑        ┐ 
Stellenbosch University  http://scholar.sun.ac.za
  
171│Chapter 3 
3.4.6 Optimal selection 
We employed stepwise-selection on the model for the PC1 trait to identify a subset of the variants 
investigated in this study that together explain most of the variation in hypertrophy in the current 
cohort. A total of six markers predicted an increase in at least one of the hypertrophy indices, 
independent of the hypertrophy covariates and the other significant variants contained in the model.  
The effect of each of the six alleles that conferred an increased risk for hypertrophy development is 
provided in terms of the estimated increase in PC1 per allele per SNP in Table 3.73. The combined 
effect of one of each of the six alleles increased the PC1 score by 2.852 with an average effect per 
allele of 0.475. Table 3.74 indicates the distribution of the number of ‘pro-LVH’ alleles in MC and 
NC individuals. 
Table 3.73 Allelic effects of variants predicting a significant increase in hypertrophy in the 
current cohort 
Gene Polymorphism Minor Allele 
‘pro-LVH’ 
Allele 
PC1 
(n = 129) 
MYL2 rs933296 A C 0.488 
MYH7 rs2277475 T A 0.425 
TPM1 rs11071720  C T 0.138 
TPM1 rs1071646 C C 1.169 
CKM rs7260463 T G 0.119 
PRKAB2 rs1348316 G G 0.513 
Combined effect on hypertrophy trait 2.852 
Average effect per allele 0.475 
Abbreviations: CKM-Creatine kinase, muscle; LVH-left ventricular hypertrophy; MYL2-Myosin light chain 2, 
regulatory cardiac, slow; MYH7-Mysoin heavy chain 7, cardiac muscle, beta; n-total; PC1-first principal component; 
PRKAB2-Protein kinase, AMP-activated, beta 2 non-catalytic subunit; TPM1-Tropomyosin 1 
Table 3.74 The distribution of the number of ‘pro-LVH’ alleles in MC and NC individuals 
Number of ‘pro-LVH’ alleles carried  2 3 4 5 6 7 8 9 10 11 
MC 0 0 4 12 9 19 14 13 5 0 
NC 1 3 2 8 11 11 9 5 2 1 
Abbreviations: MC-mutation carrier, NC-non-mutation carrier 
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CHAPTER FOUR 
DISCUSSION 
The importance of efficient patient risk stratification and treatment in HCM becomes apparent when 
considering that it is the most common inherited cardiac disorder and the leading cause of SCD in 
young adults; and that its main clinical feature, LVH, is an independent predictor of morbidity and 
mortality (Fokstuen et al., 2011;Dahlof et al., 2002). 
However, considerable genotype/phenotype disparity exists for the numerous HCM-causing 
mutations and treatment aiming to correct the direct consequences thereof remains challenging, e.g. 
achieving adequate intracellular oligonucleotide levels to ensure chronic suppression of individual 
HCM missense mutations (Ashrafian et al., 2011;Carrier et al., 1997;Dausse et al., 1993). The 
phenotypic diversity observed for a given causal mutation is seen even in homogenous individuals 
from the same family, thereby highlighting the contribution of factors other than the primary 
genetic defect. This certainly includes the influence of modifier genes, as is evident from the 
literature review presented in Chapter 1.  
A previous genome-wide analysis that identified human HCM modifier loci showed greater effect 
sizes for modifier alleles present in the homozygous state relative to the causal mutation, which 
typically presents as heterozygous in autosomal dominant disorders (Marian, 2010). Moreover, 
modifier loci can ameliorate the effects of a causal mutation and in some instances even completely 
suppress the phenotype (Wei et al., 2010). Identification of modifiers will thus improve the current 
understanding of disease development and potentially highlight new targets for patient risk 
screening and treatment (Daw et al., 2008).  
To date, efforts aimed at identifying modifiers of hypertrophy in HCM have focused mainly on 
genes encoding proteins that function in cardiac growth and hypertrophy (Friedrich et al., 2009). 
However, the few replication studies reported in the literature have delivered inconsistent results 
(Marian, 2002;Nabel, 2003). It is reasonable to suggest that the genetic factors that cause HCM also 
have the potential to modify its development and a review of the primary defects and their direct 
consequences highlight genes relating to sarcomeric structure, function and myocardial energetics 
as candidate modifier genes. This study, therefore, set out to evaluate the hypertrophy-modifying 
capacity of these factors by means of SNP-based association testing within South African HCM 
families.  
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The study identified a modifying role in the development of hypertrophy in HCM for each of the 
candidate genes investigated, in many instances for the first time, with the exception of the 
metabolic protein-encoding gene, PRKAG1. Single SNPs within the genes MYH7, TPM1 and MYL2 
which encode structural proteins of the sarcomere as well as the genes CPT1B, CKM, ALDOA and 
PRKAB2 which encode metabolic proteins, indicated significant association results and hence 
hypertrophy modifying effects. Similarly, haplotypes comprising variants within the genes ACTC, 
TPM1, MYL2, MYL3 and MYBPC3 which encode structural proteins of the sarcomere as well as the 
genes CD36, PDK4, CKM, PFKM, PPARA, PPARG, PGC1A, PRKAA2, PRKAG2 and PRKAG3 
which encode metabolic proteins, showed significant association results indicative of combined-
variant hypertrophy modifying effects. Also, a number of variants and haplotypes showed 
statistically significant differences in effect amongst the three HCM founder mutation groups.  
4.1 Caveats in association studies 
A statistically significant association between a marker and a phenotypic trait can reflect the 
functional significance of the marker itself or a marker with which it is in LD; or can be ascribed to 
chance or artefact. It is, therefore, necessary to consider and, if needed, appropriately correct for a 
number of factors, which may negatively impact on the reproducibility of association studies for 
complex genetic traits (Cardon & Palmer, 2003). The following sections will discuss these factors 
within the context of the present study.   
4.1.1 Population stratification 
The association analyses essentially aimed to correlate differences in allele frequencies for a given 
SNP with differences in trait levels using cases and unaffected relatives (Cardon & Palmer, 2003). 
In instances where the study sample comprises several population groups, as was the case for the 
present cohort, the allele frequencies and disease risks may vary amongst them and so give rise to 
spurious association between an allele and disease trait (Colhoun et al., 2003). The current study 
population comprises South African HCM families from either Caucasian or Mixed Ancestry 
decent. The latter is considered an ethnic admixture group, which originated from the intermingling 
of a number of populations, including Khoi, San, Dutch and black African individuals (Loubser et 
al., 1999). More specifically, South African individuals with mixed ancestry contain admixture 
from mainly Khoi San Africans (32-43%), non-Khoi San Africans (20-36%), Europeans (21-28%) 
Stellenbosch University  http://scholar.sun.ac.za
  
174│Chapter 4 
and, to a lesser extent, Asian populations (9-11%) (de Wit et al., 2010). Also, we incorporated both 
within- and between-family components of association in an effort to maximise the power of the 
study. 
As consequence, this study employed specialised mixed-effects models that are able to incorporate 
both fixed and random effects. Self-reported ethnicity was included as a fixed effect to partially 
control for population substructure whilst family- and individual-specific random effects were 
modelled as adjustment for intrafamilial clustering of traits and interindividual trait correlations i.e. 
confounding due to family or cryptic relatedness (Price et al., 2010).  
Although not employed in the current study, it is important to note the alternative methods of 
correcting for ancestry other than self-reported ethinicity. If genome-wide data is available for the 
study group, principal components or ancestry proportions (estimated by solving a multinomial 
model given the genome-wide data) can be used as covariates in a regression model to adjust for 
population stratification. The covariance structure between individuals, estimated from the genome-
wide data, or genomic control, that applies a correction factor to association test statistics, can also 
be used (Wu et al., 2011;Alexander et al., 2009). Alternatively, if genome-wide data is not available 
but ancestry informative markers (AIMs) have been genotyped for the individuals in the study, 
principal component or ancestry proportion covariates can be used to adjust for stratification (Daya 
M, personal communication;Paschou et al., 2008;Tsai et al., 2005). 
4.1.2 Multiple testing  
Statistical evaluation of a number of tests within a single study is believed to increase the 
probability of identifying a significant association by chance (type I error). It is, therefore often 
considered important to statistically compensate in instances of multiple testing, such as the current 
study where numerous markers were tested against various heritable hypertrophy traits. However, 
the literature is not in agreement regarding the necessity of such a correction (Rothman, 1990).  
The first option would be to perform multiple testing correction using the Bonferroni adjustment, 
which entails multiplying the p-value obtained for each of the independent tests by the total number 
of evaluations performed. However, this correction is not suitable, as it is considered to be over-
conservative. Moreover, the tests used in this study are not mutually independent, as the traits 
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investigated are all derived from the 16 wall thickness measurements; and certain SNPs are in LD, 
albeit incomplete. The alternative approach to multiple testing correction, i.e., Bayesian methods, 
utilise prior information regarding the hypothesis, i.e. the relationship between the genetic factor 
and trait investigated, to adjust the statistical significance level in an informed manner. This 
approach too is unsuitable to the current study, as the functional significance and thus the prior 
probabilities, have not been characterised for all genetic variants (Campbell & Rudan, 2002). Also, 
this study was undertaken as a hypothesis-generating rather than a hypothesis-testing investigation. 
Therefore, as mentioned in Section 2.6.6, no formal correction was made given the lack of an 
appropriate method of adjustment and the explorative nature of the genetic study. Moreover, 
existing methods of adjustment are applicable only to family trios and would have to be further 
modified for use with extended pedigrees such as those used here; however, this type of 
computational modification was beyond the scope of the present study. A further means of 
addressing the issue of multiple testing would be to consider the statistical results generated at a 
reduced threshold for significance e.g. p < 0.01.   
4.1.3 Confounding variables 
When evaluating the potential contribution of a given factor to the development of hypertrophy it is 
necessary to ensure that the groups/individuals under investigation are similar in structure with 
respect to the distribution of all factors known to confer risk of hypertrophy development, i.e. 
covariates, so as to avoid confounding defined as the distortion of the effect measure as either 
inflated or masked. To ensure that a significant association most accurately reflects the relationship 
between the investigated variant and trait rather than the influence of these confounding variables, 
the statistical models employed here made adjustments for known covariates of hypertrophy, 
namely age (Fleg & Strait, 2012;Lasky-Su et al., 2008), sex (Maass et al., 2004;Okin et al., 2000), 
BSA, HR (as a proxy measure for tachycardia i.e. elevated resting HR) (Saba et al., 2001), mean 
arterial pressure (MAP; as derived from systolic and diastolic BP) (Roman et al., 2010), presence of 
hypertension (i.e., adjustment for anti-hypertensive therapy) (Kraja et al., 2011;Levy et al., 
1990b;Puntmann et al., 2010;Sipola et al., 2011), ethnicity (as indication of recent population 
stratification) (Okin et al., 2000), and HCM-causing founder mutation (Moolman et al., 1997). 
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4.1.4 Statistical power 
The statistical power of an association study is defined as the likelihood that it will correctly detect 
a specific true association (Cardon & Bell, 2001). The purpose of a power analysis is to determine 
the minimum study group size that would enable us to detect a specific effect size. For such a 
calculation to be informative, we would have to select a minimum specific effect size and be able to 
increase our study population accordingly were it not sufficiently large. The power of the current 
study was not formally estimated for a number of reasons. Firstly, although HCM hypertrophy 
modifier investigations typically report small effect sizes (Lechin et al., 1995;Mayosi et al., 2003), 
the candidate modifiers presented here were tested in an HCM cohort in this study for the first time, 
and we were unsure of what type of effect sizes to anticipate. Secondly, as this study is considered 
to be an explorative investigation, i.e. hypothesis-generating, we wanted to report all effects and not 
merely those above a given cut-off. Furthermore, the maximum possible sample size was already 
utilised, as all consenting members of the HCM cohort were included in the evaluations, and there 
were no means of increasing the cohort size at present. Finally, no power calculation has been 
derived for family-based association studies comprising extended pedigrees. 
Rather, the study aimed to optimise the factors, other than genetic effect size, that are known to 
influence power; these included disease allele frequency (marker informativeness) and the accuracy 
of both the phenotype definition and genotyping results (Cardon & Bell, 2001;Gordon & Finch, 
2005).  
4.1.5 SNP selection 
The informativeness of a given marker is characterised by a number of factors, including its MAF 
and its ability to represent the variability throughout a given gene in a specific population. Strong 
statistical power is required to draw meaningful conclusions about rare alleles. Functional variants 
typically have low heterozygosity values that may compromise the power of an association study 
and SNP prioritisation according to potential functional significance is therefore less suitable 
(Shastry, 2007). Markers with relatively high MAFs are therefore considered more appropriate, i.e. 
informative, for modifier studies in complex diseases where the effect sizes are typically small, such 
as HCM. This is also true in instances where the study population is relatively small; and our own 
study cohort is modest in size given the estimated prevalence of HCM of 1 in 500 in young adults.  
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The potential exists, given the occurrence of LD amongst markers, to capture the total variation 
throughout a gene of interest by genotyping only a subset of all the variants therein. The LDU 
method of selection can minimise the number of SNPs required to accurately capture the variability 
throughout a candidate gene, owing to the observation that the human genome comprises sizeable 
regions of high-LD interspersed with short segments of very low LD (Goldstein, 2001;Daly et al., 
2001). The literature suggests that a small number of tag-SNPs can sufficiently represent the 
haplotype structure of these high LD regions and that the LDU method can, therefore, reduce cost 
and genotyping effort without a significant loss of power (Patil et al., 2001;Johnson et al., 
2001;Zhang et al., 2002). Moreover, Maniatis et al. (2005) described greater power for association 
mapping when utilising LDU compared to a kb map (Maniatis et al., 2005). 
In order to take into account the afore-described factors upon marker selection we would require the 
relevant SNP detail specific to our study population. However, a comprehensive study of LD in all 
the populations in South Africa is still needed. To circumvent this limitation, one could refer to a 
suitable reference population. De Bakker et al. (2006) demonstrated that tag-SNPs validated in 
HapMap population samples could efficiently capture the common genetic variation in samples 
from multiple populations, i.e. tag-SNP transferability (de Bakker et al., 2006).  
A further means to amplify the informativeness of selected markers is to perform haplotype 
analyses. Moreover, the literature suggests that the power and robustness of association tests are 
increased when using haplotypes relative to single SNPs (Akey et al., 2001). Haplotype analyses 
may provide valuable information relevant to fine mapping and/or the effect of the specific allele 
combination on the trait i.e. effect of a single variant within the context of the relevant gene (Schaid 
et al., 2002;Marian, 2002). The latter specifically refers to epistatic interactions where the 
phenotype is significantly influenced not by individual SNP effects, but rather by the interactions 
between multiple SNPs. Alternatively, individual SNPs may influence the phenotype, but may do 
so to a lesser degree than the corresponding SNP-derived haplotypes; e.g. individual variants may 
show weak effects, but their cumulative effects observed upon haplotype analysis will provide a 
more significant association (Winkelmann et al., 2003;Newton-Cheh & Hirschhorn, 2005). This is 
of specific relevance given that candidate modifier genes investigated in HCM to date have yielded 
small effect sizes (and thus there existed a potential for small effect sizes for the candidates in this 
study), the complex nature of HCM, and the definition of a modifier as dependent on the context of 
a given disease-causing mutation.  
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In this study, the selection of SNPs throughout the relevant candidate genes was achieved by means 
of the SNPbrowserTM v.4.0.1, a free resource that efficiently integrates and displays the information 
required for SNP-based association study design, thereby affording an easy interface (De La Vega 
et al., 2006). For example, the software visually depicts SNP positions and density based on either 
kb (physical map) or LDU distances (metric LD map). 
In an effort to select informative markers congruent with the afore-described considerations, the 
present study aimed to achieve an even SNP spacing of 0.5 LDU; and prioritized SNPs with a 
minimum MAF of 0.05. Moreover, SNPs were selected using the metric LD maps for the HapMap 
CEU and YRI populations. As mentioned in Chapter 2 (Refer to Section 2.3.2), previous 
association studies from our own laboratory showed that the LD structure of the CEU and YRI 
populations, at least in certain gene regions, best represent the as-yet undefined LD structure of the 
South African population and, thereby the current study cohort. Indeed, this was the case in the 
current study, as seen upon comparison of most of the MAFs from the current study cohort to those 
of the CEU and YRI reference populations (Refer to Section 3.4.1). Finally, we included haplotype 
analyses as a means of capturing the variability throughout the genes investigated; and detecting 
within-gene epistatic effects. However, no formal statistical test for epistasis was performed in the 
present study.   
4.1.6 Phenotypic heterogeneity 
As described for population stratification, comprehensive and accurate phenotype definition and 
ascertainment is imperative in optimizing the power and reproducibility of an association study so 
as to avoid spurious or null association (Rao & Gu, 2008). In HCM, this proves challenging owing 
to the marked phenotypic heterogeneity of this complex disease, especially with respect to the 
extent and distribution of cardiac hypertrophy. As a consequence, no single measure can adequately 
capture the degree of hypertrophy throughout the entire cohort. Composite scores that integrate a 
number of hypertrophy measurements to circumvent this problem, but the issue of which score best 
reflects the hypertrophy phenotype remains unresolved.  
In the present study, segmental analysis of the LV wall, i.e. 16 wall thickness measurements at three 
levels of the heart (Refer to Section 2.1.2), was achieved by means of echocardiography. Although 
not as sensitive and reproducible as evaluation via cardiac magnetic resonance imaging (cMRI), the 
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method is less costly and more readily available (Reviewed by Bauml & Underwood, 2010). To 
minimise measurement error, evaluations were performed according to a standardised protocol by a 
single experienced echocardiographer who was kept blinded to participant mutation status. 
Echocardiographically derived LVM was determined as it is a descriptor often used in the literature, 
thus allowing for comparison to similar studies. However, its accuracy as an estimate of 
hypertrophy is limited by the underlying assumption of ellipsoid geometry. PCA was, therefore 
applied to the wall thickness measurements to define a single cohort-specific measure, PC1, which 
comprehensively captures ventricle-wide hypertrophy and so the variability in LVH. In addition, we 
used single measurements of maximum hypertrophy as estimates of the extent of hypertrophy. To 
ensure accurate statistical analysis, trait values were transformed to approximate normality, thereby 
accommodating a key assumption of the association test employed. 
4.1.7 Genotyping approach 
The ABI Validated TaqMan® genotyping platform proved to be more efficient than the PCR-based 
methods previously utilised to genotype the current cohort as it offers a number of advantages 
pertaining to assay design, reaction setup and data analysis. 
Taqman® assays are pre-designed and validated, thereby eliminating the need for costly and time-
consuming design, optimization and verification (e.g. additional sequencing). In the present study, 5 
µl reactions were set up within 384-well plates by means of an automated pipetting tool, thus 
ensuring high-throughput, reproducibility and accuracy, whilst minimising cost and human error. In 
addition, the technique is DNA-sparing, as assays require a starting template in the range of only 5-
20 ng. Sample amplification, end-point data collection and automatic allele calling via the SDS 
software, as derived from sample fluorescence signals, are all achieved on the ABI Prism 7900HT 
Sequence Detection System (Applied Biosystems Inc, Foster City CA, USA), thus avoiding post-
PCR processing. To ensure stringent genotype assignment the quality value of the SDS autocaller 
was kept at the default ≥ 95.0 with samples below this cut-off marked as undetermined. Genotyping 
results were exported to text file format for direct import into the existing database further 
minimising human error, i.e. typographical errors. Collectively, the use of pre-designed assays and 
the afore-described largely automated protocol provides accurate and reproducible results.  
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It should be mentioned that conventional PCR-based genotyping methods remain less expensive 
than the ABI Validated TaqMan® genotyping system on a sample by sample basis, and that not all 
SNPs are available in the collection of predesigned assays. A TaqMan® custom assay service is 
available, but requires optimization and verification of accuracy. 
4.2 Association analyses results 
The research efforts of our laboratory are directed toward identifying genes that modify the 
development of hypertrophy in South African HCM families. The seemingly monogenic disease 
was investigated at the outset as a simpler genetic model of hypertrophy, as the LVH occurs in the 
absence of precipitating clinical factors. However, the observation of extreme phenotypic 
heterogeneity in HCM, even amongst members of the same family, highlighted the contribution of 
gene modifiers. Our research aims were expanded accordingly, with the current study focused on 
investigating sarcomeric genes and genes related to myocardial energetics as candidate modifiers of 
hypertrophy. The results of the investigations of this study will be discussed in the following 
sections. All significant associations reflect p-values calculated following adjustment for all 
relevant hypertrophy covariates and family relatedness. These adjustments are detailed in the 
foregoing section (Refer to Sections 4.1.1 and 4.1.3). 
4.2.1 Sarcomeric genes 
The sarcomeric genes included in this study have all, with the exception of ACTN3, previously been 
implicated in the development of HCM as causal mutations (Refer to Section 1.2.1). They were, 
therefore revisited with the aim of here evaluating their capacity to modify, as opposed to directly 
causing, the development of hypertrophy in HCM within the current cohort.  
i) α-Actin 
Muscle contraction essentially entails sliding of the thin filaments past the thick filaments. Actin is 
the major constituent of the thin filament and, therefore contributes to sarcomere structure and 
enables contraction. The main isoform in the heart, cardiac α-actin, is encoded by the ACTC1 gene 
(Bertola et al., 2008;dos Remedios et al., 2003;Laing & Nowak, 2005).  
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The ACTC1 SNPs, rs1370154 and rs2070664, revealed significant haplotype effects. The effect of 
the CC haplotype was an estimated decrease of 0.51 mm in mIVST and it is, therefore considered to 
be cardioprotective. Conversely, the effect of the CT haplotype was an estimated increase of 1.55 
mm in mIVST and 1.05 mm in mLVWT. The third haplotype, TT, did not have a significant effect 
on any of the traits. These effects were found in the absence of significant single SNP effects or 
significant differences in SNP/haplotype effect amongst the mutation groups. The two SNPs were 
found to be in complete LD based on the point estimate of D’ = 1. Collectively, the results suggest 
that the observed effects may be ascribed to the combined effects of the two SNPs, or markers with 
which they are in LD.  
Both SNPs are at present functionally uncharacterised, and are located in the 3’ untranslated region 
(3’ UTR) and an intron, respectively (http://www.ncbi.nlm.nih.gov/SNP). This prompted in silico 
evaluation by means of the splice site prediction program Netgene2 (Brunak et al., 1991;Hebsgaard 
et al., 1996). In silico evaluations refer to computer-based computational algorithms, i.e. 
bioinformatic tools, used to predict, in this instance, splice motifs in the human. Briefly, the 
predictive algorithm is accessed online with the variant and its flanking sequences serving as input. 
The alternative alleles of a given variant are analysed individually and the respective outputs 
comprising the various predicted splice motifs are then compared to identify any difference in 
sequence recognition. In silico analyses did not reveal significant functional consequences for either 
of the two variants as no splice site alterations were observed. The SNPbrowserTM v.4.0.1 LD maps 
for both the CEU and YRI populations indicated that the numerous variants found to be in LD with 
the investigated SNPs are all positioned intronically (http://www.ncbi.nlm.nih.gov/SNP, 
SNPbrowserTM v.4.0.1). Although not assessed in silico, any functional effect of these intronic 
SNPs in LD with the two associated SNPs is not immediately obvious. 
ii) Myosin 
Myosin is the main component of the thick filament and its (biological) interaction with actin as 
well as its role in ATP binding and hydrolysis is central in muscle contraction. The ventricular 
isoform, β-MHC, is encoded by MYH7 with mutations therein previously characterised as HCM-
causing, two of which, R403WMYH7 and A797TMYH7, segregate in the current cohort as founder 
mutations (Dalloz et al., 2001) (Refer to Sections 1.2.1 and 2.3.3.1).  
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The T-allele of rs2277475 presented as cardioprotective as its effect was an estimated decrease of 
1.19 mm in mLVWT, 8.64 mm in the CWT score and 0.54 in PC1. The A-allele, under the additive 
allelic model, would thus result in a corresponding increase in these measures. Significant 
associations with the CWT score require further interpretation, as the trait reflects the sum of the 16 
independent wall thickness measurements. Therefore, an 8.64 mm decrease in CWT, as seen for the 
T-allele of rs2277475, represents an average decrease of ~0.54 mm (8.64/16) in each of the 16 
measurements. LD evaluation revealed that the SNP is in complete LD with the two founder 
mutations, based on the point estimates of D’ = 1 (Refer to Table 3.14). However, statistical 
adjustments for founder mutation carrier status were incorporated and the observed effects can thus 
be ascribed to the variant itself or variants, other than the founder mutations, with which it is in LD.  
The SNP is intronic and in silico evaluations were performed as described for ACTC1 
(http://www.ncbi.nlm.nih.gov/SNP). The comparisons revealed no splicing motif alterations and the 
SNP is, therefore unlikely to be of functional consequence (Brunak et al., 1991;Hebsgaard et al., 
1996). Next, non-synonymous coding variants in LD with the associated SNP were considered, as 
they may be more likely to be functionally significant. Identification of such SNPs was achieved 
using the LD structures of the HapMap CEU and YRI populations, as amongst the HapMap data, 
these populations best represent the current study cohort (Refer to Sections 2.3.2 and 4.1.5, 
SNPbrowserTM v.4.0.1). A single variant, rs3729823, was in LD with rs2277475, and has been 
characterized as a missense mutation that entails the substitution of the neutral polar Serine (Ser) 
with the neutral, slightly polar Cysteine (Cys) (TCC → TGC; S1491C) 
(http://www.ncbi.nlm.nih.gov/SNP). The effects of the amino acid substitution on protein function 
was predicted using the SIFT algorithm, which showed it to be tolerated (Kumar et al., 2009). HCM 
studies have reported the presence of the variant at low frequencies in both HCM patients and 
controls (Blair et al., 2002;Hougs et al., 2005). This led Hougs et al. (2005) to describe it as a 
relatively rare polymorphism in the control population and to suggest that it may act as disease 
modifier. Furthermore, variants rs2277475 and rs3729823 were detected upon mutation screening 
of patients harbouring functionally identical Dutch truncating MYBPC3 founder mutations namely 
c.2373dupG, p.Arg943X or c.28644_2865delCT. The study did not report the exact combinations 
detected but discussed that the complex sarcomeric genetic status observed in their investigation did 
not significantly modify the severity of the HCM phenotype (Michels, 2011). 
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Moreover, the LD blocks of both the YRI and CEU populations extend to the neighbouring MYH6 
gene, and function-altering, non-synonymous coding variants therein may thus also play a 
modifying role. A single variant, rs442275, was in LD with rs2277475 in both CEU and YRI 
HapMap populations. Defined as a missense mutation, it leads to the substitution of Glutamic acid 
(Glu) by Glutamine (Gln) (CAG → GAG; E88Q), which, according to the SIFT analysis (Kumar et 
al., 2009), is predicted to be damaging to function (http://www.ncbi.nlm.nih.gov/SNP). 
Replacement of the acidic polar Glu with the neutral polar Gln may affect protein tertiary structure, 
and, thereby, protein interactions/function. Although the mutation itself has not been linked to 
HCM, the possibility cannot be excluded, as defects in MYH6 have proven to be HCM-causing 
(Refer to Section 1.2.1). Thus, the significant single SNP association of rs2277475 may reflect the 
as yet unknown consequence of the SNP itself, or the effect of an exonic (rs3729823 in MYH7 or 
rs442275 MYH6) or intronic variant(s), in either MYH6 or MYH7, with which it is in LD. The most 
significant variants are believed to be located within exons and they should, therefore be prioritised 
for further evaluation within a different and larger cohort and on a functional level.  
The rs2277475 SNP also demonstrated significant differences in effect amongst the HCM founder 
mutation groups. The effect of the T-allele was higher in the R403WMYH7 group relative to both the 
A797TMYH7 (18.2 mm for the CWT score and 1.14 for PC1) and R92WTNNT2 groups (24.8 mm for 
the CWT score and 1.55 for PC1). Therefore, the degree of variation in the CWT score and PC1 
measures as a result of rs2277475 (or a variant with which it is in LD) is significantly dependent on 
the causal mutation with which it occurs, i.e. there is SNP and founder mutation group interaction.  
This observation is somewhat surprising, considering that the statistical analyses corrected for the 
effect of individual founder mutations, which would lead one to expect that the effect size of the 
associated SNP would be equal across the founder mutation groups. One possible explanation for 
this is that the result reflects the influence of secondary mechanisms flowing from the effects of the 
founder mutations. More specifically, the effect of the modifier allele is context dependent, with the 
latter dictated by the direct consequences of the individual founder mutations and/or the resulting 
activation of signalling cascades and trophic factors (Marian et al., 2001) (Refer to Section 1.2.4). 
The exact secondary consequences and the time of activation thereof may vary amongst the primary 
causal mutations. That is, the numerous HCM-causing mutations may place varying degrees of 
stress on the sarcomere, giving rise to different secondary pathway profiles, including those 
involved in calcium handling and energy metabolism. Indeed, the molecular pathways implicated in 
Stellenbosch University  http://scholar.sun.ac.za
  
184│Chapter 4 
the development of HCM have been described as diverse and partially independent, and it is here 
where the difference in modifier effect may manifest (Marian, 2010). Considered on a biological 
level, the modifier protein may directly interact with the mutated protein encoded by a HCM causal 
mutation and/or perhaps with a protein in a secondary signalling pathway. A specific modifier allele 
may therefore be more or less relevant within different secondary pathways and at various stages of 
disease development.  
In contrast, the effect rs2277475 on mLVWT did not vary amongst the founder mutation groups. 
The SNP had a significant effect on this measure when the entire cohort was considered, but no 
significant difference in its effect on mLVWT was detected upon pair-wise comparison between 
mutation groups. Similar results were observed for a number of genes and this clarification is thus 
applicable to the relevant SNPs/haplotypes that are yet to be discussed. 
Significant differences in haplotype effects were observed for two haplotypes that differ with 
respect to the rs2277475 and rs2239578 variants (relevant alleles are underlined). The effect of the 
TTGCG haplotype was lower on PC1 (1.84) in the R92WTNNT2 group relative to the R403WMYH7 
group. The effect of the TAGCA haplotype was higher in the R92WTNNT2 group relative to the 
R403WMYH7 group: 58.4 g on LVM, 36.7 mm on the CWT score and 2.29 on PC1. These results 
reflect combined SNP effects (combined effects of loci contained in the haplotype or variants with 
which they are in LD) as they do not mirror the single SNP effect of rs2277475; and these 
haplotype effects are significantly influenced by the founder mutation context in which they occur. 
Certain comparisons could not be made owing to the unequal distribution of haplotypes in the three 
HCM mutation groups, e.g. haplotype TTGCA (Refer to Table 3.24). However, the lack of 
significant differences in effect for the TAGCG haplotype suggests that the haplotype effect may 
involve rs2239578 or a marker with which it is in LD.  
The rs2239578 SNP is intronically positioned and relevant in silico evaluations were performed. 
Netgene2 evaluations revealed no difference in splice site signals (Brunak et al., 1991;Hebsgaard et 
al., 1996). A single exonic variant, rs2069540, was found to be in LD with rs2239578, but it is 
characterised as a synonymous coding SNP. It should be noted that the haplotype effects may 
reflect the combined effects of other variants within the haplotype. It is, however, clear that the 
TTGCG and TAGCA haplotypes modify the development of hypertrophy in the current cohort and 
the extent of their effects is significantly influenced by the founder mutation context.  
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It is necessary to re-emphasize the results of rs2277475. Alone, it had a significant effect on the 
CWT score, PC1 and mLVWT. However, within the context of a haplotype, i.e. when considering 
its effect collectively with the effects of other variants in the gene (that is within gene context) its 
effects varied significantly: (rs2277475 is underlined) TAGCG influenced LVM, the CWT score 
and PC1, whilst TAGCA did not influence any of the traits. Similar ‘within gene context’ effects 
were observed for several of the genes yet to be discussed and this clarification should thus be 
considered where applicable in the remainder of the discussion.  
iii) The Troponin (Tn) complex 
The Tn complex, consisting of TnT, TnI and TnC, regulates muscle contraction via its association 
with tropomyosin, the molecule that overlays the myosin binding site on actin. More specifically, 
the complex undergoes a conformational change in response to Ca2+-binding, which facilitates the 
movement of tropomyosin from its inhibitory position, allowing for crossbridge formation and 
muscle contraction (Reviewed by Chapelle, 1999). 
a) Troponin T 
TnT links the Tn complex to tropomyosin, whilst also binding actin and regulating actomyosin 
ATPase activity. The four known cardiac isoforms are all encoded by TNNT2 and variants therein 
have previously been implicated in HCM development (Dalloz et al., 2001;Anderson et al., 
1995;Zot & Potter, 1987). One of the HCM-causing mutations therein, R92WTNNT2, segregates in 
the current cohort as a founder mutation (Refer to Sections 1.2.1 and 2.3.3.1).  
LD evaluation showed that all the investigated variants are in complete LD with one another as well 
as with the founder mutation (point estimates of D’ = 1). Statistical adjustments for founder 
mutation carrier status were incorporated into the evaluations and the lack of statistically significant 
single SNP association confirms the adequacy thereof.  
The effect of the A-allele of rs2365652 was higher on mIVST (2.30 mm) in the R92WTNNT2 group 
relative to the A797TMYH7 group. The rs2365652 variant is positioned intronically and in silico 
evaluation was performed (http://www.ncbi.nlm.nih.gov/SNP). The Netgene2 evaluations did not 
show any splice signal alterations and the observed result is either due to the as yet unknown effects 
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of rs2365652, or more likely as a result of a variant(s) with which it is in LD (Brunak et al., 
1991;Hebsgaard et al., 1996). The variant is in LD with two coding, non-synonymous variants, 
namely rs4523540 (AAC → TAC; N276Y) and rs2996496 (AGA → AAA; R139K) 
(http://www.ncbi.nlm.nih.gov/SNP, SNPbrowserTM v.4.0.1). SIFT predictions indicated that the 
first comprises a potentially functionally damaging amino acid substitution (Kumar et al., 2009). 
The change is characterised as a change from the neutral polar Aspartic acid (Asp) to the also 
neutral polar Tyrosine (Tyr); however, the latter is considered to be more polar owing to its 
hydrocarbon benzene ring (http://www.elmhurst.edu/~chm/vchembook/561aminostructure.html). 
The SNPs themselves have, to date, not been functionally characterised or linked to disease 
development. The effect of rs2365652 (or a variant with which it is in LD) on the hypertrophy 
phenotype is significantly influenced by the founder mutation with which it occurs, i.e. there is 
variant and mutation group interaction. To clarify, rs2365652 may have an effect in one founder 
mutation group and the opposite, or no effect in the other(s), and as a result no significant effect was 
observed when the combined cohort was considered. This explanation also applies to similar 
results, i.e. significant differences in SNP/haplotype effect amongst the mutation groups in the 
absence of significant SNP/haplotype effects in the total cohort, observed for a number of genes still 
to be discussed.  
The AAIG and CGIA haplotypes indicated significant differences in haplotype effect amongst the 
three mutation groups. The effect of the first was higher on LVM (23.5 g; p = 0.028) in the 
R403WMYH7 group compared to the A797TMYH7 group. The effect of the second was lower on 
mIVST (12.57 mm; p = 0.008), mLVWT (11.34 mm; p = 0.034) and the CWT score (89.4 mm; p = 
0.034) in the R403WMYH7 group relative to the A797TMYH7 group. These results do not reflect the 
afore-described significant SNP effects; therefore these haplotype effects suggest that the trait 
variance can be ascribed to the combined effects of variants contained within the respective 
haplotypes. Certainly, the extent to which the SNPs/haplotypes modify the hypertrophy in HCM is 
significantly influenced by the specific founder mutation with which it presents. 
b) Troponin I 
TnI is responsible for the binding of actin and, thereby the inhibition of actomyosin ATPase 
activity. Moreover, it conveys the conformational signal from TnC to TnT and tropomyosin. The 
cardiac isoform of TnI is encoded by TNNI3 and a total of three SNPs therein was selected for 
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statistical evaluations (Dalloz et al., 2001;Reviewed by Filatov et al., 1999). However, genotyping 
of the rs3729841 variant showed an uninformative number of heterozygous individuals and it was, 
therefore, excluded from further analyses. The variant is characterized as a synonymous change in 
the coding region.  
LD evaluation indicated that the remaining two SNPs are in complete LD (D’ = 1). The effects of 
these SNPs varied significantly amongst the mutation groups: the effect of the G-allele of 
rs3729838 was higher on mLVWT (2.45mm); and the effect of the G-allele of the rs11667847 
variant was higher on LVM (34.3 g) in the R92WTNNT2 group compared to the R403WMYH7 group. 
The effect of these SNPs (or variants with which they are in LD) on the hypertrophy phenotype is 
thus significantly influenced by the founder mutation with which it occurs, i.e. variant and mutation 
group interaction was present. To reiterate, they may have an effect in one founder mutation group 
and the opposite, or no effect in the other(s), and as a result no significant effect was observed upon 
consideration of the combined cohort. The SNPs are located intronically and in silico predictions 
where thus performed to determine their potential effects on mRNA splicing 
(http://www.ncbi.nlm.nih.gov/SNP). The Netgene2 evaluations did not indicate any splice signal 
alterations (Brunak et al., 1991;Hebsgaard et al., 1996). All the exonic variants shown to be in LD 
with the investigated SNPs are defined as synonymous changes (http://www.ncbi.nlm.nih.gov/SNP, 
SNPbrowserTM v.4.0.1).  
Significant differences in haplotype effects were observed for haplotypes CA and GA. The effect of 
the first was lower on mLVWT (1.97 mm) in the R92WTNNT2 group relative to the R403WMYH7 
group. The effect of the second was higher on mIVST (3.7 mm) and mLVWT (3.46 mm) in the 
R92WTNNT2 group relative to the R403WMYH7 group. Also, its effect was higher on mLVWT (4.47 
mm) in the A797TMYH7 group compared to the R403WMYH7 group. These results do not reflect the 
afore-described significant SNP effects; therefore these haplotype effects suggest that the trait 
variance can be ascribed to the combined effects of variants contained within the respective 
haplotypes. Moreover, the extent to which the SNPs/haplotypes modify the hypertrophy in HCM is 
significantly influenced by the specific founder mutation with which it presents. 
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iv) α-Tropomyosin 
The α-TM protein, encoded by TPM1, binds actin, thereby stabilising and stiffening the thin 
filament. In addition, it regulates muscle contraction as is clear from the preceding sections (Dalloz 
et al., 2001;Weigt et al., 1990).  
The C-allele of rs1071646 associated with increases in all hypertrophy traits: 17.3 g in LVM, 2.02 
mm in mIVST, 1.75 mm in mLVWT, 0.59 in mPWT, 17.68 mm in the CWT score and 1.10 in PC1. 
Cardioprotective effects were observed for the C-allele of the rs11071720 variant associated with a 
decrease of 0.49 mm in mPWT whilst the C-allele of the rs707602 variant associated with increases 
of 1.0 mm in mLVWT and 0.83 mm in mPWT. LD estimates showed only the rs1071646 and 
rs707602 variants to be in complete LD (D’ = 1). 
Significant differences in SNP effect amongst the founder mutation groups were also observed. The 
effect of the C-allele of the rs11071720 variant was higher on mIVST (2.65 mm) in the R92WTNNT2 
group relative to the A797TMYH7 group. The effect of the T-allele of the rs4238370 variant was 
lower in the R92WTNNT2 group compared to the A797TMYH7 group: 48.1 g for LVM, 3.84 mm for 
mIVST, 4.84 mm for mLVWT, 45.6 for the CWT score and 2.85 for PC1. Also, its effect was lower 
in the R403WMYH7 group relative to the A797TMYH7 group: 3.99 mm on mIVST, 35.8 on the CWT 
score and 2.23 on the PC1 measure. Collectively, these findings suggest that the extent to which the 
SNPs effect hypertrophy development is significantly influenced by the founder mutation context. 
As explained in previous paragraphs the effect of a SNP may vary greatly amongst the founder 
mutations i.e. its effect in one founder mutation group(s) may be masked by its opposite or no effect 
in the other(s) and as a result no significant association signal is observed upon consideration of the 
entire cohort. This may be the case for rs4238370, as it showed significant difference in effect 
amongst the mutation groups, but no significant single SNP effect in the total cohort. 
The rs11071720 and rs4238370 SNPs are both intronic (http://www.ncbi.nlm.nih.gov/SNP). The 
rs707602 SNP is positioned within the 3’-UTR and the rs1071646 SNP is characterised as a 
synonymous coding variant. The relevant in silico evaluations were performed to predict their 
potential functional significance. However, no significant differences in recognition of splice site 
motifs were identified (Brunak et al., 1991;Hebsgaard et al., 1996). The literature recently 
identified an association between the rs11071720 polymorphism and mean platelet volume (MPV) 
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stating that myosin-actin interaction is key in platelet formation (Soranzo et al., 2009). However, 
the variant is yet to be implicated in hypertrophy development and functionally characterised. 
Similarly, the remainder of the SNPs have not been linked to disease or evaluated on a functional 
level. According to the LD structures of the HapMap CEU and YRI populations, all the variants are 
in LD with one another and a single coding, non-synonymous SNP namely rs1131003. The 
missense mutation is characterised a change from the acidic polar Glu to the neutral polar Gln 
(GAA → CAA; E196Q) and predictions with SIFT suggested that the change is tolerated (Kumar et 
al., 2009). This mutation too is yet to be functionally characterised or and evaluated within the 
context of disease development. 
Statistically significant haplotype effects were identified for CGAT, CTCT and CGCT. The effect 
of the first was an estimated decrease of 18.1 g in LVM, 0.78 mm in mPWT, 9 mm in the CWT 
score and 0.56 in PC1. Conversely, the effect of the second was an estimated increase of 3.21 mm 
in mIVST, 3.13 mm in mLVWT, 30.2 mm in the CWT score and 1.89 in PC1. The effect of CGCT 
was an estimated increase of 47.9 g in LVM. The results do not mirror the observed significant SNP 
effects. More strikingly, CGAT and CGCT differ only with respect to rs4238370 (underlined), but 
show very different trait profiles. Collectively the results suggest that the trait variance can be 
ascribed to the combined effects of variants contained within the respective haplotypes. 
The CGAT haplotype that showed significant haplotype effects, as well as a further haplotype, 
TGCT, indicated significant differences in haplotype effects amongst the HCM founder mutation 
groups. The effect of the CGAT haplotype was higher on mIVST (2.98 mm) and the CWT score 
(18.4 mm) in the R92WTNNT2 group relative to the R403WMYH7 group. Also, its effect was higher in 
the R403WMYH7 group compared to the A797TMYH7 group: 3.88 mm on mIVST, 28.5 mm on the 
CWT score and 1.78 on PC1. The effect of the TGCT haplotype was lower on LVM (105 g) in the 
R92WTNNT2 group relative to the A797TMYH7 group whilst its effect was higher on LVM (105.5 g) in 
the R92WTNNT2 group compared to the R403WMYH7 group. The effects of haplotypes CGAT and 
TGCT on the hypertrophy phenotype are thus significantly influenced by the founder mutation 
context.  
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
190│Chapter 4 
v) The myosin light chains 
The functions of the myosin light chains, ELC and RLC, are twofold as they contribute to 
sarcomere structure and regulation of contractility (Poetter et al., 1996). The cardiac RLC and ELC 
are encoded by MYL2 and MYL3, respectively, and mutations in both have been implicated in the 
development of HCM (Colson et al., 2010;Harris et al., 2011;Taylor et al., 2004;Schaub et al., 
1998).  
a) MYL2 
The A-allele of rs933296 appeared to be cardioprotective as its effect was an estimated decrease of 
13.6 g in LVM, 9.57 mm in the CWT score and 0.60 in PC1. The significant haplotype effects 
observed for the AC and AG haplotypes were also seemingly cardioprotective. The effect of the 
first was an estimated 25.1 g decrease in LVM, whilst the effect of the second was an estimated 
decrease of 0.60 in PC1. The significantly associated haplotypes, interestingly, share the A-allele of 
the significantly associated rs933296 variant, whilst varying with respect to the alleles of the non-
significantly associated rs4766517 variant. Moreover, the two significant haplotype associations are 
with different traits. Collectively, the results suggest the presence of combined effects of the 
associated SNP and the second investigated SNP (or a SNP with which it is in LD). This again 
motivates the importance of investigating the effect of SNPs within the context of the entire gene.  
The rs933296 and rs4766517 variants are positioned intronically and in the 5’ near gene region, 
respectively. In silico evaluations were performed to determine their potential effects on mRNA 
splicing (http://www.ncbi.nlm.nih.gov/SNP, SNPbrowserTM v.4.0.1). Netgene2 evaluation of the 
significantly associated rs933296 indicated that the C-allele thereof was characterised by the 
recognition of an additional donor splice site relative to the A-allele.  
Briefly considered, intronic variants may affect splicing in a number of ways. In instances where 
variants give rise to additional intronic sequences homologous to donor and acceptor sites, the 
possibility exists that it would be recognised and a part of the intron then retained in the mRNA. 
This, is turn, may disrupt the splicing of the succeeding exon and in case of a frameshift, the coding 
of all of the remaining exons. If a variant leads to the loss of such a donor or acceptor site, splicing 
of a given exon may be skipped. Although such changes may only affect a section of the mRNA it 
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could ultimately disrupt functional domains and/or the 3D structure of the entire protein and 
significantly influence the disease phenotype.  
We could hypothesize that the C-allele gives rise to aberrant mRNA splicing given its association 
with increased measures of LVM, the CWT score and PC1. The variant is positioned in intron 3 and 
it may therefore significantly influence splicing of exon 4 (and the eventual DNA reading frame) 
(Andersen et al., 2001; http://www.ncbi.nlm.nih.gov/SNP). RLC mutations are typically associated 
with mild or benign phenotypes. However, exceptions include the R58QMYL2 mutation located in 
exon 4, which gives rise to a malignant phenotype characterised by increased LVWT, early onset 
and SCD (Harris et al., 2011;Mettikolla et al., 2011;Mettikolla et al., 2011;Kabaeva et al., 
2002;Flavigny et al., 1998).  
Greenberg et al. (2010) described that the RLC surrounds and thereby supports the α-helical myosin 
neck region (lever arm); and that this localization modulates force and movement by allowing 
energy transmission from the site of ATP hydrolysis (catalytic site) down the neck domain. They 
further described that the RLC may influence the mechanical properties of the lever arm which, in 
turn, determines the degree of force transmission from the myosin lever arm to the catalytic site i.e. 
strain-sensing. The latter is essential as the myosin cycle kinetics is strain-dependent. In support 
thereof, they describe that mutations that reduce the stiffness of the lever-arm give rise to mutant 
myosins that exhibit a reduction in force. The R58QMYL2 mutation abolishes the Ca2+ binding 
capacity and, as result, the structure of the RLC. Such changes may affect the ability of the RLC to 
stabilize the α-helical myosin neck region and so the transmission of strain. Moreover, R58QMYL2 
mutant transgenic mouse myosins exhibit reduced force and power output (Greenberg et al., 
2010;Harris et al., 2011). Considered within the context of these findings, the rs933296 variant 
may, similarly, influence the stiffness and strain-sensing ability of the α-helical myosin neck 
ultimately leading to a compensatory hypertrophy phenotype as reflected in its significant 
association with LVM, the CWT score and PC1.  
Allelic comparison of the rs476617 variant did not indicate differences pertaining to the recognition 
of splicing acceptor or donor sites suggesting that it may have an as yet undetermined functional 
consequence (Brunak et al., 1991;Hebsgaard et al., 1996). Alternatively, the observed results may 
be attributed to the effects a functional variant(s) in LD with rs933296 and/or rs476617. However, 
all of the coding variants shown to be in LD with the two investigated SNPs are characterised as 
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synonymous changes (SNPbrowserTM v.4.0.1 software). The SNPs themselves have, to date, not 
been functionally characterised or implicated in disease.  
b) MYL3 
SNPs rs1531136 and rs3792558 revealed significant haplotype effects in the absence of significant 
SNP effects. This suggests that the trait variance can be explained by the combined effects of 
variants contained within the haplotype which are not significantly influenced by the founder 
mutation context. The CC haplotype was seemingly cardioprotective as its effect was an estimated 
decrease of 8 g in LVM, 0.32 mm in mPWT, 3.7 mm in the CWT score and 0.23 in PC1. The effect 
of the TC haplotype was an estimated increase of 25.6 mm in the CWT score and 1.6 in PC1. LD 
estimates indicated complete LD between the two SNPs (D’ = 1.00). It is important to note that a 
third haplotype, TT, was observed, but was not significantly associated. The result clearly points to 
complex haplotype interactions, either amongst the investigated SNPs or between variants with 
which they are in LD. According to the SNPbrowserTM v.4.0.1 software, all of the coding variants 
shown to be in LD with the two investigated SNPs are characterised as synonymous changes. To 
date, neither of the SNPs have been linked to disease or characterised functionally. 
The two investigated variants are both positioned within introns; therefore, in silico evaluations 
were performed to determine their potential effects on mRNA splicing 
(http://www.ncbi.nlm.nih.gov/SNP, SNPbrowserTM v.4.0.1). The rs1531136 variant did not indicate 
any differences in splice site motifs upon Netgene2 investigation (Brunak et al., 1991;Hebsgaard et 
al., 1996). Significantly, Netgene2 evaluation of the rs3792558 showed differences in recognition 
of splices sites with the identification of an additional donor motif upon analysis of the T-allele 
(complementary strand) relative to the C-allele. The variant may thus give rise to aberrant mRNA 
splicing that, given its position in intron 1, could significantly affect the splicing of exon 2 (and 
potentially the reading frame of all succeeding exons). According to our knowledge, all MYL3 
HCM-causing mutations identified to date are located within either exon 3 or 4 (Andersen et al., 
2012;Harris et al., 2011). Interestingly, the predicted domain structure as determined by Hernandez 
et al. (2007) suggests that parts of exons 2 and 3 code for the EF-hand Ca2+-binding motif (EF1 
domain). We can therefore look to the known mutations within the relevant section of exon 3 as 
predictive of the effects of our significantly associated variant, namely E56GMYL3, A57GMYL3, 
V79LMYL3 and R81HMYL3. The ELC interacts with the myosin IQ1 motif, thereby stabilising the 
Stellenbosch University  http://scholar.sun.ac.za
  
193│Chapter 4 
lever arm of the myosin head and ensuring normal force production (Hernandez et al., 
2007;Andersen et al., 2012). The E56GMYL3 and A57GMYL3 mutations are located in the α-helix of 
the EF-hand. Significantly, the E56GMYL3 mutation reduces binding to the myosin lever arm (30-
fold reduced binding) (Lossie et al., 2012). Moreover, the V79LMYL3 and R81HMYL3 mutations are 
located close to the IQ1 motif and they may thus disrupt the stabilising interaction and give rise to 
disease. Indeed, MYH7 mutations within the IQ1 motif have been characterised as HCM-causing 
(Andersen et al., 2012).  
The rs3792558 variant may, in part, explain the significant haplotype effects via aberrant mRNA 
splicing. More specifically, it may decrease or completely disrupt ELC interaction with myosin, 
negatively impacting on the stability of the myosin lever arm and ultimately force production.  
vi) Myosin binding protein C 
MYBPC3 encodes the cardiac myosin binding protein-C, which functions in modulating contraction 
and stabilising the thick filament (Carrier et al., 1997).  
Significant differences in SNP effects were observed amongst the HCM founder mutation groups: 
the effect of the A-allele of rs4752825 and the T-allele of rs1052373 was higher, 22.6 g and 22.5 g, 
respectively, on LVM in the R92WTNNT2 group compared to the A797TMYH7 group. These results 
suggest that the extent to which these SNPs modify the hypertrophy phenotype is significantly 
influenced by the founder mutation context. Also, it is possible that the observed effects actually 
reflect one another as the effects sizes are nearly identical and the LD between the two SNPs is 
estimated to be complete (D’ = 1).  
The rs4752825 and rs1052373 variants are positioned within the 5’near gene region and in an exon, 
respectively (http://www.ncbi.nlm.nih.gov/SNP). In silico evaluations of the first SNP did not 
identify any differences in recognition of splice sites (Brunak et al., 1991;Hebsgaard et al., 1996). 
The second is characterised as a coding synonymous change (GAG → GAA; E1096E) 
(http://www.ncbi.nlm.nih.gov/SNP) (Erdmann et al., 2003). The significant differences in effect are 
potentially due to the as yet unknown effects of these two SNPs, as neither have been characterized 
functionally or implicated in disease development. The effects are more likely due to variants in LD 
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with rs4752825 and/or rs1052373. The LD structures of the HapMap CEU and YRI populations 
show that these variants are in LD with only coding, synonymous SNPs (SNPbrowserTM v.4.0.1).  
A significant haplotype effect and statistically significant differences in haplotype effect amongst 
HCM founder mutation groups was observed; and it did not reflect the significant SNP effects 
suggesting that the trait variance is due to the combined effects of variants contained within the 
haplotype. The ATGG haplotype appeared to be cardioprotective as its effect was an estimated 
decrease of 0.51 mm in mPWT. The effect of ATGA was higher on LVM (65.1 g), mPWT (1.66 
mm), the CWT score (8.6 mm) and PC1 (0.54) in the R403WMYH7 group compared to the 
A797TMYH7 group. Also, its effect was higher on LVM (29.9 g) and mPWT (1.25 mm) in the 
R92WTNNT2 group compared to the R403WMYH7 group. Finally, its effect was lower on PC1 (0.05) in 
the R92WTNNT2 group compared to A797TMYH7 group. The effect of GCGG was lower on the LVM 
measure (36.8 g) in the R403WMYH7 group compared to the A797TMYH7 group; and lower on LVM 
(30.9 g), mPWT (1.13 mm) and PC1 (1.10) in the R92WTNNT2 group relative to the R403WMYH7 
group. The ATGA and GCGG haplotypes modify the development of hypertrophy with the extent 
of their effects differing significantly depending on founder mutation context. 
vii) α-actinin-3 
The α-actinin-3 protein is encoded by ACTN3 and its function in cardiac muscle is poorly 
characterised. Based on the functions of α-actinins in skeletal muscle, this protein is speculated to 
contribute to cytoskeletal integrity and myocardial energetics at the sarcomere level (Macarthur & 
North, 2004;Rakus et al., 2003;Hance et al., 1999;Rakus et al., 2003;Squire, 1997). It interacts with 
signalling proteins, including members of the calsarcin family, which, in turn, bind to the Ca2+- and 
calmodulin-dependent protein phosphatase, calcineurin. The latter has been implicated in the 
development of skeletal and cardiac muscle hypertrophy (Olson & Williams, 2000;Molkentin et al., 
1998). Furthermore, investigation of ACTN3-knockout mice, which are homozygous for a 
premature stop codon (R577X, rs1815739), showed reduced mass in muscles known to express α-
actinin-3. The ACTN3-knockout mice and wild-type hearts did not vary in size and the expression 
of ACTN3 is believed to be restricted to skeletal muscle (Berman & North, 2010). However, 
validated ACTN3 transcripts have been identified in heart muscle and the lack of variation in heart 
size may be attributable to unknown factors (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=ACTN3&search=actn3). The functional variant was, therefore included in the 
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current study. Finally, the protein product of ACTN2, an HCM-causing gene (Refer to Section 
1.2.1), shares high sequence homology with α-actinin-3 (Macarthur & North, 2004). 
A significant difference in the haplotype effect amongst the mutation groups was observed for the 
GCC haplotype. Its effect was lower on the PC1 measure (1.02) in the R92WTNNT2 group compared 
to that in the R403WMYH7 group. The absence of any significant single SNP effects suggests that the 
haplotype effect is due to the combined effects of variants contained within the haplotype. 
Furthermore, the extent of the haplotype effect on trait variance is significantly influenced by the 
founder mutation context. 
4.5.2 Energy genes 
i) Fatty acid translocase 
The FAT/CD36 gene encodes a protein that facilitates uptake of LCFAs across the sarcolemmal 
membrane (Harmon & Abumrad, 1993;Aras & Dilsizian, 2007;Luiken et al., 2003). Expression 
QTL studies in a SHR model indicated that renal CD36 determines both BP and risk of 
hypertension (Pravenec et al., 2008). Similarly, a human study of Japanese individuals showed that 
those deficient in CD36 had higher BP relative to controls (Miyaoka et al., 2001). More recently, 
Hall and colleagues (2011) identified an association between LVM, determined by either 
echocardiography or electrocardiography, and a CD36 variant in a cohort comprising families 
recruited by means of a hypertensive proband (in the top 5% of blood pressure distribution) (Hall et 
al., 2011). Further SHR investigations, characterised by CD36 deficiency, indicated that diet 
supplementation with SCFA, the uptake of which is CD36-independent, eliminated cardiac 
hypertrophy. The results linked defective fatty acid uptake, and by implication CD36, to cardiac 
hypertrophy, leading the authors to suggest a role for SCFA supplementation in human 
hypertrophic cardiomyopathy (Hajri et al., 2001). Finally, abnormal myocardial fatty acid uptake 
and reduced CD36 expression has been linked to an HCM-like phenotype i.e. the development of a 
clinical phenotype indistinguishable from HCM (Cambronero et al., 2009;Luedde et al., 
2009;Okamoto et al., 1998;Soor et al., 2009;Ashrafian et al., 2003). 
In this study, the rs10268417 SNP showed a significant difference in effect amongst the founder 
mutation groups, indicating that the extent of its effect on trait variance is significantly influenced 
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by the founder mutation context. The effect of the A-allele was lower in the R92WTNNT2 group 
compared to A797TMYH7 group: 1.29 mm on mPWT, 20.7 mm on CWT score and 1.29 on PC1.  
The SNP is positioned intronically and in silico evaluations were performed accordingly 
(http://www.ncbi.nlm.nih.gov/SNP). However, allelic comparison did not indicate any significant 
differences in recognition of splice site motifs (Brunak et al., 1991;Hebsgaard et al., 1996). The 
difference in SNP effect is, therefore due to the as yet unknown effect of the SNP itself or a variant 
with which it is in LD. The LD structures of the HapMap CEU and YRI populations show that the 
variant is in LD with a coding, non-synonymous SNP in only the CEU population namely 
rs13306227 (SNPbrowserTM v.4.0.1). The latter is a missense mutation characterised as a change 
from the basic polar Arginine (Arg) to neutral non-polar Leucine (Leu) (CGG → CTG; R5L) 
(http://www.ncbi.nlm.nih.gov/SNP) with SIFT predictions characterising it is damaging (Kumar et 
al., 2009). This change may affect the tertiary structure of the relevant protein and perhaps give rise 
to altered protein function/interactions. The two SNPs have to date not been investigated on a 
functional level or implicated in the development of disease. 
The CGT haplotype appeared to be cardioprotective as its effect was an estimated decrease of 0.58 
mm in mPWT, 8.6 mm in the CWT score and 0.54 in PC1. This result did not mirror the single SNP 
effect, suggesting that the phenotype arises from the combined effects of variants contained in the 
haplotype. Significant differences in haplotype effect were observed amongst the founder mutation 
groups for the AGT and CGT haplotypes. The effect of the first was lower in the R92WTNNT2 group 
relative to A797TMYH7 group: 1.99 mm for mPWT, 41.6 mm for the CWT score and 2.6 for PC1. 
The effect of the second was higher in the R403WMYH7 group compared to the A797TMYH7 group: 
2.2 mm on mIVST. Again, the significant haplotype effects may be due to combined effects of 
variants contained within the respective haplotypes; and the extent to which these haplotypes 
modify the development of hypertrophy is also significantly influenced by founder mutation 
context. 
ii) Carnitine palmitoyltransferase I 
Carnitine palmitoyltransferase is responsible for the transport of LCFA across the outer membrane 
of mitochondria. The predominant cardiac isoform, CPT-1b, is encoded by CPT1b (Yamazaki et al., 
1996;McGarry & Brown, 1997).  
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The T-allele of rs1557502 was associated with an estimated increase of 0.54 mm in mPWT. The 
variant is located intronically and its potential functional significance was evaluated in silico 
(http://www.ncbi.nlm.nih.gov/SNP). Netgene2 comparison revealed differences in recognition of 
acceptor splice sites, suggesting that the variant alters mRNA splicing (Brunak et al., 
1991;Hebsgaard et al., 1996). More specifically, the T-allele was characterised by the recognition 
of three additional acceptor sites (1 in the direct strand; 2 in the complement strand) relative to the 
C-allele.  
Differential expression of CPT-1b has been observed under various physiological conditions e.g. 
decreased content in HF and upregulation thereof, hypothesized to be compensatory, in a transgenic 
rat model of HCM characterised by the overexpression of a truncated cardiac troponin T (Luedde et 
al., 2009). Its cardiac effects are diverse, as CPT-I inhibitors reverse the progression to heart failure 
in the pressure-overloaded heart, whilst, in contrast, chronic inhibition thereof can lead to moderate 
cardiac hypertrophy and increased α-MHC expression (Turcani & Rupp, 1997;Mengi & Dhalla, 
2004). Given the contradictory observations, it is difficult to speculate as to the exact consequences 
of the significantly associated SNP. However, energy compromise is hypothesised to play a key role 
in the development of HCM. We thus propose that the T-allele of the rs1557502 variant may, via 
aberrant mRNA splicing, contribute to the burden of disrupted myocardial energetics and ultimately 
increase the compensatory hypertrophy phenotype, as is evident from its association with an 
increased mPWT measure. The variant, according to our knowledge, does not affect the 
transmembrane domains or mitochondrial targeting sequence of the protein directly, but the 
proposed aberrant splicing could change the reading frame and ultimately the final protein 
product/function (van der Leij et al., 2002).   
Alternatively, the observed effect may be the result of a functional variant in LD with rs1557502. 
The SNP was found to be in LD with a number of coding, non-synonymous changes as determined 
from the CEU and YRI LD maps generated by the SNPbrowserTM v.4.0.1 software: rs1804702 
(TCC → TAC; S630Y), rs470117 (GAG → AAG; E497K), rs8142477 (TCC → TGC; S393C), 
rs2269383 (GGC → GAC; G286D) and rs3213445 (ATC → GTC; I66V). SIFT predictions 
suggested that two of these missense mutations, S630Y and G286D, may be damaging (Kumar et 
al., 2009). The first shows a change from the neutral polar Ser to the neutral polar Tyr. The Tyr 
amino acid comprises a hydrocarbon benzene ring and it is, therefore considered less polar than Ser 
(http://www.elmhurst.edu/~chm/vchembook/561aminostructure.html). The second variant is 
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characterised by the substitution of the neutral non-polar Gly by an acidic polar Aspartic acid (Asp). 
These substitutions may alter the tertiary structure of the respective proteins and, thereby potentially 
alter the protein function. However, the two SNPs have as yet not been evaluated on a functional 
level or linked to disease development.  
The effect of the CC haplotype was lower on mIVST (1.8 mm), mPWT (0.83 mm), the CWT score 
(18.3 mm) and the PC1 measure (1.14) in the R403WMYH7 group compared to the A797TMYH7 group. 
Also, its effect was higher on mIVST (3 mm), mLVWT (2.41 mm), the CWT score (25.8) and the 
PC1 measure (1.61) in the R92WTNNT2 group relative to the R403WMYH7 group. The effect of the CT 
haplotype was lower in the R92WTNNT2 group relative to the A797TMYH7 group: 3.11 mm on 
mLVWT. Moreover, its effect was lower in the R92WTNNT2 group compared to the R403WMYH7 
group: 0.95 mm for mPWT, 18.2 mm for the CWT score and 1.14 for the PC1 measure. These 
observations do not mirror the significant SNP effect of rs1557502, suggesting that the trait 
variance may be explained by the combined effect of variants contained within the respective 
haplotypes; and these haplotype effects are significantly influenced by the founder mutation 
context. The haplotypes comprise two alleles and the potential functional significance of the second 
SNP, rs470117, was, therefore considered. It was described in the foregoing section as a tolerated 
missense mutation in LD with the significantly associated single SNP.  
iii) Pyruvate dehydrogenase kinase 
The PDH complex is responsible for the conversion of pyruvate to acetyl-CoA which is utilised to 
generate ATP via the mitochondrial Krebs cycle. This step thus links glycolysis and fatty acid 
metabolism and can, therefore, regulate the choice of substrate used under various physiological 
conditions (Houten et al., 2009;Randle, 1986;Patel & Roche, 1990). PDH activity in the heart is 
mainly regulated by PDK4 as it is the predominantly expressed cardiac isoform (Roche et al., 
2001;Bowker-Kinley et al., 1998). Findings from the literature showed that PDK4 gene expression 
is decreased in neonatal rat cardiomyocytes in a phenylephrine-induced model of cardiac 
hypertrophy (Planavila et al., 2005). Conversely, cardiac-specific overexpression of the enzyme 
exacerbated calcineurin-induced cardiomyopathy in mice (Zhao et al., 2008).  
The effect of the C-allele of rs2073978 was lower in the R403WMYH7 group relative to the 
A797TMYH7 group: 30.2 g on LVM, 30.7 mm on the CWT score and 1.92 on PC1. The extent to 
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which the SNP contributes to trait variance is, therefore significantly influenced by the founder 
mutation context. The SNP is located intronically and its potential functional consequence was 
predicted in silico (http://www.ncbi.nlm.nih.gov/SNP). The allelic comparisons did not reveal any 
differences with respect to the recognition of splicing acceptor or donor motifs, suggesting that the 
SNP may have an as yet unknown functional consequence (Brunak et al., 1991;Hebsgaard et al., 
1996). These differences in effect may also be explained by a variant in LD with rs2073978. 
However, the SNP was not found to be in LD with any coding, non-synonymous changes as 
determined from the CEU and YRI LD maps generated by the SNPbrowserTM v.4.0.1 software. To 
date, the SNP has not been functionally characterised or implicated in disease.  
The effect of the CT was an estimated 1.42 mm increase in mIVST. In addition, its effect was lower 
in the R403WMYH7 group relative to the A797TMYH7 group: 3.2 mm for mIVST, 3.62 for the 
mLVWT, 31.9 mm for the CWT score and 1.99 for PC1. The results do not reflect the observed 
single SNP effect and, therefore, suggest that the trait variance can be ascribed to the combined 
effects of variants contained within the haplotype, and that the extent to which the haplotype 
modifies the hypertrophy phenotype is significantly influenced by the founder mutation context. 
The potential functional implication of the second variant, rs2301630, was, therefore also predicted 
in silico. The allelic comparison did not indicate differences with respect to the recognition of 
splicing motifs (Brunak et al., 1991;Hebsgaard et al., 1996). As previously mentioned, the variant 
may be in LD with an effect allele. However, the SNPbrowserTM v.4.0.1 software LD maps of both 
the CEU and YRI populations did not indicate any coding, non-synonymous variants. The 
rs2301630 variant has been investigated within the context of type 2 diabetes and metabolic 
syndrome, however, no significant correlations were identified (Moon et al., 2012). The afore-
described SNPs have as yet not been characterised functionally or implicated in the development of 
disease. 
iv) Creatine kinase 
Creatine kinase catalyses the reversible transfer of high-energy phosphates between creatine and 
ATP and, therefore, plays an important role in the coupling of energy supply and demand. All three 
CK isoforms i.e. MM-CK, BB-CK and MB-CK, which are encoded by the CKM and CKB genes 
(Refer to Section 2.3.3.2), show cardiac expression (Hornemann et al. 2000; Au 2004; Nahrendorf 
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et al. 2005). In addition, the muscle-specific isoform binds to the sarcomeric M-line where it is 
believed to fulfil a structural role (Clark et al., 2002;Hornemann et al., 2000).  
An in situ study in skeletal muscle showed binding of MM-CK to the I-band via aldolase and PFK. 
This CK association with glycolytic enzymes may function to supply PFK with, but prevent its 
inhibition by ATP i.e. maintaining a proper ATP/ADP ratio nearby (Kraft et al., 2000). More 
recently, mutations in the TRIM63 gene encoding MuRF1 have been associated with human 
hypertrophic cardiomyopathy. One of these mutations is located within the CK-M binding domain 
and the result was mislocalisation to the sarcomere M-line. This indirectly suggests that disrupted 
CK-M integrity may, by means of this interaction, contribute to the development of HCM (Chen et 
al., 2010). A canine model of pressure overload hypertrophy showed decreased myocardial PCr, 
creatine, PCr/ATP, and ATP. Decreased CK-MM and increased CK-MB levels with normal total 
CK activity was also reported. However, the authors remarked on the lack of CK-MB 
compartmentalisation within the cell, as is the case for CK-MM (Jameel & Zhang, 2009). Finally 
studies of CK-M-/--knockout mice showed impaired KATP channel function, with deficiency of the 
latter implicated in the development of left ventricular hypertrophy (Abraham et al., 2002). 
a) CKM 
The effect of the T-allele of rs7260463 appeared to be cardioprotective as an estimated decrease of 
0.24 mm in mPWT. The effect of the T-allele of rs344816 was lower on mLVWT in the R92WTNNT2 
group relative to both the A797TMYH7 (4.21 mm) and R403WMYH7 groups (3.42 mm) suggesting that 
its effect on trait variance is significantly influenced by the founder mutation context.  
These two variants are both located intronically and in silico evaluations were performed to predict 
their potential functional effects (http://www.ncbi.nlm.nih.gov/SNP). The variants did not show 
variation in the recognition of splicing motifs (Brunak et al., 1991;Hebsgaard et al., 1996). The 
significant association/effects may be due to a variant(s) in LD with the investigated SNPs. 
According to the LD maps for the CEU and YRI populations generated by the SNPbrowserTM 
v.4.0.1 software, only the rs7260463 SNP is in LD with a coding, non-synonymous variant (and 
only in the CEU population) namely rs17875653. However, SIFT predictions characterised the 
change from the neutral, non-polar Leucine (Leu) to the similarly neutral, non-polar Valine (Val) as 
tolerated (CTC → GTC; L127V) (Kumar et al., 2009). The rs7260463 and rs344816 variants have 
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previously been investigated within the context of elite endurance performance, but no significant 
correlations were identified (Doring et al., 2011). 
Significant haplotype effects and differences in haplotype effect amongst the founder mutation 
groups were observed for this gene. The effect of the CTAT haplotype was an estimated increase of 
3.20 mm in mIVST, 2.72 mm in mLVWT and 1.37 in PC1. The effect of the TTGA haplotype was 
an estimated decrease of 27.4 g in LVM. Its effect was higher on LVM (96.4 g) in the R403WMYH7 
group relative to the A797TMYH7 group and lower on LVM (120.3 g) in R92WTNNT2 group compared 
to the R403WMYH7 group. Also, its effect was higher on PC (13.97) in the R92WTNNT2 group 
compared to the R403WMYH7 group. The effect of the CTGT haplotype was an estimated decrease of 
17.6 g in LVM and 7.9 mm in the CWT score. Its effect was lower on mLVWT (5.1 mm) and the 
CWT score (32.1 mm) in the R92WTNNT2 group relative to the A797TMYH7 group. The effect of the 
CTGA was higher on mLVWT in the R92WTNNT2 group relative to both the A797TMYH7 (4.53 mm) 
and R403WMYH7 groups (3.70 mm). The results do not mirror the significant SNP effects identified 
for rs7260463. Rather, the extent to which the haplotypes influence the hypertrophy phenotype may 
be ascribed to combined effect of variants contained within the respective haplotypes; and these 
haplotype effects are significantly influenced by the founder mutation context.  
b) CKB 
Significant differences in haplotype effects were identified for CCT, CTT and TCG. The effect of 
the first was higher on LVM (86.5 g) in the R92WTNNT2 group relative to the R403WMYH7 group. 
The effect of the second was lower on LVM (65.1 g) in the R92WTNNT2 group relative to the 
R403WMYH7 group. Also, its effect was higher on LVM (62.9 g) in the R403WMYH7 group compared 
to the A797TMYH7 group. The effect of the third was lower on the CWT score (59.4 mm) in the 
R403WMYH7 group relative to the A797TMYH7 group. The results suggest that the modifying effects 
of the relevant haplotypes can be attributed to the combined effects of variants contained within the 
respective haplotypes which are further significantly influenced by the founder mutation context.  
The haplotypes comprise SNPs rs1803283, rs1136165 and rs2071407 of which the first two are 
considered synonymous coding variants. The rs2071407 SNP is located intronically and relevant in 
silico evaluations were performed. Allelic comparison indicated differences pertaining to the 
recognition of acceptor splice sites with, interestingly, both alleles indicating the identification of an 
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additional acceptor site relative to the other (T-allele: direct strand; C-allele: complementary strand) 
(Brunak et al., 1991;Brunak et al., 1991;Hebsgaard et al., 1996). The Netgene2 results suggest that 
the SNP alters mRNA splicing, however it is challenging to speculate about which of the two 
rs2071407 alleles confer risk as we are considering significant haplotype associations which in all 
probability reflect complex combined (biological) effects of the variants contained within the 
respective haplotypes. 
However, creatine kinase is essential in myocardial energy homeostasis. CK-MB is the predominant 
cardiac isoform showing increased levels in a canine model of pressure overload whilst CK-MM 
decreased and normal total CK activity was maintained (Jameel & Zhang, 2009). It is, therefore, 
reasonable to suggest that aberrant mRNA splicing of variants in the CKB gene will significantly 
impact on MB-CK function and, as a result, myocardial energy homeostasis. We thus propose that 
the rs2071407 variant may, via aberrant mRNA splicing, contribute to the burden of disrupted 
myocardial energetics and ultimately increase the compensatory hypertrophy phenotype as is 
evident from the haplotype associations with numerous hypertrophy traits. We aimed to further 
predict the functional consequences of rs2071407 based on current literature. However, 
investigations pertaining to CKB mutations and CKB functional domains, specifically with respect 
to cardiac disease, are, according to our knowledge, limited.  
v) Aldolase A 
Aldolases are enzymes of the glycolytic pathway responsible for catalysing the reversible cleavage 
of fructose 1,6-bisphosphate to DHAP and G3P. The ALDOA gene encodes the predominant cardiac 
isoform, Aldolase A (Mamczur et al., 2007;Asaka et al., 1983;Koeck et al., 2004;Medin et al., 
2007;Rutter, 1964). Hypertrophied left ventricles of SHR rats showed a reduction in the expression 
of Aldolase A (Zamorano-Leon et al., 2010). Moreover, a study of Dahl-salt sensitive rats allowed 
for two-phase gene expression measurements in heart muscle, i.e. during disease progression to 
cardiac hypertrophy and HF. Aldolase A expression was increased during the progression stage, but 
subsequently reduced during HF (Ueno et al., 2003). 
The T-allele of rs11860935 appeared to be cardioprotective as its effect was an estimated decrease 
of 1.88 mm in mIVST. The SNP is intronic and the relevant in silico predictions were performed 
(http://www.ncbi.nlm.nih.gov/SNP). Netgene2 evaluation of the significantly associated 
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rs11860935 indicated that the T-allele thereof was characterised by the recognition of an additional 
donor splice site relative to the C-allele (Brunak et al., 1991;Hebsgaard et al., 1996). Considering 
the association of the C-allele with increased mIVST, it is possible that the absence of the donor site 
may in fact lead to aberrant mRNA splicing. The ALDOA gene functions in glycolysis, making it a 
valuable contributor to myocardial energetics. We could, therefore, speculate that the proposed 
aberrant mRNA splicing may disrupt myocardial energy homeostasis and increase the burden on the 
sarcomere; ultimately giving rise to compensatory hypertrophy as is reflected by the significant 
association with mIVST. An alternative hypothesis is that rs11860935 may show an association 
with the hypertrophy phenotype due to Ca2+ dysregulation and, as consequence, altered 
contractility. This notion is supported by the finding that rabbit skeletal Aldolase A biologically 
interacts with and modulates the activity of Ca2+ release channels (ryanodine receptors) in vitro; and 
it may also do so in cardiac muscle (Kramerova et al., 2008).   
It is also possible that the significant effects may be attributable to a coding, non-synonymous 
variant(s) in LD with rs11860935. The SNPbrowserTM v.4.0.1 software indicated that a total of six 
missense mutations were found to be in LD with the variant within both the CEU and YRI 
populations: rs3098416 (GCG → TCG; A280S), rs3112557 (GAC → GCC; D196A), rs11553121 
(AGT → ACT; S176T), rs11553113 (CGC → TGC; R134C), rs11553115 (GCC → TCC; A41S) 
and rs11553114 (GGC → GAC; G27D). Interestingly, SIFT predictions indicated that all of these 
missense mutations are considered to be damaging (Kumar et al., 2009). However, according to the 
literature to date, none of these mutations or rs11860935 have been characterised functionally or 
implicated in disease. The effect of the C-allele of rs9928448 was lower in the R92WTNNT2 group 
compared to the A797TMYH7 group: 2.29 mm on mIVST, 23.2 mm on the CWT score and 1.45 on 
PC1. The extent to which it contributes to trait variance is thus significantly influenced by the 
founder mutation context. 
A significant difference in haplotype effect amongst the founder mutation groups, which does not 
mirror the significant rs11860935 effect, was observed, suggesting that the trait variance may be 
due to the combined effects of variants contained within the haplotype; and the degree to which the 
haplotype effect contributes to the hypertrophy phenotype is significantly influenced by the founder 
mutation context. The effect of the CC haplotype was lower on mIVST (2.7 mm) and mLVWT 
(2.65 mm) in the R92WTNNT2 group compared to the R403WMYH7 group. The rs9928448 SNP is the 
second variant of the CC haplotype and was, therefore evaluated in silico. Allelic comparison 
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revealed no differences pertaining to recognition of splicing donor or acceptor sites (Brunak et al., 
1991;Hebsgaard et al., 1996). Moreover, the effects may be attributed to a functional variant(s) in 
LD with rs9928448. The relevant coding, non-synonymous missense mutations are the same as 
described for the rs11860935 variant. 
vi) Phosphofructo-1-kinase 
Phosphofructo-1-kinase catalyses the conversion of fructose-6-phosphate to fructose-1,6-
bisphosphate which is considered to be the rate-limiting step in glycolysis (Swoboda et al., 1997). 
The predominant cardiac isoenzyme, the muscle type, is encoded by PFKM (Dunaway et al., 
1988a;Dunaway et al., 1988b). A study of PFKM deficient (Pfkm-/-) mice showed marked metabolic 
changes in the heart which resulted in cardiac hypertrophy (Garcia et al., 2009).  
The effect of the T-allele of rs10875749 was higher on mIVST (2.56 mm) in the R92WTNNT2 group 
relative to A797TMYH7 group. Also, its effect was higher in the R92WTNNT2 group compared to the 
R403WMYH7 group: 2.87mm for mIVST, 2.08 mm for mLVWT, 22.9 for the CWT score and 1.43 
for PC1. Furthermore, its effects was lower on PC1 (0.92) in the R403WMYH7 group compared to the 
A797TMYH7 group. The effect of rs10875749 (or a variant with which it is in LD) on the 
hypertrophy phenotype is thus significantly influenced by the founder mutation context. 
The rs10875749 variant is positioned intronically and in silico evaluations was performed 
accordingly (http://www.ncbi.nlm.nih.gov/SNP). Allelic comparison indicated no differences with 
respect to recognition of acceptor and donor motifs (Brunak et al., 1991;Hebsgaard et al., 1996). 
The SNPbrowserTM v.4.0.1 LD maps for both the CEU and YRI populations indicate that the 
variant is in LD with two coding, non-synonymous changes, rs2228500 (CGA → CAA; R100Q) 
and rs11552506 (GAC → TAC; D368Y). SIFT predictions characterised the first SNP as tolerated, 
whilst the second was considered damaging (Kumar et al., 2009). The rs11552506 missense 
mutation is characterised by a change from the acidic polar Aspartic acid (Asp) to a neutral polar 
Tyr, which could affect the tertiary protein structure and, thereby, protein function. The R100Q 
mutation, although predicted to be tolerated, has been implicated in the development of GSDVII 
(Musumeci et al., 2011). As previously described, certain HCM phenocopies are characterised by 
GSD and the mutation may thus play a role in the development of hypertrophy (Refer to Section 
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1.2.4.2.2). The remainder of the SNPs have not been implicated in the development of disease or 
characterised functionally. 
A significant haplotype effect, which did not reflect the significant rs10875749 effect, was 
observed, suggesting that the trait variance may be ascribed to the combined effects of variants 
contained within the haplotype. The effect of the AT haplotype was an estimated increase of 1.03 
mm in mIVST. Significant differences in haplotype effect amongst the founder mutation groups 
were also observed for haplotypes AA, AT, CA and CT suggesting that the extent to which they 
influence the hypertrophy phenotype is significantly influenced by the founder mutation context. 
The effect of the AA haplotype was higher on mPWT (0.88 mm) in the R403WMYH7 group relative 
to the A797TMYH7 group. The effect of the AT haplotype was lower in the R403WMYH7 group 
relative to the A797TMYH7 group: 3.1 mm for mIVST, 31.6 mm for the CWT score and 1.98 for 
PC1. The effect of the CA haplotype was lower in the R92WTNNT2 group compared to the 
A797TMYH7 group: 1.54 mm for mPWT, 22.1 mm for the CWT score and 1.38 for PC1. Also, its 
effect was lower in the R92WTNNT2 group relative to the R403WMYH7 group: 1.05 for PC1. The effect 
of CT was higher in the R92WTNNT2 group compared to the A797TMYH7 group: 3.7 mm for mIVST, 
3.03 mm for mLVWT and 1.32 mm for mPWT.  
The rs1859445 SNP, the second variant in the two-allele haplotypes, is intronic and it was, 
therefore, evaluated in silico. Allelic comparison indicated the recognition of an additional acceptor 
splice site upon evaluation of the A-allele relative to the C-allele, suggesting that the variant alters 
mRNA splicing (Brunak et al., 1991;Hebsgaard et al., 1996). To recap, all four possible haplotypes 
were observed, but only AT (rs1859445 underlined) showed a significant association; and it did not 
reflect the significant rs10875749 association. These observations make it difficult to speculate as to 
the exact contribution of rs1859445 to the haplotype effect. More generally, PFKM is a key 
component of myocardial glycolysis; and PFKM-deficient mice develop cardiac hypertrophy 
(Garcia et al., 2009;Swoboda et al., 1997). Incorrect splicing of the PFKM gene may thus disrupt 
myocardial energetics and give rise to a compensatory hypertrophy phenotype. Indeed, the 
rs1859445 variant may contribute to the haplotype effect via aberrant mRNA splicing of the PFKM 
gene, as is evident from its correlation with numerous hypertrophy traits.  
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Alternatively, the effects may be ascribed to the coding, non-synonymous mutations in LD with 
rs1859445 and they are the same variants described to be in LD with rs10875749. The rs1859445 
variant has to date not been evaluated functionally or linked to disease development.  
vii) Peroxisome proliferator-activated receptors (PPARs) 
PPARs contribute to myocardial energetics by regulating numerous genes essential for lipid 
metabolism (Reviewed by Desvergne & Wahli, 1999;Feige et al., 2006) 
a) Peroxisome proliferator-activated receptor alpha 
PPARα is encoded by the PPARA gene and shows high cardiac expression. It plays a key role in 
myocardial energy homeostasis, as it induces the expression of various components of lipid and 
glucose metabolism (Reviewed by Rowe et al., 2010;Reviewed by Yang & Li, 2007). Decreased 
transcriptional activity of PPARα has been observed in hypertrophied left ventricles due to aortic 
banding and cardiomyocytes following phenylephrine (PE)-induced hypertrophy (Sack et al., 
1997;Barger et al., 2000). Conversely, cardiac-specific overexpression of PPAR-α in transgenic 
mice led to the development of ventricular hypertrophy and dysfunction (Finck et al., 2002). 
Reactivation of PPARα in the hypertrophied heart setting was met with enhanced fatty acid 
oxidation (FAO), but impairment of cardiac function. These findings support the suggested adaptive 
role of decreased FAO in cardiac hypertrophy (Young et al., 2001).  
Significant haplotype effects were identified in the absence of significant SNP effects suggesting 
that the hypertrophy phenotype is modified as a result of the combined effects of variants contained 
within the respective haplotypes. The effect of the GAA haplotype was an estimated increase of 
30.1 g in LVM, 3.01 mm in mIVST, 3.40 mm in mLVWT, 21.0 in the CWT score and 1.31 in PC1. 
The effect of the GGG haplotype was an estimated decrease of 49.1 g in LVM, 3.09 mm in mIVST 
and 1.14 mm in mPWT. The haplotype comprises three SNPs, which are all located intronically and 
in silico evaluations were performed to determine their potential effects on mRNA splicing 
(http://www.ncbi.nlm.nih.gov/SNP, SNPbrowserTM v.4.0.1). However, allelic comparisons did not 
reveal any significant differences in recognition of acceptor or donor sites (Brunak et al., 
1991;Hebsgaard et al., 1996). The SNPbrowserTM v.4.0.1 LD structures of the HapMap CEU and 
YRI populations showed that these SNPs are in LD with a number of coding, non-synonymous 
Stellenbosch University  http://scholar.sun.ac.za
  
207│Chapter 4 
variants: rs1800234 (V227A), rs1800206 (L162V), rs1800204 (R127Q), rs1800243 (R409T), 
rs1800242 (D304N) and rs1042311 (A268V). Reinhard et al. (2008) investigated the potential 
association of variants rs881740, rs4823613, rs4253776 and L162V with MI; however, no 
significant association was identified. The rs4253776 variant has been associated with the 
development of type 2 diabetes (Cresci, 2007;Reinhard et al., 2008). V227A has been implicated in 
non-alcoholic fatty liver disease, whilst L162V has been linked to aspects of metabolic syndrome 
and reduced adiposity (Robitaille et al., 2004;Bosse et al., 2002;Chen et al., 2007). Such metabolic 
changes may contribute to the hypertrophy phenotype in keeping with the notion that altered 
myocardial energetics is primary in the development of HCM, as described in Chapter 1 (Refer to 
Section 1.2.4.2.2).  
Significant differences in haplotype effects amongst the founder mutation groups were observed for 
both haplotypes AAA and GGG. These results reflect the combined effects of variants contained 
within the respective haplotypes which are further significantly influenced by the founder mutation 
context. The effect of the AAA haplotype was lower on LVM (21.9 g) in the R92WTNNT2 group 
compared to the R403WMYH7 group. The effect of the GGG haplotype, found to be significantly 
associated upon evaluation of the entire cohort, was lower on mPWT (2.13 mm) in the R403WMYH7 
group relative to the A797TMYH7 group.  
b) Peroxisome proliferator-activated receptor gamma 
The PPARγ protein, encoded by PPARG, is expressed in the heart where it is believed to contribute 
to fatty acid metabolism (Luo et al., 2010;Luo et al., 2010;Mehrabi et al., 2002). The PPARγ 
isoform has been implicated in the control of human BP evident from an association between 
deleterious dominant-negative mutations in the gene and early-onset hypertension (Barroso et al., 
1999). Moreover, previous studies have shown that PPARγ activation suppresses TNF-α (Takano et 
al., 2000) and interleukin-1β (IL-1β) (Jiang et al., 1998) expression, factors considered as potential 
stimuli for myocyte hypertrophy (Hefti et al., 1997). Considering the high expression of PPARγ in 
human heart ventricles and its effects on hypertrophy signals, Mehrabi et al. (2002) suggested a role 
for the receptor in the treatment of hypertrophic cardiomyopathy. Further cardiac-protective effects 
include the development of cardiac hypertrophy in a cardiomyocyte-specific PPARγ knockout 
mouse model (Duan et al., 2005), the inhibition of aortic constriction-induced cardiac hypertrophy 
by PPARγ activators in rats (Sakai et al., 2002) and the more prominent pressure-induced cardiac 
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hypertrophy observed in heterozygous PPARγ deficient mice relative to wild-type controls 
(Asakawa et al., 2002). 
The effect of the T-allele of rs12631028 was is higher on mLVWT (1.71 mm) in the R92WTNNT2 
group compared to the A797TMYH7 group. The effect of the SNP on the trait is thus significantly 
influenced by the founder mutation with which it presents. To date, the SNP has not been explored 
functionally and its contribution to disease development, if any, remains to be established. 
The effects of the CAGA and CAGC haplotypes appeared to be cardioprotective with estimated 
decreases of 22.8 g in LVM and 0.97 mm in mPWT, respectively. The effect of the CGGC 
haplotype was an estimated increase of 27.1 g in LVM, 2.55 mm in mIVST, 2.73 mm in mLVWT, 
23.7 mm in the CWT score and 1.48 in PC1. Haplotypes CAGA and CAGC that showed significant 
haplotype effects as well as haplotypes TGAC and TGGA indicated significant differences in 
haplotype effect amongst the HCM founder mutation groups. The effect of the CAGA haplotype 
was lower on mIVST (4.98 mm) and mLVWT (4.83 mm) in the R92WTNNT2 group compared to the 
A797TMYH7 group. Also, its effect was lower on mLVWT (2.85 mm) in the R403WMYH7 group 
relative to the A797TMYH7 group. The effect of the TGAC haplotype was higher on mPWT (2.52 
mm) and PC1 (0.53) in the R92WTNNT2 group compared to the A797TMYH7 group. The effects of 
both the TGGA and CAGC haplotypes were lower on PC1 (0.12; 0.94) in the R92WTNNT2 group 
compared to the A797TMYH7 group. 
The significant haplotype effects did not mirror the significant single SNP result, suggesting that the 
phenotype arises from the combined effects of variants contained in the respective haplotypes; and 
the extent to which the CAGA and CAGC haplotypes modify the development of hypertrophy is 
also significantly influenced by founder mutation context. 
viii) Peroxisome proliferator-activated receptor gamma coactivator-1α 
PGC-1α is encoded by the PGC1 gene and shows high cardiac expression where it functions as 
coactivator for PPARα (Finck, 2007). It similarly coactivates PPARγ in brown adipose tissue and it 
may also do so in the heart (Puigserver et al., 1998;Rowe et al., 2010;Young et al., 2001). PGC-1α 
further functions in cardiac mitochondrial biogenesis by indirectly regulating mitochondrial 
transcription factor A (MTF-A). Knockout or deficiency of PGC-1α results in significant alterations 
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in cardiac function (Ren et al., 2010;Handschin & Spiegelman, 2008). Moreover, mice deficient in 
PGC-1α showed accelerated cardiac dysfunction and HF in response to transverse aortic 
constriction (TAC). Similar findings, resulting from PGC-1α repression in cultured cardiac cells, 
could be reversed upon introduction of ectopic PGC-1α, suggesting a cardioprotective function 
(Arany et al., 2006). The coordinated reduction of PPARα, PGC-1α and FAO enzymes was 
observed in hypertrophied left ventricles of mice subjected to TAC (Lehman & Kelly, 2002).  
Significant haplotype effects were observed in the absence of significant SNP effects suggesting 
that the hypertrophy phenotype is modified as a result of the combined effects of variants contained 
within the respective haplotypes. The effect of the GATT haplotype was an estimated increase of 
2.92 mm in mIVST.  
Also, significant differences in haplotype effect were observed amongst the mutation groups 
indicating that the trait variance may be explained not only by the combined effects of variants 
contained within the respective haplotypes, but the founder mutation context in which the 
haplotypes present. The effect of the GAAC haplotype was higher on LVM (103.3 g),  mIVST (7 
mm), mLVWT (7.26 mm), the CWT score (65.4 mm) and PC1 (4.09) in the R92WTNNT2 group 
compared to the A797TMYH7 group. Also, its effect was higher in the R92WTNNT2 group relative to 
the R403WMYH7 group: 82 g for LVM, 5.4 mm for mIVST, 5.84 mm for mLVWT, 54.1 mm for the 
CWT score and 3.38 for PC1. The effect of the GATC haplotype was higher on the CWT score (36 
mm) in the R92WTNNT2 group compared to the A797TMYH7 group. The effect of the GCAC 
haplotype was lower in the R92WTNNT2 group relative to the R403WMYH7 group: 48 g for LVM, 26.9 
mm for the CWT score and 1.68 for PC1.  
ix) AMP-activated protein kinase 
As described, AMPK monitors the cellular energy homeostasis via its ability to sense the 
AMP:ATP ratio (Refer to Section 2.3.3.2) (Hardie & Carling, 1997). The mammalian AMPK 
complex is a heterotrimer comprising an α-catalytic subunit and 2 regulatory, β- and γ- subunits 
(Dolinsky & Dyck, 2006). The genes that encode the respective subunits were evaluated and the 
results are subsequently described.  
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a) PRKAA1 
The PRKAA1 gene encodes the α1 catalytic subunit of AMPK. It is structurally characterised by a 
conserved N-terminal containing a Ser/Thr kinase domain activated upon phosphorylation of the 
Threonine 172 in the activation loop, an autoinhibitory sequence (AIS) inhibiting activity of the 
kinase domain and a C-terminal domain that allows binding to the β-subunit (Crute et al., 
1998;Hawley et al., 1996;Pang et al., 2007). 
Significant differences in SNP effects amongst the mutation groups were observed, suggesting that 
the extent to which these SNPs influence the trait variance is significantly influenced by the founder 
mutation with which it presents. The effect of the C-allele of rs12517210 variant and the G-allele of 
rs11747210 (the minor allele of the rs11747210 SNP is the T allele) was higher on LVM in the 
R92WTNNT2 group relative to the A797TMYH7 group (26.9 g; 26.7 g). Also, their effects were higher 
in the R403WMYH7 group compared to the A797TMYH7 group on the CWT score (18.7 mm; 17.9 mm) 
and PC1 (1.17; 1.12). Both SNPs are intronic and the relevant in silico predictions were performed 
(http://www.ncbi.nlm.nih.gov/SNP). Neither of the two variants indicated differences in recognition 
of splicing acceptor or donor motifs (Brunak et al., 1991;Hebsgaard et al., 1996). The effects may 
be attributed to functional variants in LD with rs12517210 and rs11747210. However, according to 
the SNPbrowserTM v.4.0.1 software, all coding variants in LD with the investigated SNPs are 
characterised as synonymous changes. The two SNPs have as yet not been linked to disease or 
evaluated functionally. 
Statistically significant differences in haplotype effects were seen for the CGC and TTC haplotypes. 
These results do not mirror the significant SNP effects for rs12517210 and rs11747210 suggesting 
that the trait variance may be due to the combined effects of variants contained within the respective 
haplotypes. Also, these haplotype effects are significantly influenced by the founder mutation 
context. The effect of the first was higher on LVM (21.7 g) in the R92WTNNT2 compared to the 
A797TMYH7 group. Conversely, the effect of the second was lower on LVM (36.4 g) in the 
R92WTNNT2 group relative to the A797TMYH7 group. 
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b) PRKAA2 
The human PRKAA2 gene encodes the α2 catalytic subunit of AMPK and its structure is as 
described for PRKAA1. 
The effect of the TTT haplotype was an estimated 0.45 increase in PC1. No significant single SNP 
effects were observed and the results may thus be ascribed to the combined effects of variants 
contained within the haplotype. The haplotype comprises three SNPs which are all located 
intronically and in silico evaluations were performed to determine their potential effects on mRNA 
splicing (http://www.ncbi.nlm.nih.gov/SNP, SNPbrowserTM v.4.0.1). The rs1124900 variant did not 
indicate any differences in splice site signals upon investigation with Netgene2 (Brunak et al., 
1991;Hebsgaard et al., 1996). However, the literature notes that an interaction between this variant 
and a SNP in the RAC-alpha serine/threonine-protein kinase gene (AKT1) was significantly 
associated with the percent change in mass-adjusted strength of the arm, i.e. skeletal muscle 
hypertrophy, after resistance exercise training. A similar result was seen for the interaction of the 
rs1124900 variant and a second PRKAA2 variant, rs2796516 positioned intronically (Newman & 
University of Pittsburgh, 2008).  However, no significant differences in splice signal motifs were 
identified upon in silico evaluations strongly suggesting that rs2796516 is perhaps in LD with the 
effect allele. The remaining two SNPs, rs2796495 and rs932447, have been investigated within the 
context of risk of type 2 diabetes. However, they have as yet not been characterised functionally and 
in silico evaluations were, therefore, performed. The Netgene2 results showed no differences in 
spice site signals (Brunak et al., 1991;Hebsgaard et al., 1996). Collectively, the results propose that 
the variants themselves (in combination) modify hypertrophy development via currently unknown 
mechanisms or that they are in LD with functional variants. According to the SNPbrowserTM v.4.0.1 
software, all coding variants in LD with the investigated SNPs are characterised as synonymous 
changes.  
c) PRKAB1 
The PRKAB1 gene encodes the β1 regulatory subunit of the AMPK complex. The β subunits vary 
with respect to their N-terminals, whilst the remainder is conserved including a carbohydrate-
binding molecule (CBM), which allows the AMPK complex to associate with glycogen, and a C-
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terminal domain that acts as scaffold for α- and γ-subunit binding (Iseli et al., 2005;Polekhina et al., 
2003;Steinberg & Kemp, 2009).  
The effect of the T-allele of rs278149 was higher on the CWT score (25 mm) and PC1 (1.56) in the 
R92WTNNT2 group compared to the A797TMYH7 group. The extent to which the SNP (or a variant 
with it is in LD) influences the development of hypertrophy is significantly influenced by the 
founder mutation context. The SNP is intronic and the relevant in silico predictions were performed 
(http://www.ncbi.nlm.nih.gov/SNP). Allelic comparison revealed no differences in recognition of 
splicing donor or acceptor motifs (Brunak et al., 1991;Hebsgaard et al., 1996). As mentioned, the 
effect may be owing to a functional variant in LD with rs278149. The SNPbrowserTM v.4.0.1 LD 
structures of the HapMap CEU and YRI populations showed that the variant is in LD with two 
coding, non-synonymous SNPs namely rs11546695 and rs1043354. SIFT predictions suggest that 
both these missense mutations result in amino acid changes which are tolerated (Kumar et al., 
2009). To date, none of these variants have been linked to disease or evaluated on a functional level. 
The TGGTG haplotype appeared to be cardioprotective as its effect was an estimated decrease of 
18.3 g in LVM. Also, it showed significant differences in haplotype effect amongst the founder 
mutation groups along with the GACGT haplotype. The effect of the first was higher on LVM (41.6 
g; p = 0.020) in the R92WTNNT2 group relative to A797TMYH7 group. The effect of the second was 
lower on mPWT (1.21 mm; p = 0.004) in the R403WMYH7 group compared to the A797TMYH7 group. 
The significant haplotype effects did not mirror the significant single SNP result, suggesting that the 
phenotype arises from the combined effects of variants contained in the respective haplotypes; and 
the extent to which the TGGTG and GACGT haplotypes modify the development of hypertrophy is 
also significantly influenced by founder mutation context. 
d) PRKAB2 
The PRKAB2 gene encodes the β2 regulatory subunit of the AMPK complex and its structure is as 
described for PRKAB1.  
The effect of the G-allele of rs1348316 was an estimated increase of 0.36 mm in mPWT. The 
effects may be due to the SNP itself or variants with which it is in LD. The SNP is intronic and the 
relevant in silico predictions were performed (http://www.ncbi.nlm.nih.gov/SNP). The allelic 
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comparison with Netgene2 did not indicate any differences in splice site motifs (Brunak et al., 
1991;Hebsgaard et al., 1996). According to the SNPbrowserTM v.4.0.1 LD structures of the 
HapMap CEU and YRI populations, the SNP is in LD with two coding, non-synonymous SNPs 
namely rs1048051 and rs3413734. SIFT predictions suggest that the first as damaging, whilst  the 
second is tolerated (Kumar et al., 2009). The rs1048051 missense mutation is characterised by the 
change from the basic polar Histidine to the neutral polar Tyrosine (CAT → TAT; H211Y), which 
could affect the tertiary protein structure and, thereby protein function. These afore-described SNPs 
have not yet been investigated functionally or implicated in disease development. 
e) PRKAG1 
The γ-subunit isoforms are, with the exception of their varying N-terminals, similar in domain 
structure sharing a conserved β-subunit binding region and four conserved cystathionine β-synthase 
motifs (CBS). The CBS motifs interact pairwise creating two Bateman domains responsible for 
binding two ATP or two AMP molecules, antagonistically (Scott et al., 2004;Viana et al., 2007). 
The human PRKAG1 gene encodes the γ1 non-catalytic, regulatory subunit of AMPK. More 
specifically, the Asp-90 residue binds AMP ribose, which in turn activates AMPK activity 
(Steinberg & Kemp, 2009). No statistically significant results were identified for the PRKAG1 gene 
and it is, therefore, not considered a modifier of hypertrophy in HCM within the current cohort.  
f) PRKAG2 
The PRKAG2 gene encodes the γ2 non-catalytic, regulatory subunit of AMPK and mutations 
therein have previously been implicated in the development of an HCM phenocopy (Blair et al., 
2001b). Its structure and functions are as described for PRKAG1. 
The effect of the C-allele of rs8961 was higher on LVM (23.8 g) in the R92WTNNT2 group relative to 
the A797TMYH7 group. Also, its effect was higher in the R403WMYH7 group compared to the 
A797TMYH7 group: 3.25 mm for mIVST, 3.23 mm for mLVWT and 24 mm for the CWT score. The 
effect of the G-allele of rs6464170 was higher on mIVST (3.09 mm) in the R92WTNNT2 group 
compared to the A797TMYH7 group. The effect of the G-allele of rs13240743 was lower in the 
R92WTNNT2 group relative to the A797TMYH7 group: 15.4 g for LVM, 0.77 mm for mPWT, 13.3 for 
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the CWT score and 0.83 for PC1. In addition, its effect was lower in the R92WTNNT2 group 
compared to the R403WMYH7 group: 44.7 g for LVM, 3.63 mm for mIVST and 3.30 mm for 
mLVWT. The results suggest that the extent to which the SNPs modify hypertrophy development in 
the current cohort is significantly influenced by the founder mutation context. The literature showed 
a marginal association of rs6464170 with colon cancer (Slattery et al., 2010). However, none of the 
variants have been linked to hypertrophy development or evaluated on a functional level.  
Statistically significant haplotype effects and significant differences in haplotype effects amongst 
the founder mutation groups, which did not reflect the significant SNP effects, were observed, 
therefore suggesting that the trait variance can be ascribed to the combined effects of variants 
contained within the respective haplotypes. The effect of the CACC haplotype was an estimated 
increase of 1.48 mm in mIVST. The effect of the TGGG haplotype was an estimated decrease of 
2.03 mm in mLVWT. The effect of the CGCC haplotype was higher on LVM (42.6 g) in the 
R403WMYH7 group relative to the A797TMYH7 group. Also, its effect was higher in the R92WTNNT2 
group compared to the A797TMYH7 group: 57.3 g for LVM, 4.4 mm for mIVST, 3.76 mm for 
mLVWT, 30.1 for the CWT score and 1.88 for PC1. The effect of the CGCG haplotype was lower 
in the R92WTNNT2 group compared to the R403WMYH7 group: 90 g for LVM, 7.6 mm for mIVST, 
7.6mm for mLVWT, 92.3 for the CWT score and 5.77 for PC1. Furthermore, its effect was lower in 
the R92WTNNT2 group relative to the A797TMYH7 group: 1.72 mm for mPWT and 0.68 for PC1. The 
effect of the CGGC haplotype was lower on mIVST (7.3 mm) in the R92WTNNT2 group than the 
A797TMYH7 group. The effect of the TAGC haplotype was lower in the R403WMYH7 group compared 
to the A797TMYH7 group: 7.4 mm for mIVST and 7.18mm for mLVWT. The significant effects of 
haplotypes CGCC, CGCG, CGGC and TAGC are thus the result of the combined effects of variants 
contained within the respective haplotypes, which are further significantly influenced by the 
founder mutation context.  
g) PRKAG3 
Similar to PRKAG1 and PRKAG2 genes, PRKAG3 encodes the γ3 non-catalytic, regulatory subunit 
of AMPK.  
A significant haplotype effect was observed in the absence of significant SNP effects, suggesting 
that the effects may be due to the combined effects of variants contained within the haplotype. The 
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effect of the TT haplotype was seemingly cardioprotective as an estimated decrease of 13.4 g in 
LVM. The haplotype comprises rs1000935 and rs16859382 found to be in complete LD which each 
other (D’ = 1.00). Both SNPs are intronic and the relevant in silico predictions were performed to 
determine the potential effects thereof on mRNA splicing (http://www.ncbi.nlm.nih.gov/SNP, 
SNPbrowserTM v.4.0.1). However, Netgene2 comparisons did not reveal any differences in splice 
signal motifs amongst the two alleles (Brunak et al., 1991;Hebsgaard et al., 1996).   
The results suggest that the alleles interact to modify hypertrophy development by altering mRNA 
splicing (or an as yet unknown mechanism for rs16859382) or that they are in LD with interacting 
effect alleles. According to the SNPbrowserTM v.4.0.1 software, a total of four coding, non-
synonymous variants are in LD with the investigated SNPs namely rs34720726 (GCT → GTT; 
A482V), rs33985460 (CGG → TGG; R340W), rs35050588 (CTG → GTG; L153V) and rs692243 
(CCA → GCA; P71A). The effects of the amino acid substitutions on the function of relevant 
proteins were predicted using the SIFT algorithm and all, but one substitution was predicted to be 
tolerated (Kumar et al., 2009). The rs33985460 missense mutation is characterised as a change from 
the basic polar Arginine (Arg) to the neutral, slightly polar Tryptophan (Trp) (CGG → TGG; 
R340W) which may affect the tertiary protein structure and so protein interactions. The afore-
described SNP and mutations have to date not been characterized functionally or implicated in the 
development of disease. 
4.6 Optimal selection 
We identified a set of six variants that together explained most of the variation in hypertrophy in the 
current cohort. We estimated that an individual carrying all of the risk alleles for these variants 
would have a 5.7 higher PC1 measure compared to an individual with none of the risk alleles. 
However, neither of these individuals existed in our study group. The highest number of risk alleles 
carried by a single individual in the current cohort was eleven, observed for a single NC individual, 
whose mLVWT of >12mm placed him in a clinically affected category within an HCM family in 
the absence of knowledge of his mutation status. Second to this, a total of ten risk alleles were 
observed in each of five MC individuals. The average effect per allele on PC1 was 0.475 for our set 
of polymorphisms; an MC individual harbouring ten risk alleles is therefore predicted to have a PC1 
4.75 points higher. 
Stellenbosch University  http://scholar.sun.ac.za
  
216│Chapter 4 
4.7 Future studies  
The current explorative study forms part of a larger research effort aimed at identifying genetic 
modifiers of hypertrophy in HCM within a South African cohort. It succeeded in identifying a 
modifying role, in many instances for the first time, for each of the candidate genes investigated 
with the exception of PRKAG1. It is, therefore clear that sarcomeric genes and genes relating to 
myocardial energetics influence the development of hypertrophy within the present study 
population and it may also do so in other HCM and hypertrophy cohorts. Table 4.1 provides a 
priority list of genes for future studies under the following headings: number of associations 
between multiple SNPs and a trait, number of haplotype and trait associations and number of 
SNP/haplotype associations with multiple SNPs. Each ‘x’ corresponds to an association identified 
per criteria. We chose to group and prioritize the results in this way so as to ascertain the degree to 
which individual genes are involved in hypertrophy development i.e. whether they showed fairly 
consistent effects with significant results for all four of the tests of association performed or 
marginal effects with significance in only some instances. For example, a gene that showed 
significant associations for all tests should be prioritized above a gene that indicated a single 
significant single SNP result with only one trait.  
Table 4.1 Priority list of genes for future studies  
Candidate 
gene 
Number of associations 
between multiple SNPs 
and a trait 
Number of haplotype and 
trait associations 
Number of SNP/haplotype 
associations with multiple 
traits 
Thin filament components 
ACTC1 - xx - 
TNNT2 - xxxx x 
TNNI3 - xxxx x 
TPM1 xxx xxxxxxxxxxxxx xxxx 
ACTN3 - x - 
Thick filament components 
MYL3 - xxxxxx xx 
MYH7 - xx xx 
MYL2 - xx xx 
Intermediate filament component 
MYBPC3 x xxxxxxx xx 
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Candidate 
gene 
Number of associations 
between multiple SNPs 
and a trait 
Number of haplotype and 
trait associations 
Number of SNP/haplotype 
associations with multiple 
traits 
Fatty acid metabolism components 
CD36 - xxxxxxx xxx 
CPT1B - xxxxxxxxx xx 
PPARA - xxxxxxxxxx xx 
PPARG - xxxxxxxxxxxx xxx 
PGC1A - xxxxxxxxxx xx 
Glucose metabolism components 
ALDOA - xx x 
PFKM - xxxxxxxxxxx xxxxxxx 
PDK4 - xxxxx xx 
Creatine kinase energy shuttle components 
CKM - xxxxxxxxxxx xxxx 
CKB - xxx - 
Cellular energy homeostasis 
PRKAA1 xxx xx xx 
PRKAA2 - x - 
PRKAB1 - xxx - 
PRKAB2 - - - 
PRKAG1 - - - 
PRKAG2 xxxxx xxxxxxxxxxxxxxx xxxxx 
PRKAG3 - x - 
Abbreviations: ACTC1-Actin, alpha, cardiac muscle 1; ACTN3-Actinin, alpha 3; ALDOA-Aldolase A, fructose-
bisphosphate; CD36-CD36 antigen, thrombospondin receptor; CKB-Creatine kinase, brain; CKM-Creatine kinase, 
muscle; CTP1B- Carnitine palmitoyltransferase 1B, muscle; MYBPC3-Myosin binding protein C, cardiac; MYH7-
Mysoin heavy chain 7, cardiac muscle, beta; MYL2-Myosin light chain 2, regulatory cardiac, slow; MYL3-Myosin light 
chain 3, alkali, ventricular, skeletal slow; PDK4-Pyruvate dehydrogenase kinase, isozyme 4; PFKM-
Phosphofructokinase, muscle; SNP-single nucleotide polymorphism; TNNI3-Troponin I type 3, cardiac; TNNT2-
Troponin T type 2, cardiac; TPM1-Tropomyosin 1; PPARA-Peroxisome proliferator-activated receptor alpha; PPARG-
Peroxisome proliferator-activated receptor gamma; PGC1A-Peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha; PRKAA1-Protein kinase, AMP-activated, alpha 1 catalytic subunit; PRKAA2-Protein kinase, AMP-
activated, alpha 2 catalytic subunit; PRKAB1-Protein kinase, AMP-activated, beta 1 non-catalytic subunit; PRKAB2-
Protein kinase, AMP-activated, beta 2 non-catalytic subunit; PRKAG1-Protein kinase, AMP-activated, gamma 1 non-
catalytic subunit; PRKAG2-Protein kinase, AMP-activated gamma 2 non-catalytic subunit; PRKAG3-Protein kinase, 
AMP-activated, gamma 3 non-catalytic subunit 
The modifying capacity of the single SNPs and haplotypes that indicated significant effects should 
now be corroborated by means of association studies in larger study populations from different 
origins. In addition, the single SNPs and coding non-synonymous variants with which they are in 
LD should be prioritised for functional studies based on their predicted functional significance. 
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Such investigations should, were relevant (i.e. in the presence of significant differences in effect 
amongst the founder mutation groups), extend to the evaluation of SNP effect in combination with 
individual founder mutations, that is as proposed, the influence of compensatory mechanisms 
secondary to the effect of the causal mutations. According to the SNPbrowserTM v.4.0.1 software, 
all SNPs in LD with the investigated variants were limited to either intronic or coding sequences. 
However, the possibility that the significantly associated variants could be in LD with SNPs in the 
promoter and/or other regulatory sequences cannot be excluded and may become apparent with the 
continuous updating of current LD maps. Functional evaluations with respect to significant 
haplotype effects are most complicated as it reflects the combined effects of variants contained 
within the respective haplotypes i.e. it may include any and all alleles within the haplotype. Again, 
the variants within the haplotype (and coding non-synonymous variants of predicted functional 
consequence with which they are in LD) should be prioritised based on proposed functional 
significance and further investigated in combination with the aim of elucidating the exact effect loci 
and their precise interrelations on a molecular level. These investigations too should, where 
applicable, explore the influence of founder mutation and haplotype interaction.  
A number of the intronic variants which were evaluated in silico, which indicated differences with 
respect to the recognition of splicing motifs upon comparison of their respective alleles, thereby 
suggesting that they affect mRNA splicing. There is value in subjecting these variants to further in 
silico evaluations aimed at predicting their eventual effects at protein level. However, the 
bioinformatic tools currently available for splicing predictions have a number of limitations. 
Thomassen et al. (2012) describe these shortcomings as a need to improve the sensitivity and 
specificity with which the likelihood of disrupted splicing is predicted, specifically for variants 
located outside the acceptor and donor AG and GT sequences; as well as poor prediction of 
alternatively used mechanisms, particularly with respect to cryptic splice sites (Thomassen et al., 
2012). It is, therefore necessary to perform these predictions in conjunction with RNA-based assays. 
Such analyses were beyond the scope of the current study. 
It is important to note that the probands in this study were previously subjected to mutation 
screening for HCM-causal mutations in the MYBPC3, MYH7, TNNT2 and TNNI3 genes, but 
carried only one of the founder mutations. The potential, therefore exists that the probands or family 
members may carry HCM-causing mutations in causal genes other than those screened for. Also, 
family members may harbour causal mutations in the genes screened that are not present in the 
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probands. However, it may be considered unlikely given that the probands are typically worst 
affected and, therefore, in all probability carry the strongest risk allele(s). The exception would be 
when a family member carries an HCM-causing mutation and the effects thereof are masked by a 
protective modifier allele(s). Short of screening the entire cohort, future studies should address this 
issue by subjecting the most severely affected mutation carriers to mutation screening for those 
HCM-causing genes included in the current study. If, upon screening, additional mutations are 
identified, family members should undergo relevant screening to determine their carrier-status. 
As described in Section 1.2.1, TNNC is an HCM susceptibility gene and we therefore considered it 
as candidate modifier of hypertrophy development. However, according to the SNPbrowserTM 
v.4.0.1 software none of the TNNC SNPs characterised, to date, met our SNP selection criteria; i.e., 
the software indicated the presence of only one TaqMan validated SNP, rs2070914, which had an 
insufficient heterozygosity value (equal to 0 in both the YRI and CEU populations) for use in 
statistical analysis of transmission disequilibrium. Screening of our cohort for mutations in the 
TNNC gene is currently being performed as part of a novel study in our laboratory. The gene could 
therefore be revisited as a potential modifier pending the outcome of the aforementioned study 
and/or the continuous updating of LD maps. 
As mentioned, amongst others, significant results were identified for the CKM and PDK4 genes. It 
is thus of interest to evaluate whether genotypes correlate with the relevant enzyme concentrations 
and/or activity levels. The recruitment of patients for blood sample collection, which would allow 
for determination of their relevant CK and pyruvate measures, is currently being performed. 
However, this is an ongoing effort as patient recall is challenging. In addition, these tests are not 
currently done in our laboratory and blood assays are performed by commercial pathology 
laboratories at considerable cost. This aspect of the study will, therefore, be concluded as a future 
aim.  
4.8 Conclusion 
The study, performed as a hypothesis-generating investigation, identified sarcomeric modifiers of 
hypertrophy within a South African cohort of HCM families. The extent of the identified modifying 
effects can be described as substantial considering that overt hypertrophy is defined as an mLVWT 
of 35 mm or more in adults and that the diagnostic cut-off value in HCM pedigrees is an mLVWT 
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of 11 mm. For example, the smallest of the effects is a 0.24 mm decrease in the mPWT measure 
(after adjusting for all the relevant confounders), owing to the T-allele of the rs7260463 CKM 
variant. Therefore, the heart of a G/G homozygous individual will be nearly 0.5 mm thicker relative 
to that of a T/T homozygous individual, if all other factors are equal. This effect size may appear 
modest, but it should be considered within the context of complex disease that is the cumulative and 
synergistic result of many smaller effects. In contrast, the largest significant difference in effect 
pertaining to the LVM measure was seen for the CKM gene haplotype TTGA. It indicated a 120.3 g 
lower effect on LVM in R92WTNNT2 group compared to the R403WMYH7 group. This example clearly 
illustrates the sizeable variation in the risk of developing LVH owing to the compound effect of the 
modifier and the individual founder mutations. 
As discussed, the therapeutic correction of primary HCM-causing mutations is challenging. The 
significant results observed for sarcomeric genes may, for the moment, improve only the 
understanding of genotype/phenotype relationships and potentially patient risk stratification and 
choice of treatment, e.g. whether the risk-profile of a given patient warrants implantation of an ICD 
or whether drug intervention would be sufficient. The significant results observed for the genes 
relating to myocardial energetics may also hold promise for metabolic modulation of disease. 
However, much functional research, as described in the foregoing future studies section, is required. 
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APPENDIX I 
1. DNA EXTRACTION SOLUTIONS 
 
Cell Lysis Buffer 
Sucrose        0.32M 
Triton-X-100       1% 
MgCl2        5mM 
Tris-HCl (pH 8)      10mM 
Add sterile water to a final volume of 1L 
 
3M Sodium Acetate  
NaAc.3H2O       40.18g 
Sterile water       50ml 
Adjust the pH to 5.2 with glacial acetic acid and add sterile water to final volume of 100ml 
 
Na-EDTA Solution 
NaCl        18.75ml of 4mM stock solution 
EDTA        250ml of 100mM stock solution 
Mix well 
 
Phenol/Chloroform 
Phenol, saturated with 1X TE     50ml 
Chloroform       48ml 
8-Hydroxiquinoline      2ml 
Mix well and store at 4°C 
 
Chloroform/Octanol (24:1) 
Chloroform       96ml 
Octanol       4ml 
Mix well and store at 4°C 
 
 
10X TE-buffer Stock Solution 
TrisOH       0.1M (pH 8) 
EDTA        0.01M (pH 8) 
Sterile water 
Mix well 
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2. ELECTROPHORESIS STOCK SOLUTIONS 
 
20X SB Stock Solution 
di-Sodium tetraborate decahydrate    38.14g 
Add sterile water to a final volume of 1 L 
 
1X SB Solution 
20X SB solution      50ml 
Add sterile water to a final volume of 1 L 
 
3. GELS 
 
2% Agarose gel 
Agarose        2g 
SB Buffer (1X)      100ml 
Microwave for 1 min on maximum power and add 5µl ethdium bromide (10mg/ml) when 
temperature of ±55°C is reached 
 
4. LOADING DYES 
 
Ethidium Bromide Stock (10mg/ml)  
Ethidium bromide      500mg 
Sterile water       50ml 
Stir well on magnetic stirrer for 4h and store in dark container at 4°C 
 
Bromophenol Blue Loading Dye 
Bromophenol Blue      0.1% (w/v) 
Add sterile water to a final volume of 100ml. Store at 4°C 
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